Cochlear implantation in deaf children with complex needs by Vesseur, A.C.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/191617
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.

ISBN
978-94-92896-33-9
Design/lay-out  
Promotie In Zicht, Arnhem
Cover design 
Leonoor Vesseur
Print
Ipskamp Printing, Enschede
© Annemarie Vesseur, 2018
All rights reserved. No part of this thesis may be reproduced, distributed, stored in a retrieval system,  
or transmitted in any form or by any means without written permission by the author.
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op donderdag 5 juli 2018
om 10.30 uur precies
door
Annemarie Christine Vesseur
geboren op 2 april 1984
te Rotterdam
Cochlear Implantation  
in Deaf Children with Complex Needs
A Descriptive Study on Cochlear Implantation in Children with CHARGE Syndrome,
Congenital Cytomegalovirus Infection or Kabuki Syndrome
Promotoren
Prof. dr. ir. A.F.M. Snik
Prof. dr. E.A.M. Mylanus (Universiteit Gent, België)
Prof. dr. C.M.A. van Ravenswaaij (Rijksuniversiteit Groningen) 
Manuscriptcommissie 
Prof. dr. I. Dhooge (Universiteit Gent, België)
Prof. dr. M.A.A.P. Willemsen
Prof. dr. H.E.T. Knoors
voor pappa en mamma

Contents
Chapter 1 General Introduction 9
Chapter 2 CHARGE Syndrome 23
2.1  CT findings of the temporal bone in CHARGE syndrome: aspects  
of importance in cochlear implant surgery 
25
2.2  Influence of hearing loss and cognitive abilities on language 
development in CHARGE Syndrome
51
2.3  Suggestions for a guideline for cochlear implantation in  
CHARGE syndrome
67
2.4  Hearing restoration in cochlear nerve deficiency: the choice 
between cochlear implant or auditory brainstem implant
93
Chapter 3 Cochlear Implantation in Patients Deafened by  
Congenital Cytomegalovirus
115
3.1  Cytomegalovirus DNA detection in dried blood spots and 
perilymphatic fluids from pediatric and adult cochlear implant 
recipients with prelingual deafness
117
3.2  A Case-control study: quality of life in children post cochlear 
implantation with congenital cytomegalovirus-related deafness
131
Chapter 4 Cochlear Implantation in Kabuki syndrome 147
Cochlear implantation in a patient with Kabuki syndrome 149
Chapter 5 Closure 159
5.1 General Discussion 161
5.2 Summary 173
5.3 Nederlandse samenvatting (summary in Dutch) 181
5.4 Addendum 191
 5.4.1 List of abbreviations
 5.4.2 Dankwoord (acknowledgement in Dutch)
 5.4.3 Curriculum Vitae
 5.4.4 List of Publications
193
195
199
201

General Introduction
1
10
Chapter 1
11
General Introduction
1
In 1990 at the conclusion of a multicentre trial, the US Food and Drug Administration (FDA) 
approved cochlear implantation in children with severe to profound hearing loss. The FDA 
had approved cochlear implantation in adults six years earlier. The first cochlear implantation 
in a child in the Netherlands occurred in 1987 at the Radboud University Medical Centre 
Nijmegen. Ten years of research and reports to the National Health Council (for example 
Cochleaire Implantatie bij kinderen, Eindverslag Ontwikkelingsgeneeskundeproject 1993 – 
1996) were required before general reimbursement of cochlear implantation for adults 
and children was approved. 
 The initial eligibility criteria for children were quite strict and, for example, residual 
hearing, developmental delays, and anatomical malformations of the cochlea and the 
cochlear nerve were considered exclusion criteria. As research highlighted the beneficial 
outcome of rehabilitation of deaf children with cochlear implants in terms of audition, 
speech and language development and social and emotional development, the age at 
implantation gradually decreased to below 12-months of age. In general, evidence 
indicates implantation at a very young age results in improved hearing performance [1] 
and improved language and reading capacities [2] compared to children who are 
implanted at a later age. Over time, increasing numbers of children with developmental 
delays have joined the cochlear implant program. In many cases this was done knowingly 
but in many cases the developmental delay was not apparent until some years after 
cochlear implantation.
 In due course, our clinical team gained considerable experience in the area of cochlear 
implantation in children with developmental delays [1]. There are two well-recognized 
groups of children who can have severe to profound hearing loss with or without 
intellectual disabilities: children with CHARGE syndrome and children with congenital 
 cytomegalovirus (cCMV) infection. Children with cCMV infection are frequently included 
in the paediatric cochlear implant program at our medical centre. To counsel parents on 
possible outcomes of cochlear implantation in terms of hearing performance or quality of 
life, more information was required on the benefit of cochlear implantation in these 
children. Thus, an important goal of this thesis was to obtain performance and subjective 
data through evaluative, retrospective and cross-sectional research in children with severe 
to profound hearing loss and developmental delays. In this thesis we focus on CHARGE 
syndrome, cCMV infection and Kabuki syndrome. 
 Children with CHARGE syndrome, cCMV or Kabuki syndrome with severe to profound 
hearing loss present particular challenges for a cochlear implant team related to the 
combination of impaired cognition and anatomical variety seen in these children. 
This variety can be observed at the level of external auditory meatus, middle ear cavity, 
cochleo vestibular system and cochlear nerve. 
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Anatomy and physiology of the ear
To appreciate the function and the impact of positioning of the cochlear implant, it is 
important to understand the anatomy of the auditory system. Similarly, to appreciate the 
challenges of cochlear implantation in a malformed middle ear cavity and compromised 
cochleovestibular system, it is necessary to discuss the anatomy of the facial nerve, 
particularly the facial nerve’s pathway as it relates to the middle ear and mastoid [2].
 The ear is imbedded in the petrosal bone and comprises three parts: the external 
part, the middle ear and the inner ear (Figure 1). The external part consists of the pinna and 
external auditory meatus. The pinna contributes to spectral cues when it collects sound 
waves, which are conducted to the external auditory meatus. The auditory meatus ends 
at the tympanic membrane. The tympanic membrane, tympanic cavity, Eustachian tube 
and the middle ear ossicles and their ligaments are anatomical structures of the middle 
ear. The facial nerve travels from the brainstem into the internal auditory canal and runs 
parallel to the cochleovestibular nerve. The route of the facial nerve in the middle ear is 
initially horizontal and superior to the oval window and is followed by a vertical segment 
just posterior of the round window of the cochlea. Its close proximity to the cochlear 
windows, especially the round window, has implications for cochlear implant surgery.
Figure 1  The ear
Image courtesy of Virtual Medical Centre
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Sound waves cause the tympanic membrane to vibrate and, in turn, move the malleus, 
incus and stapes. These three structures are referred to as the ossicular chain and this 
chain stimulates the intracochlear fluid via the oval window. The inner ear comprises the 
cochlea, labyrinth and inner ear canal. The cochlea is a spiral channel with approximately 
2.5 turns and consists of three ducts: the scala tympani (tympanic duct), scala media 
(cochlear duct) and scala vestibuli (vestibular duct) (Figure 2). The labyrinth, consisting of 
the vestibulum and semicircular canals, is the organ that controls balance. At the level of 
the footplate of the stapes, sound waves travel through the fluid-containing ducts of the 
cochlea and deflect the basilar membrane between the scala tympani and scala media as 
“a travelling wave”. The differential stiffness of the basilar membrane means high-frequency 
sounds affect the membrane close to the oval window whereas low-frequency sounds 
affect the membrane more apical to the oval window. This organisational frequency 
structure, or principle, is referred to as ‘tonotopic organization’. 
The basilar membrane contains the sensory organ, also referred to as the organ of Corti 
(Figure 2). This organ comprises the inner and outer hair cells, of which the stereocilia are 
connected to a stiff tectorial membrane. This membrane makes the hair cells susceptible 
to movements of the basilar membrane. Stimulation of the sterocilia of the inner hair cells 
elicits an action potential of the dendrites of the cochlear nerve. From there on, action 
potentials are conducted to the central auditory system: the brainstem and auditory 
cortex.
Figure 2  The cochlea
Image courtesy of Virtual Medical Centre
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Hearing loss in children
Dysfunction of the outer ear, middle ear or cochlea can cause hearing loss. Inefficient 
airborne sound transmission by the external or middle ear causes a so-called ‘conductive 
hearing loss’. Conductive hearing loss may be congenital (e.g. anatomical anomaly of the 
external auditory meatus and/or the middle ear) or secondary to ear disease or trauma. 
Dysfunction of the cochlea or neural pathway to the brain causes a ‘sensorineural hearing 
loss’. Cochlear dysfunction can be due to genetic abnormalities of the inner ear and is 
common in CHARGE, Branchio-oto-renal, Pendred, Waardenburg and Noonan syndromes. 
Sensorineural hearing loss can also be secondary to congenital infections (e.g. cytomega-
lovirus or Rubella) or to injury and medications that are toxic to the auditory system. 
A combination of sensorineural hearing loss and conductive hearing loss is termed ‘mixed 
hearing loss’. 
Cochlear implant
Conventional hearing aids are an effective solution for children with a mild to severe 
hearing loss. For children with severe to profound hearing loss or ‘deafness’, conventional 
Figure 3  Cochlear implant
1.  Microphone; 2. Coil; 3. Electrode; 4 Cochlea. 
Image courtesy of Virtual Medical Centre
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hearing aids are no longer effective. In the 1970s and 1980s, a device termed a ‘cochlear 
implant’ (CI) was developed. A CI is a semi-implantable device designed to electrically 
stimulate the auditory nerve endings in the cochlea. Over time, the initial single-elec-
trode/single channel CI system evolved to a multiple-electrode/multiple channel CI 
system. These multiple-electrode systems have sophisticated speech-coding algorithms 
that are continually developed and refined. 
 The CI system consists of two parts: an external part and an internal part (Figure 3). 
The external part contains the microphone, speech processor and battery compartment. 
The external part communicates transcutaneously with the internal part via electro-
magnetic induction. The internal part comprises a receiving antenna (coil) and a chip. 
The chip decodes the electromagnetic signal into electrical pulses that are conducted 
through the electrical leads to the electrode array. This array is surgically placed in the 
scala tympani and it directly stimulates the cochlear nerve (spiral ganglia and dendrites).  
 There are several surgical approaches to implanting the internal part of the CI. The 
technique used at our centre requires cortical mastoidectomy and posterior tympanotomy. 
The proximity of vascular structures, the facial nerve, chorda tympani and ossicular chain 
necessitates careful surgery to avoid complications during this elective surgical procedure.
Indication criteria
Cochlear implantation has become a regular treatment option for children and adults with 
severe or profound sensorineural hearing loss who cannot be treated with conventional 
hearing aids. Research indicates that in general, children who are born deaf, without 
co-morbidities and are implanted at a young age with a CI go on to develop age-appro-
priate speech and language skills. Based on these positive results with CI in children with 
isolated deafness, the criteria for implantation have gradually become more flexible and, 
for example, allowing children with cognitive delay to undergo implantation [3]. 
 Whether a child profits from the CI depends on implant-related factors, environmental 
factors and several individual factors. Major concerns are the anatomy of the ear, for safe 
and effective surgery, proper fitting of the device enabling proper processing of auditory 
signals and, finally, the social, emotional and cognitive abilities and capabilities of the 
children.
 CHARGE syndrome, cCMV infection and Kabuki syndrome are complex in nature and 
children with these syndromes can have (severe to profound) hearing loss. Children with 
the above syndromes or infection can be eligible for cochlear implantation, but the 
complexity of these syndromes makes it difficult to predict the success of CI.
CHARGE syndrome
In 1979, Hall noted that choanal atresia could be accompanied by a specific set of multiple 
anomalies [4]. In the same year, Hittner reported ten patients with the combination of 
coloboma, heart defect, external ear abnormalities, hearing loss and developmental delay. 
16
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In 1981, Pagon et al. used the acronym “CHARGE” to describe the association of Coloboma, 
Heart disease, Atresia of the choanae, Retarded growth and development and/or CNS 
anomalies, Genital hypoplasia, and Ear anomalies and/or deafness [5]. Blake revised this 
definition in 1998 into major and minor characteristics [6]. In 2005, Verloes suggested 
the following CHARGE diagnostic criteria: coloboma, atresia of choanae and hypoplastic 
semicircular canals as majors signs; Rhombencephalic dysfunction, hypothalamo- hypo-
physeal dysfunction, abnormal middle or external ear, malformation of mediastinal organs 
and intellectual disability were considered as minor signs [7]. Cranial nerve dysfunction of 
multiple nerves, including the acoustic and facial nerves, is seen in the majority of patients. 
In 2004, the causative gene was identified as CHD7 on chromosome 8q12 [8] and the 
name changed to CHARGE syndrome (MIM, Mendelian Inheritance in Man, 214800). 
 The presentation of the syndrome is diverse with most children showing a variable 
combination of multiple congenital anomalies. Hearing loss and cognitive delays are 
frequently described in CHARGE syndrome [9, 10]. Hearing loss, present in 80–100% of the 
patients, is one of the most common characteristics and can be due to anatomical 
anomalies of the middle or inner ear, to aplasia or hypoplasia of the cochlear nerve, or to 
middle ear disease. As a consequence, hearing in children with CHARGE syndrome can 
range from normal to profound hearing loss [6, 9, 11]. As one of the minor characteristics, 
delayed cognitive abilities are also often described in children with CHARGE syndrome. 
The delay in cognitive development varies and is rarely expressed in “Intelligence 
Quotient” (IQ). Instead, cognition is expressed in relation to developmental age, abilities 
and educational level. Between 50% and 75% of children with CHARGE syndrome have 
below average intellectual development [12-16]. Language delays have been described 
[16] but little is known about language development in this group of children. 
 Children with CHARGE syndrome who have a profound to severe hearing loss could 
benefit from cochlear implantation as studies have reported children with CHARGE 
syndrome were more responsive and receptive after implantation than before implantation 
[17-20]. However, cochlear implantation in this group is not without challenges. One of the 
features seen in CHARGE syndrome is deficiency of the cochlear nerve [21] and the surgical 
procedure may be complicated by anatomical anomalies of the petrosal bone and facial 
nerve abnormalities [20]. In addition, development of speech and language after 
implantation may be difficult because of cognitive or physical impairments [17-20].
Congenital cytomegalovirus infection
Congenital cytomegalovirus infection is a common condition. In Western Europe and the 
USA, the prevalence is approximately 1%. The minority (10%) of these infants shows 
symptoms such as jaundice, hepatosplenomegaly, petechiae, microcephaly and chorio-
retinitis at birth. The remaining infants (90%) are asymptomatic. Infants symptomatic at 
birth have greater neurological sequelae, sensorineural hearing loss and visual abnormalities 
than asymptomatic children. The neurological sequelae consist of intellectual disability 
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and neurological abnormalities (hypotonia, spasticity, delayed motor development and 
seizures) [22, 23].
 Diagnosis of cCMV infection is established either by isolation of the virus in urine, 
blood or saliva of the newborn or by identifying CMV-specific IgM in cord blood or in the 
infant’s blood. In retrospective, diagnosis can be confirmed by PCR (polymerase chain 
reaction) on the dried blood spot on the Guthrie card. 
 For some individuals, cCMV infection can be indicated after brain imaging. Different 
intracerebral abnormalities are described in the literature. In children with an asymptomatic 
infection, the abnormalities are milder and occur less often than in symptomatic children 
[24]. The anomalies generally seen are intracerebral calcifications, ventriculomegaly, white 
matter abnormalities, neuronal migrations disorders and encephalopathy [25, 26]. Children 
with intracerebral anomalies have a greater chance to develop sensorineural hearing loss, 
neurological problems (motor and cognitive delays) and visual disturbances [25, 27-29].
 Children with an asymptomatic infection have a 15-25% chance of developing hearing 
loss in the first few years of life; Children with a symptomatic infection have a 60% chance 
of developing hearing loss. The hearing loss is sensorineural, ranges from a mild to 
profound hearing loss and the severity of the hearing loss may fluctuate over time [30]. 
Symptomatic and asymptomatic children with profound or severe hearing loss are eligible 
for cochlear implantation. The results of cochlear implantation in these groups vary but 
the majority of studies report two findings: (1) asymptomatic children with a CI perform 
equal to or better than peers with idiopathic hearing loss with a CI [31, 32] and (2) children 
with symptomatic cCMV can achieve substantial auditory and language skills but lag 
behind asymptomatic peers or peers with idiopathic hearing loss with a CI. This last 
finding has been attributed to poor attention control, cognitive disabilities, autistic 
spectrum disorders or central nervous system impairment [33-37].
Kabuki Syndrome
Kabuki syndrome, first described by Niikawa et al. in 1981, has characteristics such as a 
distinctive facial features, cognitive disabilities, postnatal growth deficiency, dermatoglyphic 
abnormalities and skeletal anomalies [38]. Hearing loss is one of the associated anomalies 
in Kabuki syndrome and is observed in 65% of cases [39]. The hearing loss can be 
conductive, sensorineural or of mixed origin. Anomalies of the middle ear and inner ear 
have been described [40, 41]. To the best of the authors knowledge, there are no published 
studies of cochlear implantation in children with Kabuki syndrome. 
Aims of the study
The aim of this thesis is to describe the challenges and benefits of cochlear implantation 
in children with complex needs. With the expansion to the eligibility criteria for implantation, 
cochlear implantation is now possible for children with co-morbidities including cognitive 
delay in addition to a hearing loss. The difficulty becomes how to adequately prepare 
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parents and caregivers on possible outcomes when there is a lack of research investigating 
CI use in these cohorts. Because, the more complex the disorder, the more difficult to 
counsel the parents on the possible outcome. In this thesis, CI use is investigated in 
children with hearing loss due to three aetiologies: children with CHARGE syndrome, 
children with severe to profound hearing loss as a result of cCMV infection and a child with 
Kabuki syndrome. 
 A second aim is to identify predictive factors for performance outcome and quality of 
life with a CI that could be evaluated during the pre-implantation assessment. Identification 
of predictive factors would greatly assist with preparing parents and caregivers for possible 
CI outcomes. 
 Multiple factors should be considered when considering CI in children with CHARGE 
syndrome. Chapter 2 focuses on several factors, such as anomalies of the petrosal bone, 
which can be challenging in CI surgery. Such anomalies of the temporal bone are 
described in Section 2.1. For optimal planning of the CI procedure, the potential impact of 
anomalies we found, needs to be considered by the surgical team. For reference purposes, 
developmental norms of children with CHARGE syndrome without severe to profound 
hearing loss were acquired. In Section 2.2 we describe the relationship of either hearing 
loss or cognitive abilities on language development in CHARGE syndrome. Section 2.3 
provides an overview of the challenges and benefits encountered in cochlear implant 
surgery in CHARGE syndrome. Based on this overview, a suggested guideline is presented. 
Section 2.4 presents a case report that highlights the diagnostic dilemma of when to implant 
and when to refrain from cochlear implantation in cases of cochlear nerve deficiency. 
 Chapter 3 focuses on cochlear implantation in children with severe to profound 
hearing loss as a result of cCMV infection. Section 3.1 focuses on the prevalence of cCMV 
infections among CI recipients with prelingual deafness and the pathophysiology of 
cCMV and severe to profound hearing loss. In children with cochlear implant, benefit is 
not necessarily best expressed in improvement of speech and language abilities; rather it 
can be expressed in terms of changes to quality of life. Section 3.2 presents the outcomes 
of this quality of life investigation. 
 Chapter 4 describes the challenges of cochlear implantation in a child with Kabuki 
syndrome. 
 Chapter 5 presents the final conclusions and general discussion and is followed by a 
thesis summary written in English and in Dutch. 
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Abstract
Objectives
To provide an overview of anomalies of the temporal bone in CHARGE syndrome relevant 
to cochlear implantation (CI), anatomical structures of the temporal bone and the 
respective genotypes were analysed.
Materials and Methods
In this retrospective study, 42 CTs of the temporal bone of 42 patients with CHARGE 
syndrome were reviewed in consensus by two head-and-neck radiologists and two 
otological surgeons. Anatomical structures of the temporal bone were evaluated and 
correlated with genetic data. 
Results
Abnormalities that might affect CI surgery were seen, such as a vascular structure, a 
petrosquamosal sinus (13%), an underdeveloped mastoid (8%) and an aberrant course of 
the facial nerve crossing the round window (9%) and/or the promontory (18%). The 
appearance of the inner ear varied widely: in 77% of patients all semicircular canals were 
absent and the cochlea varied from normal to hypoplastic. A stenotic cochlear aperture 
was observed in 37%. The middle ear was often affected with a stenotic round (14%) or 
oval window (71%). More anomalies were observed in patients with truncating mutations 
than with non-truncating mutations. 
Conclusion
Temporal bone findings in CHARGE syndrome vary widely. Vascular variants, aberrant 
route of the facial nerve, an underdeveloped mastoid, aplasia of the semicircular canals, 
and stenotic round window may complicate cochlear implantation. 
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2.1
Introduction
The criteria for the clinical diagnosis of CHARGE syndrome (MIM, Mendelian Inheritance in 
Man, 214800), have been defined by Blake et al. and Verloes [1][2]. CHARGE syndrome is an 
acronym of Coloboma, Heart disease, choanal Atresia, Retardation, Genital hypoplasia and 
Ear anomalies. Organ involvement and severity is highly variable amongst affected 
patients. A major criterion includes the condition of the temporal bone, which may be 
hypoplastic or show an absence of the semicircular canals, according to Verloes. Anomalies 
are seen in the external, middle and inner ear, such as the typically low-set, cup-shaped 
ears, ossicular malformations, an aberrant course of the facial nerve, hypoplastic internal 
auditory canal, and an abnormally developed cochlea. Some of these malformations can 
cause hearing loss: 60-90% of patients with CHARGE syndrome have moderate to severe 
hearing loss due to conductive, sensorineural or mixed defects. In most patients, hearing 
loss can be partially compensated with hearing aids. When hearing aids do not have the 
desired outcome due to the presence of profound to severe hearing loss, cochlear 
implantation may be considered. If cognitive disabilities, developmental and behavioural 
problems do not preclude cochlear implantation, a thorough assessment of the temporal 
bone anatomy is necessary. Anatomical alterations pose additional surgical risks during 
the implantation, by hampering the surgical approach to the cochlea or the insertion of 
the electrode array into the cochlea, and they may influence the surgical results in terms 
of speech perception.
 In 2004, the causative gene for CHARGE syndrome was identified as CHD7 on 
chromosome 8q12.1 [3]. Since then, 528 different mutations of the gene have been 
described, but no clear genotype-phenotype correlation could be recognized (www.
CHD7.org) [4]. In the CHD7 mutation positive patients, the most common clinical findings 
were temporal bone anomalies (98%), external ear malformations (91%), and hearing loss 
(89%) [5]. 
 The main goal of this retrospective study was to analyse the presence of the anomalies 
of the temporal bone in patients with CHARGE syndrome and their potential impact on 
cochlear implant surgery planning. The secondary goal was to study possible geno-
type-phenotype correlations.
Materials and Methods 
We collected analogue and digital CT studies of the temporal bone of patients attending 
the Dutch CHARGE centre of expertise (University Medical Centre Groningen, the Netherlands), 
after obtaining written informed consent from all patients or their legal representatives. 
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All patients had molecularly confirmed CHARGE syndrome, or clinically typical CHARGE 
syndrome according to the Blake or Verloes criteria (table 1, 4) except for one patient with 
atypical CHARGE syndrome (patient 12), because the parents did not wish further 
investigation [1; 2].
The patients were investigated in different time periods and in different Dutch hospitals, 
so the scans were made with different scanner types and variable scan parameters. 
 We evaluated CTs of 84 ears of 42 patients (22 male, 20 female) with CHARGE syndrome 
(29 digital and 13 analogue scans). The scans were performed between 1996-2010. The mean 
age of the patients at the time of scanning was 6.4 years, median 2.5 years (SD 9.8; min 0, 
max 47 years). 
Table 1  Characteristics of CHARGE syndrome
1a. Major and minor signs of CHARGE syndrome2
Major Signs
Coloboma (iris or choroid, with or without microphthalmia)
Atresia of choanae
Hypoplastic semicircular canals
Minor signs
Rhombencephalic dysfunction (brainstem dysfunctions, cranial nerve VII to XII palsies and 
neurosensory deafness)
Hypothalamo-hypophyseal dysfunction (including GH and gonadotrophin deficiencies)
Abnormal middle or external ear
Malformation of mediastinal organs (heart, oesophagus)
Intellectual disability
1b. Definition of typical, atypical, and partial CHARGE syndrome2
Typical CHARGE syndrome
3 major signs
2/3 major signs + 2/5 minor signs
Partial/incomplete CHARGE
2/3 major  signs + 1/5 minor signs
Atypical CHARGE
2/3 major  signs + 0/5 minor signs
1/3 major signs  + 3/5 minors signs
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Imaging analysis
All imaging studies were evaluated by four observers (two head-and-neck radiologists 
with 13 and seven years of experience and two otorhinolaryngologists with ten and 
15 years of experience), who then met to reach a consensus opinion. The reviewers had no 
access to patients’ names nor their clinical information. Each ear was evaluated separately, 
in axial and coronal planes, if available. The anatomic structures and normative measures 
determined are presented in appendix A and figure 1.
Figure 1  Measurements in axial CT images
1a. Mastoid size A: Anterior-posterior (AP) size, measured in the middle of the external 
meatus (cranial/caudal) as the minimal distance from the external meatus to sigmoid sinus 
B: Lateral-medial (LM) size, distance between outer cortex and sigmoid sinus, measured 
perpendicular to A; 1b. Angle cochlear basal turn; 1c. Vestibulum size A: Longitudinal 
extension, B: Transversal diameter (right ear) 
a
c
b
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All the scans were analysed as extensively as possible, using a standardized form (appendix B) 
compiled specifically for this study. Items that could not be analysed, e.g. due to a missing 
coronal plane or to slice thickness, were scored as ‘unable to identify’ (UTI).
 The digital scans were analysed on a viewing station (IMPAX, Apache Software 
Foundation, Version 2.0, January 2004). Measurements were obtained in millimetre (to two 
decimal places) with electronic calipers provided by the pacs-system. Analogue films 
were evaluated on an illuminated view box and measurements were performed with an 
analogue ruler. If a structure could not be properly assessed, it was scored as ‘unable to 
identify’ (UTI). 
 SPSS 20 was used to collect all data and perform statistical analyses. We used the 
X2-test to test for significant correlations. 
CHD7 analysis
The results of CHD7 analysis were already known for all but one (patient 12) patients. 
The analyses were performed on DNA isolated from peripheral blood cells according to 
standard procedures. The 37 coding exons of CHD7 (exons 2–38, RefSeq NM_017780.02) 
and their flanking intron sequences were amplified by PCR and sequenced as described 
earlier[3]. If no mutations were identified, CHD7 was screened for whole exon deletions 
and duplications by multiplex ligation-dependent probe amplification (MLPA) using a 
commercially available set of probes: the SALSA P201 kit (MRC-Holland, Amsterdam, 
the Netherlands; http://www.mrc-holland.com) [6].
 Nonsense and frameshift mutations and whole-gene or whole-exome deletions 
were categorised as truncating mutations, while missense and splice site mutations were 
categorised as non-truncating. 
Figure 2  Petrosquamosal sinus
Axial (a) and coronal (b) CT image of a right ear showing this emissary vein coursing along 
the lateral superior surface of the temporal bone. The petrosquamosal sinus originates 
at the transverse sinus and drains either into the retromandibular vein or the pterygoid 
venous plexus.
a b
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Results
Mastoid and vascular structures (tables 2,3)
The first part of a cochlear implantation, the mastoidectomy, can be challenging in an 
underdeveloped mastoid. The AP-size (anterior-posterior) and the LM-size (lateral-medial) 
of the mastoid could not be measured in 21 ears (25%), because of a hardly developed 
mastoid or moderate quality of the scan. These patients were particularly young (median 
age 5 years, mean 8.5 years, 22% < 1-year old). In 25 ears (29.8%), an emissary vein with a 
diameter larger than 1 mm was present (figure 2a,b).
Table 2  Ear structure observations
Structure on CT Normal Abnormal UTI
Pneumatisation mastoid Good No cells UTI 
73 (87%) 7 (8%) 4 (5%)
Middle ear cavity size Normal Small/large UTI
84 (100%) 0 0
Jugular bulb Normal High UTI 
59 (70%) 23 (27%) 2 (2%)
Emissary veins Total >1mm PSS 
28 (33%) 25 (30%) 11 (13%)
Windows Present Absent/stenotic UTI
Oval 22 (26%) 60 (71%) 2 (2%)
Round 70 (83%) 12 (14%) 2 (2%)
Ossicles Normal Dysplastic UTI
Malleus 83 (99%) 1 (1%) 0
Incus 75 (89%) 9 (11%) 0
Stapes 27 (32%) 42 (50%) 13 (15%)
Facial nerve Normal Aberrant course UTI
Tympanic 54 (64%) 24 (29%) 6 (7%)
Mastoid 70 (83%) 6 (7%) 8 (10%)
Vestibular aqueduct Normal Aberrant course UTI
12 (14%) 57 (68%) 12 (14%)
Cochlear apertura Normal Stenotic UTI
51 (61%) 31 (37%) 2 (2,4%)
SCC Normal Aplastic Dysplastic
2 (2%) 65 (77%) 17 (20%)
Number of ears: 84; UTI unable to identify; PPS persistent petrosquamosal sinus; SCC semicircular canals.
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Middle ear (windows/ossicles/facial nerve) (tables 2, 3)
Middle ear anomalies can be a challenge in preparing and making the cochleostomy. 
The size of the middle ear cavity was within normal limits in all patients and thus will not 
pose a problem in surgery. Overall, there was an aberrant course of the tympanic part 
of the facial nerve crossing the promontory in 16 ears (19.0% of the total number of ears) 
and in eight ears also the round window (9.5% of the total number of ears). The aberrant 
mastoidal portion of the facial nerve seemed to run more medially than normal in four 
ears. The windows and ossicles were difficult to assess due either to otitis media or to the 
moderate quality of the scan in 20 patients (23.8%).
 In 43 ears (51.2%) with a stenotic oval window, the stapes was not identifiable or 
dysplastic, either presenting as a monopod stapes (one ear), or displaced on the promontory 
or into the middle ear cavity (six ears) (figure 3). 
Cochleovestibular system (tables 5, 6)
Abnormalities of the cochlea can complicate the insertion of the electrode array. Table 5 
shows the distribution of cochlear type, omitting patient 12 (who had no mutation found 
(table 4) and normal cochleas), and patient 30 (who had an ‘unknown variant’ missense 
mutation (table 4), one normal cochlea and one cochlear hypoplasia type IV). In 32 (38.1%) 
ears, an abnormal cochlea was seen. The ears with an incomplete partition type II (IPII) 
deformity of the cochlea did not show an enlarged vestibular aqueduct or dilated 
vestibulum. In 22 (26.2%) ears, the cochlea appeared abnormal, but the type of dysplasia 
could not be determined according to Sennaroglu’s classification (Figure 4a,b,c). In these 
cochleae, the second turn seemed not to have developed fully, but the apex and basal 
Table 3  Ear structure measurements
Structure Mean (mm) Median (mm) SD (mm) Max (mm) Min (mm) UTI (ears)
Mastoid
AP-size 10.6 11.0 3.2 19.4 5.0 21
LM-size 7.9 7.0 6.2 40.0 1.2 22
Vestibulum
length 4.7 4.7 1.0 9.0 2.9 0
width 2.3 2.3 0.6 5.0 1.0 1.0
VA diameter1
0.7 0.6 0.3 1.9 0.1 11
IAC
3.6 3.5 0.9 7.0 2.0 0
Number of ears: 84; 1 only digital scans (n= 58); AP anterior-posterior; LM lateral-medial; VA vestibular aqueduct; 
IAC internal auditory canal; SD standard deviation; UTI: unable to identify
33
CHARGE Syndrome
2.1
turn were normal, with normal presence of interscalar septae and spiral osseous lamina, 
and in all but two of them the modiolus was normal. We will refer to this as hypoplasia 
type IV. 
 The angle of the basal turn was only measured on the digital scans; the mean was 
57 degrees (SD 6.3), with a range from 43.5 degrees to 78.6 degrees. The mean age of this 
group was 3.7 years.
Figure 3  Examples of window stenosis
3a. Axial CT image showing stenosis of the round window niche (grey arrow) in a left ear. 
Note also dysplastic stapes on the promontory (white arrow); 3b-d. Axial CT images 
showing atresia of the oval window (thin arrow), aberrant course of the facial nerve 
crossing the round window (arrowhead) and a dysplastic stapes positioned at the sinus 
tympani (thick arrow). Note aplasia of the semicircular canals.
a
c d
b
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Table 6  shows the distribution of SCC malformations excluding patient 12 (no mutation found 
and dysplasia of LSCC bilaterally) and patient 30 (UV missense mutation and total aplasia 
of SCC bilaterally). Aplasia of all SCCs was seen in 65 ears (77.3%), while dysplasia of one or 
all SCCs was seen in 17 ears (20.2%) and ranged from the strongly reduced development 
of one canal, like a bud, to just one affected canal (while the other two were present and 
normal) (figure 5a,b). In ears with a solitary canal aplasia or dysplasia, it was the lateral 
semicircular canal that was most often affected. If the superior semicircular canal was 
dysplastic, the lateral and posterior semicircular canals were absent. 
 Generally, the vestibulum was smaller than normal, both in length and width. The aberrant 
vestibular aqueducts had a course mainly in a perpendicular line from the vestibulum to 
the posterior fossa. If SCCs were absent, the aqueduct showed a more medial course than 
when they were severe or mild dysplastic. We found one ear with a large vestibular 
aqueduct (1.9mm diameter), but normally developed cochlea.
Figure 4  Range of abnormalities of the cochlea seen in axial CT images
4a. Incomplete partitioning type II: normal development of the basal turn, but fusion of 
the second and apical turn seen in axial and coronal planes; 4b. Hypoplasia type III: 
cochlea with less than 2 turns; 4c. Cochlea type ‘IV’: the basal, second and apical turns are 
present, but the second turn seems shortened, giving the cochlea an asymmetric, 
flattened appearance.
a b c
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Figure 5  Range of abnormalities of the vestibular system seen in axial CT images
5a. Aplasia of the semicircular canals; 5b. Dysplasia of the vestibule and semicircular 
canals in a left ear, with a malformed vestibule,  shortened and dilated horizontal semi- 
circular canal with small bony island, incomplete formation and dilatation of the posterior 
semicircular canal.
a b
Table 5  Distribution of cochlear types for different types of mutations
Cochlear type Normal IPII1 Hypoplasia 
type III
Hypoplasia 
type IV
Total 49 (61.2%) 7 (8.3%) 3 (3.8%) 21 (26.3%)
Truncating mutations 27 (33.8%) 6 (7.5%) 3 (3.8%) 14 (17.5%)
Non-truncating mutations 22 (27.5%) 1 (1.3%) 0 7 (8.8%)
Number of ears: 80 (patients 12 and 30 excluded); IPII1: incomplete partition type II without enlarged vestibular 
aqueduct or dilated vestibulum;  P = 0.194 (X2)
Table 6  Distribution of semicircular canal malformations for different types of mutations
Defect SCC  
normal
PSCC
dysplasia
SSCC
dysplasia
PSCC  
+ LSCC 
dysplasia
SCCC 
+LSCCC
dysplasia
All  
aplastic
All 
dysplastic
Total 2 (2.5%) 4 (5.0%) 5 (6.3%) 1 (1.3%) 2 (2.5%) 63 (78.8%) 3 (3.8%)
Truncating 0 0 3 (3.8%) 0 0 46 (57.5%) 1 (1.3%)
Non-truncating 2 (2.5%) 4 (5.0%) 2 (2.5%) 1 (1.3%) 2 (2.5%) 17 (21.3%) 2 (2.5%)
Number of ears: 80 (patients 12 and 30 excluded); SCC semicircular canals; PSCC posterior semicircular canal; SSCC 
superior semicircular canal; LSCC lateral semicircular canal; P = 0.004 (X2)
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Cochlear aperture and inner ear (table 2)
In 13 of 31 ears with a stenotic aperture, the cochlea was abnormal (one incomplete 
partitioning type II, three hypoplasia type III, and nine type IV) (table 2, figure 6). 
Surgical challenges
Table 7 summarizes the observed anomalies expecting to be challenging in cochlear 
implant surgery. Figure 7 illustrates the differences in mastoid size between an ear with a 
small mastoid and an ear with a wide mastoid (AP-size).
Phenotypes 
No typical CHARGE phenotype of the temporal bone, i.e. a constant combination of 
several anomalies, could be determined. Some combinations of anomalies which were 
often seen are presented in table 8. More than two-thirds of the patients (68%) had an 
aberrant course of the vestibular aqueduct, and more than two-thirds (77%) had aplasia 
of the SCC. 
Figure 6  Cochlear aperture – axial CT image shows a lacking cochlear aperture
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Table 7  Surgical challenges in cochlear implantation
Surgical step Structure  
on CT
Anomaly Surgical challenge
Mastoidectomy Mastoid Underdeveloped Reduced access to the middle ear
Vascular 
structures
Large emissary vein Unexpected bleeding 
PSS Bleeding, reduced mastoid size
Semicircular 
canals
Aplasia Loss of landmark
Post. 
tympanotomy
Facial nerve More medial route Facilitates entrance to the middle ear
Cochleostomy Ossicles Dysplasia Obstructed vision by the incus
Facial nerve Aberrant route Impedes cochleostomy
Windows Round window 
stenosis
Choosing optimal side for cochleostomy
Jugular bulb High Preparing cochleostomy
Insertion Cochlea Aplasia Insertion 
Post.: posterior; PSS: petrosquamosal sinus
Figure 7   Mastoid size - axial CT images of a small mastoid (a) and a wide mastoid (b); 
both ears had a grommet in situ.
a b
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Genotypes (table 4)
The results of CHD7 analysis were available for all 42 patients. We had 25 patients (50 ears, 
59.5% of 84 ears) with a truncating mutation (of which were 56% nonsense, 20% frameshift, 
4% deletions) and 15 patients (30 ears, 35.7% of 84 ears) with a non-truncating mutation 
(47% missense, 53% splice site). In one patient an unclassified CHD7 variant was detected 
(UV-missense) and in another patient no CHD7 mutation was found. Remarkably, 12/42 
patients did not fully comply with the clinical diagnostic criteria [2]. Of these 12 patients, 
eight had a non-truncating mutation, in one patient no mutation was found, and in 
another only an unclassified variant could be detected in CHD7. Thus, only 2/12 atypical 
patients (16.7%) had a truncating mutation. In contrast, truncating mutations were found 
in 23/30 patients (76.7%) who had clinically typical CHARGE syndrome.
 Because no constant combination of anomalies could be identified, no correlation 
could be made between phenotype and genotype. Nevertheless, of the surgical 
challenging anomalies, SCC aplasia (table 6) and oval window atresia (truncating 72%, 
P=0.001) were found more frequently in patients with truncating mutations than in those 
with non-truncating mutations (P<0.05) (chi-squared test). Cochlear anomalies (table 5), 
petrosquamosal sinus (73% truncating, P=0.679) and an aberrant course of the tympanic 
portion of the facial nerve (67% truncating, P=0.602) were also found more frequently in 
patients with truncating mutations than in those with non-truncating mutations, but 
these results were not significant (chi-squared test).
 The patient without anomalies of the SCC, cochlea and windows, had a non-truncating 
mutation. In contrast, in the group with truncating mutations, there were no patients 
without anomalies of at least one of these structures. 
Table 8  Combinations of anomalies often seen
Anomaly In combination with Number of patients
 (percentage of all patients)
Absent RW Absent OW 12 (14.3%)
Stenotic OW Dysplastic stapes 23 (27.3%)
Aberrant tympanic  
portion facial nerve
Dysplastic stapes 24 (28.6%)
Total SCC hypoplasia OW stenosis 21 (25.0%)
Aberrant VA SCC hypoplasia with SCA SCC 
hypoplasia without SCA
14 (16.7%)
14 (16.7%)
OW: oval window; RW: round window; SCC: semicircular canals; SCA: stenotic cochlear aperture; VA: vestibular 
aqueduct
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Table 4  Mutations
Patient no. Mutation Mutation type Blake/Verloes criteria
1 nonsense truncating positive
2 missense non-truncating negative
3 nonsense truncating positive
4 nonsense truncating positive
5 splice-site non-truncating negative
6 splice-site non-truncating positive
7 nonsense truncating positive
8 missense non-truncating positive
9 splice-site non-truncating atypical
10 splice-site non-truncating atypical
11 missense non-truncating atypical
12 no mutation atypical
13 missense non-truncating negative
14 frameshift truncating positive
15 frameshift truncating positive
16 nonsense truncating positive
17 nonsense truncating positive
18 missense non-truncating positive
19 nonsense truncating positive
20 frameshift truncating positive
21 splice-site non-truncating negative
22 nonsense truncating positive
23 splice-site non-truncating positive
24 nonsense truncating positive
25 frameshift truncating positive
26 frameshift truncating positive
27 frameshift truncating positive
28 missense non-truncating positive
29 frameshift truncating positive
30 UV missense atypical
31 frameshift truncating partial
32 nonsense truncating positive
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Discussion
Analysis of available imaging material and genetic information of the Dutch cohort of 
patients with CHARGE syndrome revealed a great variability in anomalies of the temporal 
bone with possible implications for cochlear implantation.  More anomalies were found in 
patients with truncating CHD7 mutations than in those with non-truncating mutations. 
A shortcoming of this study is the variability in image quality leading to missing values of 
several fine anatomical structures (the imaging data were collected from different 
hospitals). Nevertheless, we were able to analyse the temporal bone and the anomalies, 
and to assess the potential impact on plans for cochlear implant surgery.
 Temporal bone anomalies detected by CT are important when planning an operation. 
Vascular variations, missing anatomical landmarks such as the lateral semicircular canal 
or the vestibular system, an aberrant course of the facial nerve, or stenosis of the round 
window may hamper safe surgical access to the round window. Given our findings, when 
planning CI or ear surgery, care must be taken with regard to the reduced development 
of the mastoid, leading to a smaller access to the middle ear, especially in young children. 
In these cases, an endaural approach instead of a mastoidectomy [7], or a temporary intra- 
operative removal or anterior displacement of the posterior wall of the outer ear canal 
could be considered. Vascular anomalies could also complicate a mastoidectomy, since 
these may cause uncontrollable bleeding during surgery or postoperative thrombosis of 
the sigmoid sinus [8-10]. In our group of CHARGE patients, large emissary veins and a 
persistent petrosquamosal sinus were often present. Whereas emissary veins through the 
temporal squama are a common anatomical variant [11; 12] and easily dealt with during 
Table 4  Continued
Patient no. Mutation Mutation type Blake/Verloes criteria
33 splice-site non-truncating Positive
34 missense non-truncating positive
35 splice site non-truncating Atypical
36 nonsense truncating Positive
37 nonsense truncating Positive
38 frameshift truncating Positive
39 nonsense truncating Positive
40 frameshift truncating Positive
41 nonsense truncating Atypical
42 deletion truncating Positive
UV: unknown variant
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surgery, a persistent petrosquamosal sinus is rare in the general population (Koesling et al. 
[11] estimated this at 1%). However, several authors have reported it to be present in 
11–89% of CHARGE patients [9; 13-15]. The highest incidence was described by Giesemann 
et al. in 2011, in patients who all had aplasia of the SCCs. In our patient population, which 
included patients with partially and fully developed vestibular systems, a persistent 
petrosquamosal sinus was seen in 13%. The persistent petrosquamosal sinus can impede 
the surgical approach, this can be a reason to choose the contra lateral ear for CI.
 SCC aplasia is a hallmark of CHARGE syndrome. CHD7 is highly expressed in the 
developing ear and is required for development of the SCCs. Delayed fusion and altered 
gene expression contribute to SCC defects in CHD7-deficient mice [16]. Currently, the 
presence of SCC abnormalities is considered an important indication for performing 
sequencing of the CHD7 gene and diagnosis [17]. In our study, we found that normal SCC 
were present in only one patient. However, during mastoidectomy, the lateral SCC serves 
as an important anatomical landmark, so the appearance of the SCCs, ranging from 
complete absence of all canals to normal development, should be meticulously described 
[7; 13]. In case of a lateral SCC aplasia, the tegmen serves as an paramount marker to direct 
the surgeon towards the antrum. Anomalies of the SCCs were associated with hypoplasia 
of the vestibule and a shortened vestibular aqueduct coursing straight to the posterior 
fossa. This confirms what was reported by Morimoto et al.: ‘An aberrant course of the 
vestibular aqueduct is hypothesized to be the result of semicircular aplasia and the 
associated displacement of normal surrounding structures’ [9].
 The facial nerve is another structure at risk during cochlear implantation. As described 
in the literature, the facial nerve often showed an aberrant course in its tympanic or 
mastoidal portion [9; 13; 18]. The more medial course of the mastoidal portion of the facial 
nerve allows a surgeon to create a wider entrance to the middle ear (through a posterior 
tympanotomy). However, the aberrant course of the tympanic segment of the facial 
nerve, in particular when it covers the round window, may complicate creating the 
cochleostomy for intracochlear insertion of the cochlear implant. The aberrant facial nerve 
may be at risk of injury during cochleostomy [19] or may even be a reason to abort the 
implantation [20]. The association we observed of an aberrant course of the facial nerve 
with dysplastic stapes and absence of the oval window was described by Zeifer et al. in 
different aetiologies without CHARGE syndrome [21]. 
 Absence or stenosis of the oval window was present in more than two-thirds of our 
patients and is a well-known feature in CHARGE syndrome [9; 13; 22; 23]. Stenosis or 
absence of the round window was seen less often (as confirmed in the literature). Yet this 
poses an additional challenge for the surgeon in choosing the optimal site for a 
cochleostomy.
 The size and shape of the cochlea will influence the choice of CI-type. According to 
the literature, the cochlea is dysplastic in between 20-100% of the ears described in 
patients with CHARGE syndrome [9; 18; 24; 25]. The anomalies vary from a fused second 
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and apical turn to a cochlea with 1.5 turns [26-28]. We describe several cases with a 
shortened cochlea despite the presence of a basal, second and apical turn (referred to as 
hypoplasia type IV). To the best of our knowledge, this cochlear appearance has not been 
described in CHARGE syndrome before, but it appears to be consistent with the description 
of cochlear hypoplasia type IV in a recently published study by Sennaroglu [29] or may be 
comparable with the flattened cochlea observed by Elmaleh et al. [30] in patients with 
Waardenburg syndrome. However, the other temporal bone anomalies described in 
Waardenburg syndrome, besides SCC aplasia and the flattened cochlea, differ from our 
findings. 
 Both this cochlear anomaly, as well as the IPII and hypoplasia type III found in this 
study, should not cause any problems for the insertion of an electrode array as opposed 
to more severe malformations [31; 32]. The successful outcome of a cochlear implantation 
also depends on the presence of the cochleovestibular nerve. 
 In our phenotype-genotype analysis we showed that total aplasia of the SCC and 
oval window aplasia is more common in patients with truncating mutations than in those 
with non-truncating mutations– in agreement with the results of Corsten-Janssen et al., 
showing more anomalies in patients with truncating mutations [33]. Remarkably, the 
distribution of mutations present in our cohort differs from that reported for large cohorts 
in the literature. Our percentage of patients with non-truncating mutations (splice-site 
and missense) was relatively high with 35.7% in comparison to Zentner et al. [5] and to 
Janssen et al. [4] who reported 23% and 20% of patients with non-truncating mutations, 
respectively. This discrepancy might be because a CT is often used in mildly affected 
patients to check the semicircular canals and to provide further proof for the clinical 
diagnosis. Our cohort might be enriched with more mildly affected patients (12/42), and 
thus of missense mutations.
In general, we conclude that temporal bone findings in patients with CHARGE syndrome 
vary widely and should therefore be studied meticulously before performing any surgery. 
Imaging may exclude patients from cochlear implantation or reveal an aberrant course of 
the facial nerve , vascular and middle ear abnormalities that could complicate CI surgery. 
Such information is valuable and should be combined with records on the developmental 
and behavioural problems that are also common in CHARGE syndrome. Moreover, patients 
with CHARGE syndrome often have post-surgical complications due to their neurological 
and anatomical abnormalities [34]. A balance between the benefit of CI, the surgical 
procedure’s chance of success, and the anaesthetic risks should be sought by a multi- 
disciplinary team working with the patient and his/her family. 
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Appendix A  Radiologic criteria for the os petrosum in patients with CHARGE syndrome
Mastoid and vascular structures
Mastoid Observation: pneumatisation of one or more cells 
Measurement: AP size: minimal distance from external meatus wall to 
sigmoid sinus taken at the middle of the meatus in the axial plane.
Measurement: LM size: minimal distance from cortex to sinus at the most 
anterior border of the sinus perpendicular to the mastoid AP size.
Emissary veins
Jugular bulb
Observation: emissary veins through temporal squama, persistent 
petrosquamosal sinus [13] 
Measurement: >1 mm and <1 mm
Observation: high if at the level or cranial of the round window in axial 
plane
Middle ear
Ossicles
Windows
Facial nerve
Observation: dysplasia
Observation: stenotic
Observation: normal with present SCC: in transverse plane caudal of the 
LSCC and lateral and superior of the oval window. In coronal plane lateral 
and medial of the SCC.
Normal with absent SCC: coronal plane cranial of the oval window, 
posterior of the axis of the basal turn of the cochlea at the level of the 
anterior rim of the round window.
Cochlear vestibular system
Cochlea
SCC
Vestibulum
Vestibular aqueduct
IAC 
Cochlear aperture
Nerves in IAC
Measurement: angle basal turn and midline skull (54.6 degrees (range 
46.8–63.8 degrees; standard deviation, 3.5) [24] 
Observation: dysplasia [31] with separate judgment of modiolus. 
Absent, dysplastic, normal
Measurement length: maximum longitudinal extension, width maximum 
transversal diameter, perpendicular to the length.[22] (normal (6.18-6.42) 
x (3.44-3.59) mm, interval) 
Measurement: diameter at midpoint (normal 1.5-2 mm)
Observation: course
Measurement: Midline in axial plane(normal 2-8 mm)
Observation: present or bony stenosis
Observation on MRI: normal, hypoplastic or aplastic
AP anterior-posterior; LM lateral-medial; SCC semicircular canal; LSCC lateral semicircular canal; IAC internal 
auditory canal
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Appendix B  Radiologic set of criteria for CT scan
Name Observer
Date
ID scan
Quality Image  good
 moderate
 bad
Item AD AS
Cochlea –
External contours: 
2.5 turn?
 yes
 no
 unable to identify
 yes
 no
 unable to identify
Cochlea internal:
Interscalar septa present?
 yes
 no
 unable to identify
 yes
 no
 unable to identify
Modiolus  present
 absent
 unable to identify
 present
 absent
 unable to identify
Angle of basal turn
Cochlear aperture:
Is an aperture visible?
 yes
 no
 unable to identify
 yes
 no
 unable to identify
Internal Auditory Canal
(mm)
Notes Cochlea
PSCC  normal
 aplastic
 dysplastic/hypoplastic
 unable to identify
 normal
 aplastic
 dysplastic/hypoplastic
 unable to identify
SSCC  normal
 aplastic
 dysplastic/hypoplastic
 unable to identify
 normal
 aplastic
 dysplastic/hypoplastic
 unable to identify
LSCC  normal
 aplastic
 dysplastic/hypoplastic
 unable to identify
 normal
 aplastic
 dysplastic/hypoplastic
 unable to identify
SCC – NOTES
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Appendix B  Continued
Item AD AS
Vestibulum Length  
(mm)
Vestibulum width  
(mm)
Vestibular Aqueduct Diameter 
(mm)
Vestibular Aqueduct Course  normal 
 aberrant
 unable to identify
 normal 
 aberrant
 unable to identify
Vestibular aqueduct – NOTES
Oval window  present
 absent/stenotic
 unable to identify
 present
 absent/stenotic
 unable to identify
Round window  present
 absent/stenotic
 unable to identify
 present
 absent/stenotic
 unable to identify
Windows – NOTES
Stapes  normal
 dysplastic
 unable to identify
 normal
 dysplastic
 unable to identify
Incus  normal
 dysplastic
 unable to identify
 normal
 dysplastic
 unable to identify
Malleus  normal
 dysplastic
 unable to identify
 normal
 dysplastic
 unable to identify
Ossicles – NOTES
Facial nerve tympanic segment  Normal
 aberrant
 unable to identify
 Normal
 aberrant
 unable to identify
Facial nerve tympanic segment 
– NOTES
Facial nerve mastoid segment  Normal
 aberrant
 unable to identify
 Normal
 aberrant
 unable to identify
Facial nerve mastoid segment 
– NOTES
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Appendix B  Continued
Item AD AS
Mastoid AP-size 
(mm)
Mastoid LM-size 
(mm)
Mastoid pneumatisation?  yes
 no
 unable to identify
 yes
 no
 unable to identify
Jugular Bulb  normal
 high
 unable to identify
 normal
 high
 unable to identify
Emissary veins  absent
 <1 mm
 >1 mm
 unable to identify
 absent
 <1 mm
 >1 mm
 unable to identify
Petrosquameuse sinus  absent
 present
 unable to identify
 absent
 present
 unable to identify
Vascular structures NOTES
NOTES overall
PSCC posterior semicircular canal; SSCC superior semicircular canal; LSCC lateral semicircular canal; SCC semi- 
circular canal; AP anterior-posterior; LM lateral-medial
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Influence of hearing loss and  
cognitive abilities on language development  
in CHARGE syndrome
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Abstract
Objectives
Hearing loss and cognitive delay are frequently occurring features in CHARGE syndrome 
that may contribute to impaired language development. However, not much is known 
about language development in patients with CHARGE syndrome.
Materials and Methods
In this retrospective study, hearing loss, cognitive abilities and language development are 
described in 50 patients with CHARGE syndrome. After informed consent was given, data 
were collected from local medical files.
Results
Most patients (38.3%; 18/47 patients) had moderate hearing loss (41-70dB) and 58.5% 
(24/41 patients) had an IQ below 70. The mean language quotients of the receptive and 
expressive language were more than one standard deviation below the norm. Both 
hearing loss and cognitive delay had an influence on language development. Language 
and cognitive data were not available for all patients, which may have resulted in a pre- 
selection of patients with a delay.
Conclusion
In conclusion, while hearing thresholds, cognitive abilities and language development 
vary widely in CHARGE syndrome, they are mostly below average. Hearing loss and 
cognitive delay have a significant influence on language development in children with 
CHARGE syndrome. To improve our knowledge about and the quality of care we can 
provide to CHARGE patients, hearing and developmental tests should be performed 
regularly in order to differentiate between the contributions of hearing loss and cognitive 
delay to delays in language development, and to provide adequate hearing amplification 
in the case of hearing loss.
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Introduction
Hall was the first to note that choanal atresia could be accompanied by a specific set of 
multiple anomalies [1]. In 1981, Pagon et al. first used the acronym ‘CHARGE’ to describe 
the association of Coloboma, Heart disease, Atresia of the choanae, Retarded growth and 
development and/or CNS anomalies, Genital hypoplasia, and Ear anomalies and/or 
deafness [2]. Because of increased knowledge about the syndrome, Blake revised this 
definition in 1998 into major and minor characteristics [3]. The major characteristics, which 
are the features that occur commonly in the then-called CHARGE association but rarely in 
other conditions, include coloboma, choanal atresia, cranial nerve involvement and ear 
abnormalities. The minor characteristics, which occur less frequently or are less specific, 
include cardiovascular malformations, genital hypoplasia, cleft lip/palate, tracheoesopha-
geal fistula, distinctive CHARGE face, growth deficiency and developmental delay. In 2005, 
Verloes suggested changes to the diagnostic criteria, as shown in table 1 a, b [4]. In 2004, 
the causative gene was identified as CHD7 on chromosome 8q12.1 [5] and the name 
changed to CHARGE syndrome (MIM, Mendelian Inheritance in Man, 214800).
 The presentation of the syndrome can be very diverse, with most patients showing a 
variable combination of multiple congenital anomalies. Hearing loss and cognitive delays 
are frequently described in CHARGE syndrome [6, 7]. Hearing loss, present in 80-100% of 
the patients, is the most common characteristic and can be due to anatomical anomalies 
of the middle or inner ear, to aplasia or hypoplasia of the cochlear nerve, or to middle ear 
disease. As a consequence, hearing in CHARGE syndrome can range from normal to 
profound deafness [3, 6, 8]. As one of the minor characteristics, delayed cognitive abilities 
are also often described in CHARGE syndrome. The delay in cognitive development varies 
and is rarely expressed in ‘Intelligence Quotient’ (IQ), but is based instead on developmental 
age, abilities and educational level. More than 50%, and possibly up to 75%, of patients 
have an intellectual development below average [9-13]. Little is known about language 
development in this group of patients, but language delays have been described [13]. One 
might argue that intellectual disability and hearing loss, or the combined presence of 
both, may have a strong influence on language development. Thus language development 
needs special attention in this vulnerable group of children with CHARGE syndrome, a 
finding further supported by Thelin, who found that parents rank hearing loss as the 
factor with the largest effect on the ability of their child to communicate [14].  
 The aim of this study is twofold. Firstly, we aim to improve our knowledge of hearing 
loss, cognitive ability and language development in a large group of patients with CHARGE 
syndrome. Secondly, we want to establish an indicative dataset for a group of patients 
with multiple needs by analyzing the relationship of both hearing loss and cognitive 
abilities with language development.
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Patients and methods
In this retrospective study, the data of patients registered at the Dutch CHARGE centre of 
expertise (University Medical Centre Groningen, the Netherlands) were used after written 
informed consent was obtained from patients or their legal representatives. 
 Patients who received a cochlear implant (CI) were excluded because the language 
development of patients with CI is the topic of a separate study. Data from the present 
study can be used as reference data for the evaluation of the results of language 
development in patients with CHARGE syndrome and CI. 
Table 1  Characteristics of CHARGE syndrome
1a. Major and minor signs of CHARGE syndrome [4]
Major signs
Coloboma (iris or choroid, with or without microphthalmia)
Atresia of choanae
Hypoplastic semicircular canals
Minor signs
Rhombencephalic dysfunction (brainstem dysfunctions, cranial nerve VII to XII palsies and 
neurosensory deafness)
Hypothalamo-hypophyseal dysfunction (including GH and gonadotrophin deficiencies)
Abnormal middle or external ear
Malformation of mediastinal organs (heart, esophagus)
Intellectual Disability
1b. Definition of typical, atypical, and partial CHARGE syndrome [4]
Typical CHARGE syndrome
3 major signs
2/3 major signs + 2/5 minor signs
Partial/incomplete CHARGE
2/3 major  signs + 1/5 minor signs
Atypical CHARGE
2/3 major  signs + 0/5 minor signs
1/3 major signs  + 3/5 minors signs
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In total 56 patients (or their legal representatives) gave permission for the use of their data. 
Fifty-one patients had molecularly confirmed CHARGE syndrome (CHD7 mutation). 
The patients were classified according to Verloes’ criteria (table 1) [4]. Five patients who 
had no molecular confirmation were excluded. One other patient was excluded because 
of a lack of audiometric, cognitive and language data. For all 50 patients included, audio - 
metric data were available. For 41 of these patients, cognitive data were available and 
for 22 patients language data were available (figure 1). The study group was divided into 
two groups: group A without language developmental data and group B with available 
language data. Data were obtained from medical records available in hospitals, Audiologic 
Centres and institutes for children with hearing problems and intellectual disability.  
Figure 1  Patient selection
The numbers are the absolute numbers of patients. White: patients described in the study; 
light grey: excluded patients.
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Audiometric data
For 45 patients a tone audiogram was available (headphone or free-field). Per patient, 
between one and eight tests were available (mean 3, median 2). The average hearing loss 
at 0.5, 1 and 2 kHz (Pure Tone Average or PTA) of all available tests of the best ear was used. 
In five cases, only the objectively obtained hearing thresholds (Brainstem Evoked Response 
or BER) had been carried out; in these cases, the BER thresholds were used for the analysis. 
On the basis of the PTA or the BER thresholds, patients were categorized as normal hearing: 
threshold 0-20 dB; mild hearing loss: 21-40 dB; moderate hearing loss: 41-70 dB; severe 
hearing loss: 71-90 dB; or profound hearing loss: >90 dB. For the analysis, ‘functional 
hearing thresholds’ were used, including the ‘aided PTA’ in patients using hearing aids and 
the ‘unaided PTA’ in patients who did not use hearing aids. The patients using hearing aids 
were excluded from the analysis if the aided thresholds were unknown. Speech perception 
was measured by the NVA lists, a standardized Dutch monosyllable test [15].
Cognitive ability tests 
Cognitive data were available for 41 patients. The cognitive ability tests used in our cohort 
were validated intelligence tests in which the use of spoken or written language is not 
necessary. These tests are especially suitable for children and adults with language 
disabilities, like hearing impaired patients, or patients with autism or intellectual disability. 
The standardized tests used included the Dutch version of the Bayley Scales of Infant 
Development (BSID-NL-II) [16] and the Dutch version of the Wechsler Intelligence Scale for 
Children Revised and Third edition (WISC-RN and WISC-III-NL)[17, 18]. 
 When longitudinal data were available, data from the most recent evaluation were 
used. Based on the non-verbal-IQ outcome or the developmental age, we categorized 
the patients into low IQ <70, subnormal IQ 70-85, normal IQ 86-115, and above average IQ 
>115. The developmental age was scaled in retrospect by psychologists skilled in assessing 
hearing impaired children using an informal procedure. In patients without available 
cognitive data, the school type was used in the descriptive analysis. 
 Both audiometric and cognitive data were categorized to observe the distribution 
among the patients and to filter small measurement differences. 
Language development tests
Standardized age- and capacity-related tests were used, this was generally the Dutch 
version of the Reynell Developmental Language Scales [19], but any other standardized 
test was used if available. All tests are well validated and with available norms. Scores of 
these tests can be expressed as a standard score, percentile or an age-equivalent score. In 
case of longitudinal data, the data of the most recent evaluation of each patient were 
used. Both receptive and expressive language subtests were used. We express the 
language development in Language Quotient (LQ = age equivalent/chronological 
age*100). 
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Statistical analysis
SPSS 20 was used to collect all data and perform statistics. We made use of the Spearmans’ 
correlation test to test for significant correlations. 
Results
The study group consisted of 50 patients, 32 male and 18 female. Of all patients, 33 patients 
had typical CHARGE syndrome, four patients had atypical CHARGE syndrome, one patient 
had partial CHARGE syndrome and six did not meet the criteria. For six other patients it 
was not possible to score them for the Verloes criteria[4]. 
Audiometric data
Audiometric data were available for all 50 patients. The mean age at the most recent 
audiometric test was 10.9 years (median 9; minimum 5 months; maximum 48 years, SD 10.4). 
Table 2  shows the hearing threshold classification of the best ear. For three patients, only 
aided thresholds were retrievable, meaning they could not be included in the unaided 
threshold classification. For eight patients, no aided thresholds were available. The majority 
(83.0%) of the patients had hearing loss and were equally divided among the various 
categories (between 10.6 and 19.2%), with the exception of the group of patients with 
moderate hearing loss, who make up 38.3%. Of the total study group, 29 patients used 
hearing aids (including three bone-anchored hearing aid users), which resulted in better 
hearing thresholds that we further refer to as “functional hearing thresholds”. Ten patients 
wore no device due to refusal, recurrent infections (with moderate/severe hearing loss) 
or poor auditory responses. In four patients with poor auditory responses, CI had been 
considered but rejected because of cochlear nerve hypo-/ aplasia or surgical risks.
Cognitive abilities
Cognitive developmental tests were available for 41 patients. Table 3  shows the distribution 
of cognitive levels within the group. The mean age of the patients at the time of the 
cognitive developmental tests was 10.5 years (median 9; minimum 1; maximum 56 years; 
SD 9.7). The majority of the patients (58.5%) had an IQ below 70. Nine patients were 
excluded from table 3: for the four patients who attended mainstream schools, no 
cognitive tests were conducted; for five other patients, no cognitive development tests 
were available and the school type was unknown. 
Group A (patients without data on language development) 
For 28 patients, no language development data were available. Their characteristics are 
shown in table 4. Four patients for whom only audiometric data were available were 
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excluded from this table. Five patients attended or have attended mainstream schools in 
childhood and no language development tests had been conducted with them, but we 
assumed that they communicated in spoken language. All five patients had a CHD7 
mutation, but none fulfilled the CHARGE criteria according to Verloes [4].
 In ten patients, no language tests were performed because they had very limited 
spoken language levels. They had insufficient communication skills and communicated 
with pictograms, signal behavior and finger spelling. All of these patients had an IQ below 
70 and moderate to severe functional hearing thresholds. All ten patients fulfilled the 
CHARGE criteria according to Verloes [4]. 
 For nine patients, there was no information available on language development or 
educational level. The cognitive abilities of these patients range from normal to low. 
Of these nine patients, one patient (ID 51), did not meet the Verloes’ criteria [4], for one 
patient (ID 22) this was unknown and one had atypical CHARGE syndrome (ID 6). 
Table 2  Hearing thresholds
Category 
hearing threshold
Unaided
N %
Functional
N %
Normal (0-20dB) 8 16.6 9 20.9
Mild (21-40dB) 6 12.5 13 30.2
Moderate (41-70dB) 18 37.5 13 30.2
Severe (71-90dB) 9 18.8 3 7.0
Deaf (>90dB) 7 14.6 5 11.7
Total 48 100 43 100
No unaided/aided data available 31 82
N: number of patients; 1 aided, no unaided data; 2 aided, but no aided data available.
Table 3  Cognitive abilities
IQ N %
Above average (IQ>115) 0 0
Normal (IQ=86-115) 10 23.8
Subnormal (IQ70-85) 8 19.0
Low (IQ<70) 24 57.2
Total 42 100
No data available 9
N: number of patients, IQ: Intelligence Quotient.
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Group B (language data)
Table 5 presents group B, comprising the 22 patients with complete records, except for 
three patients (ID 17, 23 and 54) using hearing aids, but without known aided thresholds, 
and one patient (ID15) whose cognitive abilities are unknown. At the most recent 
evaluation of the language development, the age of the patients varied between one and 
Table 4  Characteristics of Group A (patients without language developmental tests)
ID Cognitive 
ability
Functional 
hearing 
threshold
Speech 
perception
Language 
development
Comments
26 Normal Normal 100% 50dB Mainstream school
6 Normal Moderate* 85% 80dB aided No info HA
22 Normal Moderate 50% 65dB No info HA
51 Normal Moderate* 95% 55dB aided No info
4 Subnormal Mild No info
14 Subnormal Moderate No info HA
49 Subnormal Normal No info
28 Subnormal Deaf No info No HA
8 Low Moderate Very limited HA not accepted
24 Low Moderate Very limited HA
25 Low Moderate Very limited BAHA
29 Low Severe Very limited No HA, because poor 
auditory performance
31 Low Severe  Very limited Started with CI evaluation
36 Low Deaf Very limited NvIII aplasia
37 Low Deaf Very limited HA
43 Low Deaf Very limited No HA because recurrent 
otitis
45 Low Deaf Very limited Parents canceled CI
52 Low Severe Very limited HA
42 Low Deaf No info nVIII hypoplasia
34 Low Mild No info BAHA
39 No test Mild Mainstream school
48 No test Normal 100% 55dB Mainstream school
50 No test Normal Mainstream school
18 No test Normal Mainstream school
Number of patients: 24; HA: hearing aid; BAHA: bone anchored hearing aid; * aided but no data; 4 patients 
excluded with only audiometry available.
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25 years, with a mean of 7.1 years (median 4.5; SD 6.7). In one patient, the receptive 
language age was age adequate; this patient had no hearing loss and normal cognitive 
abilities. One patient achieved better scores than expected for his age with subnormal 
cognitive abilities (IQ 75-85). The remaining patients scored below the age equivalent 
scores. 
 The mean receptive language quotient of the 22 patients was 59.7 and the median 
was 62.0 (SD 28.47). Both the mean and the median were close to two standard deviations 
below the norm (85). The mean and median of the expressive language quotient (14 patients) 
were also more than one standard deviation below the norm, with 70.5 and 69.2 (SD 22.5), 
respectively. Cognitive abilities in this subgroup were normal in 22.7% of patients (5/22), 
subnormal in 22.7% (5/22) and low in 50% (11/22). The functional hearing thresholds varied 
from normal to deaf, with 50% of patients (11/22) showing moderate hearing loss. Patients 
with restricted spoken language scores used other modes of communication like sign 
language or sign-supported spoken language.
 Two patients had ‘atypical CHARGE’ (ID 3, 23), three did not fulfill the Verloes criteria 
(ID 5, 54, 57) and one patient could not be scored (ID 20). 
Relationship between hearing loss, cognitive abilities and  
language development
Of the 22 patients in group B, four patients were excluded: three because of unknown 
aided thresholds, and one because of missing cognitive abilities. In the remaining 18 patients, 
the following significant correlations were found: between receptive language quotient 
and degree of functional hearing loss (Spearman p 0.006, r2 -0.622); between receptive 
language quotient and cognitive abilities (p 0.038, r2 0.493); and between expressive 
language quotient and degree of functional hearing loss (p 0.001, r2 -0.845). No significant 
correlation was found between expressive language quotient and cognitive abilities 
(p 0.651, r2 0.154), and between cognitive abilities and hearing loss (p 0.310, r2 -0.246). 
Figure 2 and figure 3 show that the receptive language quotient and the expressive 
language quotient decrease with an increase of functional hearing thresholds in patients 
with normal or subnormal cognitive abilities. 
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Figure 2  Receptive language quotient
Figure 3  Expressive language quotient
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Discussion
The present study gives an overview of hearing loss, cognitive abilities and language 
development of a cohort of Dutch patients with CHARGE syndrome. Large variability is 
shown, but the majority of the patients had moderate hearing loss and cognitive abilities 
were below average in slightly over half of the patients. Both hearing thresholds and cognitive 
abilities influenced language development, resulting in delayed language development. 
 The range in hearing loss in the whole study group (60-90% had moderate to total 
hearing loss) corresponds with that reported for CHARGE syndrome in the literature [6, 10, 
20]. Some patients had unaided hearing loss because of recurrent otitis media, refusal of 
hearing aids or fitting problems because of the shape of the auricle or poor auditory 
responses. Alternatives to conventional hearing aids, like a bone anchored hearing aid and 
CI, were considered in these patients. These difficulties in adequate hearing amplification 
were also described by Thelin and Fussner [14] and show that it can be challenging to give 
the optimal therapy in children with CHARGE syndrome. Based on our results, we 
emphasize the importance of early screening and follow up of the hearing thresholds in 
order to begin adequate hearing revalidation as soon as possible because hearing loss has 
a big impact on language development.
 Comparing the outcome of cognitive abilities with the literature is difficult because of 
the different tests and the different definitions of levels of cognitive ability that were used. 
The distribution of patients with subnormal or low cognitive abilities in our study (78%) is 
slightly higher compared with results from other studies [9, 11, 21], possibly due to our 
exclusion, of patients attending mainstream schools with an assumed average cognitive 
abilities. Factors like behavioral problems (autism, obsessive-compulsive disorders, tics, 
attention deficits disorders) frequently described in CHARGE syndrome [22-24] were not 
intensively studied in the present study, but could influence development, making this a 
topic for further research. 
 In ten patients, no language developmental data could be gathered because their 
receptive language was highly delayed due to their cognitive delay. These patients 
suffered from severe hearing loss and severe cognitive developmental delays. For the five 
patients with mild or no hearing loss who had attended mainstream schools, we assume 
they had normal language development because of the educational level of mainstream 
schools. A possible explanation for this is that developmental tests are normally not 
applied at mainstream schools.  
 To the best of our knowledge, the language development in a cohort of patients with 
CHARGE syndrome has not been previously described in this detail. In group B the majority 
had language development and cognitive abilities more than one standard deviation 
below the norm, suggesting that IQ and LQ are broadly similar, confirmed by the significant 
correlation of cognitive abilities and receptive language quotient. This is in line with 
Santoro et al. who showed  that cognitive developmental delay has a significant impact 
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on communication, even if the expressive communication skills are preserved [25]. No 
significant correlation of cognitive abilities and expressive language quotient was found. 
Particularly patients with lower cognitive abilities did not show expressive language 
quotients and could not be included in the calculations, probably causing a bias. In this 
study we also show that patients with CHARGE syndrome with lower functional hearing 
thresholds reach lower levels of language development. 
 A shortcoming of this study is the variability in data sources. Data were collected from 
different professionals and institutions, leading to missing language and cognitive 
developmental testing data. Despite these problems, enough data were gathered to give 
an impression of the hearing loss, cognitive development and language development 
and to do an analysis of the impact of hearing loss and cognitive development on 
language development in CHARGE syndrome in, as far as we know, the largest group of 
CHARGE patients in which this has been described. 
 The tests described in the group B patients were probably conducted for a specific 
reason such as a delay in cognition and/or language development, that made knowledge 
about the patient’s development necessary for, for instance, educational advice. Reasons 
for non-availability of the tests could be: patient unable to perform the test, patient 
performing at average levels with no reason to be tested, or tests had been conducted 
but were no longer available. In addition, patients with CI were omitted from the 
descriptive analysis. It is possible that the group with available cognitive (and language) 
data represented a pre-selection of patients with a developmental delay by excluding 
those too well-performing to have tests done and those too poor-performing to 
participate in language tests. If this was the case, the results of this study may not reflect 
the entire population of patients with CHARGE syndrome, but are biased towards to the 
more moderate group. In the future this could be resolved by performing a standard 
language and cognitive developmental test with every CHARGE syndrome patient. 
Although some parents of patients think the abilities of their children are underestimated 
by most standard tests [14], a standardized collection of data is still needed to analyse the 
properties of CHARGE syndrome and to improve care for these patients. 
 In general we can conclude that the auditory abilities, cognitive abilities and language 
development in CHARGE syndrome vary widely, but are mainly below average. Therefore, 
these children should be tested regularly with respect to auditory and cognitive development 
in order to be able to differentiate between the contributions of hearing loss and cognitive 
delay to delays in language development. This is especially critical for hearing loss because 
it has great impact on language development and adequate amplification is therefore 
important. 
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Abstract 
Objectives
Identifying aspects for establishing cochlear implantation guidelines for patients with 
CHARGE syndrome . 
Material and Methods
In this explorative retrospective study, the challenges and benefits of cochlear implantation 
were described of ten patients with CHARGE syndrome.  They  received a cochlear implant 
between 2002 and 2012 in one of the cochlear implant centres of tertiary referral centres 
in the Netherlands.  Imaging and surgical findings, language development and Quali-
ty-of-life (QoL), were compared with two control groups: (1) 34 non-syndromic CI-users 
and (2) 13 patients with  CHARGE syndrome without CI because of sufficient hearing.
Results
Subjective and objective audiometry and MRI were necessary to confirm the presence of 
the cochlear nerve. Surgery in CHARGE syndrome was challenging due to enlarged 
emissary veins, semi-circular-canal aplasia, aberrant facial nerve and dysplastic cochlear 
windows, making CT indispensable in surgical preparations. No major intra-operative 
complications occurred. Despite additional handicaps, all patients showed auditory 
benefit and improvement in disease-specific QoL. Patients implanted at a relatively 
young age (≤37 months) followed by a long period of CI-use (>five years) and with minor 
additional problems, developed spoken language at a basic level comparable to that of 
the control group of CHARGE syndrome patients. 
Conclusion
A CI should be considered in all patients with CHARGE syndrome and severe sensorineural 
hearing loss. A careful work-up is required, comprising CT, MRI, objective and subjective 
audiometry and assessment by a specialized multidisciplinary team. Cochlear implantation 
in CHARGE syndrome might be complicated by syndrome-related temporal-bone 
anatomy, and the outcome of the CI is more individually determined. Early implantation 
should be aimed for. 
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Introduction 
Cochlear implants (CI) have become instrumental in the treatment of children and adults 
with severe or profound sensorineural hearing loss. Based on the positive results with CI in 
patients with isolated deafness, the criteria for implantation have gradually become less 
strict, allowing patients with additional handicaps, including patients with cognitive delay, 
to undergo implantation [1].
 Patients with CHARGE syndrome fall within the group of patients with complex 
needs. Their major features are ocular coloboma, choanal atresia, heart defects and aplasia 
of the semicircular canals (SCC) [2]. Hearing loss is one of the most common features seen 
in CHARGE syndrome and is present in 60-90% of patients [3, 4]. CI can be a solution in 
these patients if conventional hearing aids or bone-anchored hearing aids do not provide 
them with optimal hearing abilities [5-10]. 
 Cochlear implantation in CHARGE syndrome is not without challenges. One of the 
features seen in CHARGE syndrome is deficiency of the cochlear nerve [11].  The surgical 
procedure may be complicated by anatomical anomalies of the petrosal bone including a 
narrow mastoid, an aberrant course of the facial nerve, absent SCC, absent or covered 
cochlear windows and/or a dysplastic cochlea [9]. In addition, development of speech and 
language after implantation may be difficult because of cognitive disabilities or physical 
handicaps [6-10]. Despite the reduced development of speech and language, most CHARGE 
patients with cognitive disabilities showed more responsiveness and receptiveness to the 
world around them after implantation [6-10]. 
 The aim of this study is to identify factors to be considered when establishing cochlear 
implantation guidelines for patients with CHARGE syndrome by giving an overview of the 
challenges and benefits encountered with cochlear implantation in these patients. We 
describe the pre-operative imaging, surgical findings and the results of spoken language 
development and quality-of-life (QoL) after implantation. Our results are compared with 
those of non-syndromic patients with CI and with those of patients with CHARGE 
syndrome with normal hearing or successfully fitted with conventional hearing aids. 
Patients and Methods
Participants
In this exploratory retrospective study, the databases of contributing CI-centres in the 
Netherlands were searched for data from patients with CHARGE syndrome who received 
a CI. One patient was implanted in Belgium. Ten patients were included who underwent 
implantation between 2002 and 2012. All ten patients had molecularly confirmed CHARGE 
syndrome and clinically typical CHARGE syndrome according to the Verloes criteria [2]. 
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All patients were pre-operatively assessed by a multidisciplinary team consisting of an 
otologic surgeon, an audiologist, a speech therapist and a psychologist. The radiological 
and medical data of the ten patients were reviewed and analysed after informed consent 
was obtained from the patients and/or their parents according to Dutch legislation. 
 Language data and QoL data of the study group were compared with data that was 
already available for a control group of patients with unilateral CI and without co-morbidity 
who were implanted at the Radboud University Medical Centre Nijmegen. This control 
group consists of 34 prelingual deaf patients with an IQ above 85. The etiology of hearing 
loss in these patients is genetic/hereditary (14 patients) or unknown (20 patients). Patients 
with hearing loss caused by meningitis or a syndrome were excluded. This group is 
hereafter referred to as ‘non-syndromic CI-users’. 
 Language development in our study cohort is also compared with a second control 
group consisting of 13 patients with CHARGE syndrome with adequate hearing, with or 
without hearing aids, and with an IQ below 85. These patients have been described in 
more detail in a previously published paper [12].  
Imaging
All patients had a pre-operative CT of the petrosal bone, and all but one patient had a MRI 
of the inner ear. The radiologic data of nine patients have been described previously [13].
Cognitive data
Non-verbal IQs were obtained by validated tests suitable to the ages and abilities of 
the patients using the Dutch versions of either the Bayley Scales of Infant Development 
(BSID-NL-II[14]), the Snijders Oomen non-verbal intelligence test (SON-R [15]) or the Kent 
Infant Development Scale (KID-N[16]). 
Audiological data
Objective hearing thresholds were obtained pre-operatively by Brainstem Evoked Response 
Audiometry (BERA). Pure tone audiometry and speech perception tests were done 
pre-implantation and at 12, 24, 36, 60 months and ten years post-implantation. Speech 
perception was measured by the NVA-test, a standardized Dutch monosyllable test [17]. 
The communication mode was observed at the evaluation moments and classified as 
body- or sign language or spoken language with or without sign support.
Language development
Language data were collected at the same standard evaluation moments as the 
audiological tests. Depending on the age and abilities of the patients, the following tests 
were conducted: the NNST (Dutch Non-speech Test) [18], the Reynell test [19], the Taaltest 
voor Kinderen [20] (Dutch language test), the Peabody Picture Vocabulary [21] and the 
Schlichting test [22]. For each test, the ‘language age’ was used as the outcome variable. 
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Quality of Life
Three standardized parent-proxy questionnaires were used to evaluate the QoL. 
The questionnaires were completed using a 5-point Lickert scale. The Glasgow Children’s 
Benefit Inventory (GCBI [23]) is a disease-specific QoL-questionnaire developed for different 
interventions in otorhinolaryngology. The Nijmegen Cochlear Implant Questionnaire 
(NCIQ [24]) is a disease-specific questionnaire for CI-users. The PedsQL [25] measures 
general health-related-QoL in children and adolescents. 
Data analysis
SPSS 20.0 was used for statistical analysis. Descriptive statistics were used to define the 
baseline characteristics. The effect of CI on QoL was statistically analysed using multiple 
linear regression. 
Results 
Patient characteristics
Table 1 shows the characteristics of the study group. All patients were congenitally deaf 
and had cognitive abilities below average (IQ<85). Patient 4 was known to have autistic-like 
behavior, while no behavioral problems were reported in the other patients. For patient 3 
and 6, only psychological observation was available, no cognitive test results. Six patients 
had coloboma, causing limited vision in three patients (5, 6 and 8), while patient 7 was 
suspected to have a limited vision but could not be tested. With the exception of patient 
6, all patients had repeated major surgery prior to cochlear implantation (choanal, cardiac 
or cleft lip/palate surgery) compared to the control group in which 11 of 34 patients had 
only minor surgery (grommets and/or adenotomy). 
 The implantation age of the study group ranges from 16 months-20 years and the 
follow up period varied from 24-120 months post-implantation (table 2). The implantation 
age of the non-syndromic CI-users ranges from nine months-15 years and follow up 
period from 24-120 months post-implantation. The implantation age, years of CI-use and 
CI-use in hours per day (based on subjective information) of our CHARGE study group did 
not differ significantly from the non-syndromic CI-user control group (Mann-Whitney U 
test). The majority (43%; 6/13 patients) of the CHARGE patients without CI had aided mild 
hearing thresholds (21-40dB) and a mean age of 9;7 years (range 1;11-25;02). 
BERA and MRI findings 
Table 2 shows BERA en MRI findings of the implanted ear. We found in three patients (1, 4 
and 6) reliable responses while using hearing aids and during subjective audiometry, 
without responses with BERA and with no confirmation of presence of the cochlear nerve 
on MRI. The cochlear nerve was not identifiable on MRI possibly due to absence of the 
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nerve, a poor quality of scan or blurry images due to movement artefacts. The other 
patients had responses with BERA and/or a present cochlear nerve on MRI. 
CT and intra-operative findings (table 3)
All patients underwent a retro-auricular approach with a cortical mastoidectomy. 
The mastoidectomy was anticipated to be more complicated because of absence of 
the lateral SCC, which is an important landmark in ear surgery. The incus was identified in 
all patients and dysplastic in three patients. In four patients, the incus was removed to 
improve the view on the promontory. In one patient, a defect of the tegmen was found 
with an exposed middle fossa dura. 
 As shown in table 3, there were subtle differences between the pre-operative CT 
and the intra-operative findings, mainly concerning the round window, the stapes or the 
route of the facial nerve. The oval window was often diagnosed as aplastic on CT. As a 
result of the absent lateral semicircular canal, the facial nerve seems to have a more inferior 
course at the oval window region and a more anterior course in its vertical segment, in 
some cases coinciding with aplasia of the oval window, and, if present, a stapes only 
connected to the incus. Finding the round window as a landmark for use in performing 
the cochleostomy was often challenging. If the facial nerve covered the round window, 
the cochleostomy was placed anterior of the (supposed) round window. In patient 8, 
the cochleostomy was drilled through the posterior tympanotomy as well as transmeatal 
(after lifting the tympanic membrane) because the lumen of the scala tympani could not 
Table 2  Implantation
 
Patient 
No.
Age at 
implantation 
(months)
Implant type Side Insertion Response 
on NRT
Time 
since CI 
(months)
Hearing 
aid 
contra-
lateral
1 16 CI24RE AS Full Yes 60 No 
2 25 Nucleus freedom AS Full Partial 60 Yes
3 37 Nucleus contour AD Full NC 120 No
4 68 Nucleus contour 
advanced soft tip
AS Full No 60 No
5 79 Nucleus 24 contour AD Full Yes 120 No
6 249 Nucleus freedom AS Full Partial 60 No
7 99 Nucleus 24 contour AD Full Yes 60 No
8 31 HiRes90k AS Full NC 60 No 
9 49 Nucleus freedom AS Full Yes 24 Yes
10 17 Nucleus freedom AD Full Yes 36 No 
NRT: neural response telemetry; NC: not conducted
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be found directly. Twice, a per-operative CT was performed in this patient to confirm 
the right location and direction of the cochleostomy and position of the electrode. 
The electrode was fully inserted, but the CT showed buckling of the basal part of the 
electrode array. In all other patients, full insertion of the electrode was achieved despite 
five dysplastic cochleas on CT. In patient 2, the scala tympani had to be drilled out because 
of a narrow proximal scala tympani.
Complications
During surgery, the main complication was bleeding from (enlarged) emissary veins. 
In four patients, excessive bleeding occurred while lifting the periosteum. Hemostasis 
was achieved with bone wax or absorbable hemostat. In patient 5, a wound drain had to 
be left in situ and postsurgical supplementation with ferrous fumarate was necessary 
for six weeks because of anemia (Hb 5.8mmol/L). In patient 8, there was a temporary pre- 
operative desaturation to 47%, possibly caused by bronchospasm with dislocation of 
the tube. The patient recovered after two re-intubations, and intensive care was needed 
post-operatively because of pneumonia from which the patient recovered completely. 
Table 3  CT and intra-operative findings
Patient  
No.
Cochlea Oval window Round window Stapes nVII1 Vascular
CT Insertion CT Surgery CT Surgery CT Surgery CT Surgery CT Surgery
1 type IV3 full aplasia dysplastic: 
slitshaped
N aplasia dysplastic fusion of crurae, no contact with 
footplate
N more anterior, near 
RW
none N
2 N full aplasia ND N covered by nVII dysplastic N N N large EV bleeding 
3 type IV3 full aplasia rudimentary N rudimentary dysplastic monopodal, no contact with 
footplate
N N EV, HB N
4 IPII2 full aplasia rudimentary N rudimentary 
covered by nVII 
dysplastic no stapes aberrant over RW and OW EV, PSS N
5 N full aplasia ND N N dysplastic surrounded by mucosa N N none bleeding 
6 N full N ND N More posteriorly N ND N N none N
7 type IV3 full aplasia ND N ND dysplastic N N not identified EV bleeding
8 type IV3 full aplasia ND aplasia aplasia dysplastic ND aberrant not identified, 
thickened mucosa
EV N
9 N full aplasia aplasia N N N no contact with footplate, crurae 
pointed at nVII
N inferior of OW none bleeding 
10 N full aplasia covered by nVII N covered by nVII dysplastic rudimentary aberrant over RW and OW, 
mastoidal portion: 
siphon like
none N
EV: emissary vein; HB: high riding jugular bulb; N: normal; ND: not described; OW: oval window;  
PSS: petrosquamosal sinus; RW: round window; 1 mastoidal and tympanic facial nerve; 2 incomplete partitioned  
type II (28); 3 Type IV: shortened cochlea
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Patient 1 had a temporary worsening of his pre-existing unilateral facial paresis but 
recovered quickly without treatment. Patient 10 suffered from mastoiditis at the implanted 
ear two years after implantation. A mastoidectomy was performed with drainage of the 
purulence (caused by streptococcus intermedius), but the electrode and receiver seemed 
unaffected and were left in situ. Gentamycin sponges were left behind and removed after 
five days during a re-mastoidectomy because of the suspicion of mastoiditis, but appeared 
to be edema. Systemic antibiotics were applied for one week, resulting in a good recovery. 
Use of the CI
The number of hours of CI-use per patient was variable. Eight patients used their CI during 
most of the day, as indicated at their last follow up. Patient 5 stopped using the CI after ten 
years due to epileptic seizures and limited auditory benefit. Patient 10 did not use his CI 
frequently because of recurrent airway infections and related hospital admissions with his 
revalidation being focused on physical recovery.
Table 3  CT and intra-operative findings
Patient  
No.
Cochlea Oval window Round window Stapes nVII1 Vascular
CT Insertion CT Surgery CT Surgery CT Surgery CT Surgery CT Surgery
1 type IV3 full aplasia dysplastic: 
slitshaped
N aplasia dysplastic fusion of crurae, no contact with 
footplate
N more anterior, near 
RW
none N
2 N full aplasia ND N covered by nVII dysplastic N N N large EV bleeding 
3 type IV3 full aplasia rudimentary N rudimentary dysplastic monopodal, no contact with 
footplate
N N EV, HB N
4 IPII2 full aplasia rudimentary N rudimentary 
covered by nVII 
dysplastic no stapes aberrant over RW and OW EV, PSS N
5 N full aplasia ND N N dysplastic surrounded by mucosa N N none bleeding 
6 N full N ND N More posteriorly N ND N N none N
7 type IV3 full aplasia ND N ND dysplastic N N not identified EV bleeding
8 type IV3 full aplasia ND aplasia aplasia dysplastic ND aberrant not identified, 
thickened mucosa
EV N
9 N full aplasia aplasia N N N no contact with footplate, crurae 
pointed at nVII
N inferior of OW none bleeding 
10 N full aplasia covered by nVII N covered by nVII dysplastic rudimentary aberrant over RW and OW, 
mastoidal portion: 
siphon like
none N
EV: emissary vein; HB: high riding jugular bulb; N: normal; ND: not described; OW: oval window;  
PSS: petrosquamosal sinus; RW: round window; 1 mastoidal and tympanic facial nerve; 2 incomplete partitioned  
type II (28); 3 Type IV: shortened cochlea
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Auditory
All patients had hearing thresholds with their CI between 25-40dB at the implanted ear, 
except patients 5 and 8 who had unfavorable hearing thresholds of 60dB at the implanted 
ear. Table 4 shows the speech perception scores at the most recent follow up. Three 
patients (2, 3 and 4) showed speech perception scores of more than 60%, and one patient 
(6) could discriminate 90% of the vocals and 50% of the consonants. These four patients 
were tested after 60 or 120 months. In the other six patients, speech perception could not 
be measured with standard tests, but with the CI these patients could detect sounds 
adequately. Typically, these patients have been tested after a shorter follow up period 
(24-60 months) than patients with measurable speech perception, except patient 5. No 
speech perception tests were conducted at the more recent follow up visits in patients 6, 
who  already had satisfying scores, and patient 8, who was not able to perform speech 
perception measurements even after a long period of CI-use, which was consistent with 
the restricted audibility of this patient. 
Communication mode
The main communication mode is shown in figure 1 as well as the changes in spoken 
communication mode over time in six patients. In the other four patients, no change in 
communication mode was observed. Patient 5 had restricted hearing abilities. Patient 6 
Table 4  Speech perception at most recent follow up
Patient  
No.
Time  
since CI 
(months)
Age at 
evaluation 
(months)
Speech perception
1 60 76 Could not be tested but could discriminate and identify sounds
2 60 85 62% NVA test
3 120 157 78% NVA test
4 60 128 75% NVA test
5 120 199 No speech perception but enjoyed music
6 24 273 Discrimination of vocals 90%, consonants 50%
7 60 159 Could discriminate four sounds
8 24 55 Could not be tested but could identify sounds
9 24 73 Could not be tested but could discriminate and identify sounds
10 24 41 Could not be tested but enjoyed music
CI: Cochlear implant; NVA test: Dutch speech perception test
Test was carried out in standardized conditions using the pre-recorded test or live voice if it was difficult to hold 
the attention of the patient. The test results obtained with the most optimal hearing amplification were used (i.e. 
with CI and, if used, a contra-lateral hearing aid). In patient 6 and 8 no speech perception tests were conducted 
at more recent follow up moments, while their last evaluation moment was 60 months post-implantation
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was 19 years old at implantation and already using spoken language with lip-reading 
before implantation. Patient 7 had very limited cognitive development. Patient 10 did not 
use the CI frequently. 
Language development
Figure 2a and 2b show the receptive language and expressive language age of eight of 
the ten patients with CHARGE syndrome and CI over time (see Supplement 1 for individual 
data). The data are plotted against the language development of the non-syndromic 
CI-users (grey lines, see Supplement 2 for individual data) and the cross-sectional data of 
receptive and expressive language of the control group with CHARGE syndrome and 
adequate hearing (see Supplement 3 for individual data). The language age of the study 
patients developed more slowly than in the non-syndromic control group but seems 
comparable with the control group of CHARGE patients without CI. The patients in the 
study group with measurable speech perception scores (patients 2, 3 and 4) showed the 
largest improvement in language development. In patient 8, the tests were conducted 
supported by signs. Patient 6 was too old for the language developmental test. Patient 7, 
9 and 10 had poor language abilities and therefore conducting a standard test reliably was 
not possible. 
Figure 1   Communication mode of the study group at 0, 24 and 60 months  
post implantation
1 2 3 4 5 6 7 8 9 10
preimplantation
24 months postimplantation
60 months postimplantation
body language
sign language
spoken language
supported by signs
spoken language
patient
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Figure 2   Language development
2a. Receptive language development
2b. Expressive language development
Longitudinal data of the study group (without patient 6 and 7; patient 8 supported by 
signs) and non-syndromic control group, plotted against cross-sectional data of the 
control group ‘CHARGE without CI’.   
Longitudinal:  patient 1;  patient 2;  patient 3;  patient 4;  patient 5;  patient 8; 
 patient 9;  patient 10;  age adequate;  non-syndromic patients with CI; 
Cross-sectional:  CHARGE without CI (figure 2a 13 patients, figure 2b 7 patients) 
For detailed (individual) data see Supplement 1, 2, 3
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Quality of life 
The QoL of the patients with CHARGE syndrome and CI is compared with the control 
group of non-syndromic CI-users (see Supplement  4 for detailed data). The parents of five 
patients (with varying performances) of the study group completed the questionnaires 
(patients 1, 3, 5, 7 and 9). The parents of the other five patients did not respond or choose 
not to fill in the questionnaires. In all questionnaires, the absolute scores were lower in the 
patients with CHARGE syndrome than in the control group. In all domains of the 
questionnaires the scores were higher than zero for all patients of the study group, 
showing a positive effect of the CI on QoL. No statistical differences were found on the 
domains of the GCBI between the study group and the control group. The study group 
only showed statistically significant lower scores than the control group on the ‘sound 
perception basic’ (p<0.05), ‘sound perception advanced’ (p<0.0001), and ‘speech 
production’ (p<0.005) subdomains of the NCIQ. Statistically significant lower scores were 
found on the total PedsQL score (p<0.001), on the ‘psychosocial’ domain (p<0.005), the 
‘emotional’ (p<0.005) and the ‘social’ (p<0.0001) subdomains of the study group in 
comparison with the control group. Some parents added positive comments about the 
changes they observed in their children post implantation to the questionnaires. For 
example, one patient understood conversations not directly addressed to her despite her 
limited vision (patient 7) while another made more sounds and responded to hearing his 
name called when using the CI (patient 9). 
Discussion
This study shows the challenges and benefits of cochlear implantation in CHARGE 
patients. The assessment phase is complicated because of the complexity of the syndrome 
and the possibility of cochlear nerve aplasia. The surgical procedure of implantation is 
challenging in this syndrome because of widely variable temporal bone findings. However, 
all patients with CHARGE syndrome and severe sensorineural hearing loss show some 
benefit from cochlear implantation in terms of auditory functioning, language development 
and/or QoL. Based on the results of this study, and on the discussion below, we have 
developed a proposal for guidelines to be used when considering CI for CHARGE patients.
 The presentation of CHARGE syndrome can be vary divers, with a variable combination 
of multiple anomalies [2]. A multidisciplinary team, familiar with the syndrome specific 
problems, should be involved in the assessment of mental and physical health status 
(table 5). 
 One of the features seen in CHARGE syndrome is deficiency of the cochlear nerve [11]. 
MRI findings of the cochlear nerve do not always correlate with the BERA results or with 
the auditory benefits of CI. In three patients in the study group, both the outcome of 
the MRI and the BERA could not rule out an aplasia of the cochlear nerve. The decision 
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Table 5  Guideline suggestion
1. Target Group
Molecularly confirmed CHARGE syndrome or clinically typical CHARGE syndrome (Verloes [2]) 
and severe to profound hearing loss and no benefit of hearing aids
2. Assessment phase
2.1 Assessment by a multidisciplinary team consisting of
o  Otologic surgeon 
With experience of surgery of abnormal anatomy of the petrosal bone
o  Speech therapists 
To evaluate the communicative skills and intentions
o  Psychologists familiar with patients with complex needs 
To evaluate the cognitive abilities
2.2 A positive result in at least one of the following examinations 
o BERA 
o Subjective audiometry
o MRI: to identify the presence of the cochlear nerve
2.3 Contra-indications
o Cochlear nerve aplasia (no response on BERA, no reaction with hearing aids and no 
cochlear nerve on MRI)
o Poor general (physical/mental) health status
3.  Pre-implantation phase
3.1 CT: imaging the surgical route and challenging anomalies
 Radiologic report should contain at least:
o development of mastoid and presence of venous anomalies
o route of the facial nerve
o anatomy of semicircular canals
o description of the location and aspect of the windows
o anatomy of the cochlea
3.2 Pre-anesthesia assessment 
o Pediatric cardiologist 
 Congenital heart defects are present in 74% of patients with CHARGE syndrome [28] 
o Pediatrician 
 To evaluate the general health status
o Pediatric anesthetist
 Be aware of micrognatia and laryngomalacia. Consider discussing tracheotomy (26).
3.3  Counseling of parents including the risks and possibility of failure due to, e.g., unforeseen 
nVIII aplasia
4. Surgical phase
4.1 Choice for side of implantation 
  Depends on presence of petrosquamosal sinus, large emissary veins, route of the facial nerve, 
development of the mastoid, presence cochlear nerve and development of the cochlea
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to implant was based on responses on subjective audiometry and led to satisfying 
outcomes for all three patients. Therefore we always recommend performing MRI, BERA and 
subjective audiometry to establish the presence of the cochlear nerve in CHARGE patients. 
 Surgery and anesthesia could result in respiratory complications in CHARGE syndrome, 
which we also experienced in one patient [26-28]. Micrognatia, laryngomalacia and 
postintubational arythenoid dislocation may compromise the airway. These issues need 
to be discussed during the pre-operative counseling, including the performance of a 
tracheotomy if needed.
 In the temporal bone of patients with CHARGE syndrome the high percentage of 
aberrant vascular structures like PSS [29] is specific to the syndrome. These structures can 
cause surgical problems. An aplastic lateral SCC, an inferior-anterior displacement of the 
facial nerve at the second genu, an aplastic oval window and an aplastic round window 
are frequently seen in CHARGE syndrome. We advise the detection and localization of 
these structures, before implantation and the incorporation of this knowledge into surgical 
planning. Per-operatively, a navigation system may be of value [9]. As we demonstrated, 
the presence of an aberrant facial nerve may complicate the creation of the cochleostomy 
but does allow full insertion of the electrode. More space and a better view of the facial 
Table 5  Continued
4. Surgical phase
4.2 Surgical steps
o Facial nerve monitoring
o Facial nerve stimulation
o Consider using a navigation system
o Mastoidectomy: use the tegmen as a guide to the antrum 
o  Posterior tympanotomy: facilitated by the more medial route of the facial nerve but  
 may require removal of the incus to extend vision in the middle ear.
o  Cochleostomy: consider a combined approach (transmastoidal and transtympanic) in 
cases where nVII is blocking the RW
4.3 Complications: bleeding from emissary veins, gusher, incomplete insertion of the electrode. 
 Anesthetic complications (airway management).
4.4 Prolonged post-anesthesia surveillance [27]
 Risk of postoperative airway dysfunction through post-intubation arytenoid dislocation
5. Rehabilitation phase
5.1  Outcomes are variable from signal function to open speech perception and spoken 
language, depending on individual variables and implantation age 
5.2 Improvement in disease specific quality of life
5.3 The post-operative auditory rehabilitation should be tailored to the individual patient’s needs
BERA: brainstem evoked response audiometry; nVII: facial nerve; RW: round window; SCC: semicircular canal
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nerve may be achieved by removal of the incus. The surgeon should use facial monitoring 
and stimulation to diminish the risk of the facial nerve injury. A transtympanic route can 
also be added to the transmastoidal and posterior tympanotomy in order to perform 
the cochleostomy to the scala tympani anterior to the facial nerve. The electrode may 
then be routed through the posterior tympanotomy prior to insertion or through a 
temporary slit in the external meatal wall post insertion.  
 Cochlear malformations, like incomplete partition or cochlear hypoplasia are present in 
patients with in CHARGE syndrome. Nevertheless, in all our patients, a standard electrode 
could be deployed. More severe malformations might necessitate a different choice of 
electrode. We did not observe the perilymfe gushers described in patients with CHARGE 
syndrome by other authors [6, 7, 30]. 
 Despite their cognitive disabilities and additional handicaps, all patients showed 
auditory profit that ranged from enjoying music up to speech perception scores of 78%. 
Seven of the ten patients changed their communication mode, with five tested patients 
showing increased spoken language abilities. General health status influenced CI-use, and 
possibly language development, in two patients including one non-user. In five patients, 
an increase of spoken language abilities was observed. These were all patients who 
received their implants at relatively young ages (≤37 months) and who had used their CI 
for a relatively long period of time (60 and 120 months). These patients had relatively 
higher IQ’s (70-85) and were using sign-language pre-operatively. The non-syndromic 
CI-users performed better than the patients with CHARGE syndrome and CI, but the 
performance of tested CHARGE patients with CI is quite similar to that of CHARGE patients 
without CI. Thus, overall, the performances with CI are quite satisfactory for a complex multi- 
impairment syndrome, however three patients did not show spoken language. Despite one 
non-user (after ten years), no negative effects of the CI were identified. Although based on only 
five patients (with different performance), the results of the QoL-questionnaires support 
an improved disease-specific QoL after implantation, and without significant differences 
when compared with the non-syndromic CI-users. The general health-related-QoL is 
significantly lower in comparison with non-syndromic CI-users, possibly due to the 
additional handicaps and restricted cognitive abilities. 
 This study was performed retrospectively and describes a small study population, 
which is a logical consequence of the low incidence of this syndrome (1:15,000-1:17,000 
in the Netherlands [31]). As far as we know, this is the first study to compare language 
development in CHARGE patients with CI with ‘general’ language development in CHARGE 
syndrome. However, due to the retrospective study design, the development of our 
patients could not be compared with that in patients with CHARGE syndrome who had 
received negative advice for CI. Reasons not to implant a patient with CHARGE syndrome 
could be cochlear nerve aplasia, low cognitive abilities, autism or poor general health 
status. This may have produced a positive bias in our results because more seriously 
affected patients could not be part of the study.  
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Based on these challenges and benefits, and taking into account the considerations 
described above, we have composed the guidelines presented in table 5. These guidelines 
are necessary because, as we have shown, CI in CHARGE syndrome is complicated by 
the syndrome-related temporal bone anatomy and additional features. Nonetheless, 
given their improved performance and QoL, CI should be considered in patients with 
CHARGE syndrome and severe sensorineural hearing loss. The outcome of the CI seems to 
be more individually determined. However, the goal for these patients should be early 
implantation. We invite other groups to use and comment on our guideline in order to 
reach best practice for children with CHARGE syndrome and severe hearing loss. 
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Supplement 1
Receptive language study group
Follow up (months)
0 0 0 6 6 6 12 12 12 24 24 24 36 36 36 60 60 60 120 120 120
NR TEST Age LA TEST Age LA TEST Age LA TEST Age LA TEST Age LA TEST Age LA TEST Age LA
1 N 12 11 N 17 13,5 N 34 18 N 48 14 R 58 15 R 79 27
2 N 22 15 N 33 22 R 43 28  R 68 34 R 86
3 N 33 14  R 54 24 R 65 29 R 77 31 R 97 46 P 158 75
4 R 67 30  R 81 31 R 95 33 R 108 39  
5    R 105 17 R 120 19 R 139 13
6       
7       
8  N 33 11 N 51 12  R 81 30
9 N 38 18
10 N 12 11
age in months; LA: language age in months; N: NNST; P: Peabody; R: Reynell
Expressive language study group
Follow up
 0 0 0  6 6 6  12 12 12  24 24 24  36 36 36  60 60 60
NR TEST Age LA TEST Age LA TEST Age LA TEST Age LA TEST Age LA TEST Age LA
1 N 12 11 N 17 16,50 N 34 18 N 48 22  S 79 18
2 N 22 18 N 33 22 S 43 24  S 68 40 S 86 48
3 N 33 18  S 54 18 S 65 23 S 77 30 S 97 47
4 S 67 23  S 81 29 S 95 37 S 108 42  
5      S 139 14
6       
7       
8  N 33 11 N 51 16 N 52 17   
9 N 38 18      
10 N 12 11     
age in months; LA: language age in months; ; N: NNST; S: Schlichting
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Supplement 2
Receptive language control group (non-syndromic)
Follow up (months)
0 0 0 12 12 12 24 24 24 36 36 36 60 60 60 120 120 120
ID Test Age LA Test Age LA Test Age LA Test Age LA Test Age LA Test Age LA
D1 N 23 21 R 41 42 R 53 58 R 66 76 P 87 99   
D2 R 48 30 R 63 45 R 76 64      
D3 R 82 28 R 100 41 T 112 57 P 127 72 P 146 71   
D4 T 85 63   P 126 112     
D5 R 76 27 R 94 31 R 111 38   T 145 112 P 206 171
D6 T 93 76 T 121 95  T 134 121 T 218 218
D7      P 246 93   
D8          
D9 R 33 13   R 54 23 P 77 35     
D10 R 58 28 R 74 46 T 86 76 T 99 97 T 120 113   
D11 N 7 11 R 26 18 R 45 29 R 58 45 P 72 75   
D12 R 31 11 R 30 26 R 41 33 R 51 48     
D13 R 27 15   R 55 24 R 67 27 R 100 44   
D14     
D15     
D16   R 69 38 R 83 50 R 94 59 T 120 96   
D17           
D18      R 80 39     
D19             
D20   R 117 36 R 90 36 R 103 43 R 126 67  
D21 R 133 33          
D22 R 47 23   T 94 73   T 125 102  
D23   R 48 26 R 58 30 R 73 40   
D24       R 133 31    
D25       R 175 41     
D26 R 105 30   T 137 95 T 147 161     
D27 N 18 21 R 35 32   P 80 79   
D28 N 32 22  R 58 35 P 69 46     
D29 N 7 8 R 21 14 R 38 28 R 51 41 P 71 78   
D30 N 11 11 N 27 12 R 40 26 P 50 49     
D31 N 9 11 R 23 21 R 40 32 P 57 51 P 73 81   
D32 N 19 18 R 34 26 R 46 41 R 59 51 P 80 67   
D33  R 36 24 R 46 38 R 60 53 P 86 89   
D34 N 16 11 N 31 12 R 43 25 R 55 33 T 77 75 P 141 144
Age: in months; LA: language age in months; N: NNST; P: Peabody; R: Reynell; T: tvk (taaltest voor kinderen, Dutch 
Language test)
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Expressive language control group (non-syndromic)
Follow up (Months)
0 0 0 12 12 12 24 24 24 36 36 36 60 60 60 120 120 120
ID Test Age LA Test Age LA Test Age LA Test Age LA Test Age LA Test Age LA
D1 N 23 22   S 53 55 S 66 75  
D2 S 48 35 S 63 46 S 76 73    
D3 S 82 29 S 100 43 T 112 66    
D4   T 101 61      
D5 S 76 30 S 94 36 S 111 43   T 145 73 P 206 171
D6 T 93 71 T 121 99   T 134 121  
D7          
D8          
D9     S 54 20    
D10 S 58 23 S 74 47 T 86 66 T 99 80 T 120 121
D11 N 7 11 S 26 21 S 45 32 S 58 40 P 72 87
D12   S 30 20 S 41 30 S 51 36  
D13     S 55 18 S 67 28 S 100 40
D14          
D15          
D16   S 69 47 S 83 75 T 94 75 T 120 95,5
D17          
D18       S 80 39  
D19          
D20  
D21          
D22 S 47 25   T 94 73   T 125 102
D23     S 58 34 S 73 50  
D24       S 133 44  
D25       S 175 34  
D26 S 105 46   T 137 74 T 147 90  
D27 N 18 21 S 35 36 S 51 48  
D28 N 32 22 S 45 22 S 58 28  
D29 N 7 8 S 21 20 S 38 28 S 51 40  
D30 N 11 11 N 27 19 S 40 26 S 50 31  
D31 N 9 11 S 23 22,5 S 40 34 S 57 52  
D32 N 19 18 S 34 25 S 46 39 S 59 52  
D33   S 36 23,5 S 46 35 S 60 58  
D34 N 16 11 N 31 18 S 43 23 S 55 37 T 77 53 P 141 144
Age: in months; LA: language age in months; N: NNST; P: Peabody; R: Reynell; S: Schlichting; T: tvk (taaltest voor 
kinderen, Dutch Language test)
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Supplement 3
Patient characteristics and language age control group  
(patient with CHARGE syndrome without CI)
NR IQ Hearing 
loss
Test Receptive 
test age
Receptive 
language 
age
Test Expressive 
test age
Expressive 
language 
age
c7 <70 severe NNST 23 12 NNST 23 12
c10 <70 mild Reynell 302 18
c12 70-85 severe  Peabody 274 34
c16 <70 moderate Reynell 34 25
c20 <70 moderate Peabody 171 27
c30 70-85 normal Reynell 62 69 Schlichting 63 56
c35 70-85 normal Reynell 54 43 Schlichting 39 38
c40 70-85 mild Reynell 39 32 Schlichting 39 30
c41 70-85 mild Reynell 39 34 Schlichting 39 34
c44 <70 moderate Reynell 113 21
c53 <70 mild  Reynell 65 42 65 44
c55 <70 mild TVK 194 87 TVK
c57 <70 mild  Peabody 127 55 Peabody 127 66
TVK: taaltest voor kinderen (Dutch language test)
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Results of the step-wise regression analysis of the PedsQL scores. CHARGE versus control 
group (non-syndromic).
PedsQL Total Physical Psychosocial Emotional Social School
(Constant) 88.784 94.974 85.357 78.850 82.099 88.116
Diagnosis -26.828** -7.474 -22.580* -23.850* -30.991** -13.116
IQ 71-85a  -81.250     
CI use: 4-6 hours/dayb  81.250     
CI use: 12-16 hours/dayc     10.837  
CI use: >16 hours/dayd -21.744 -15.954 -24.712  -29.599 -26.451
*p<0.005, **p<0.001 
B-values: regression coefficients of the regression model of the total PedsQL score and the different subdomain 
scores.  
a B-values of the IQ 71-85 group compared with the other IQ subgroups.
b B-values of the CI use 4-6 hours/day group compared with the other CI use subgroups.  
c B-values of the CI use 12-16 hours/day group compared with the other CI use subgroups. 
d B-values of the CI use >16 hours/day group compared with the other CI use subgroups.
Supplement 4
Results of the step-wise regression analysis of the GCBI scores. CHARGE syndrome versus 
control group (non-syndromic)
GCBI Total Emotion Physical Learning Vitality
(Constant) 33.897 34.040 19.376 46.122 32.797
Diagnosis 7.838 6.585 13.659 8.043 5.953
B-values: regression coefficients of the regression model of the total GCBI score and the different subdomain 
scores. 
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Abstract 
Objectives  
To answer the dilemma clinician’s face when deciding between cochlear implant (CI) 
and auditory brainstem implant (ABI) treatment options in patients with cochlear nerve 
deficiency (CND).
Material and Methods
In this study, a case study is supplemented with literature review and meta-analysis. 
The case study describes a child with CHARGE syndrome and congenital deafness. 
The child received an ABI as there was no benefit after bilateral cochlear implantation. 
Speech and language development and quality of life were the main outcome 
measurements. 
Results 
In one ear the cochleovestibular nerve was present on MRI without preoperative ABR 
responses. In the contra lateral ear the nerve could not be identified, despite present ABR 
responses. Nevertheless,  there was no positive outcome with CI. The patient had positive 
changes to speech and language and quality of life with ABI. 
 Of the 108 cases of patients with CND and CI identified in the literature review, 
25% attained open-set speech perception, 34% attained closed-set speech perception 
and 41% detected sounds or less. The aspect of the cochlear nerve on MRI was a useful 
predictor of success, with cochlear nerve aplasia on MRI associated with a smaller chance 
of a positive outcome post cochlear implantation compared to patients with cochlear 
nerve hypoplasia.
Conclusions
Although patients with (apparent) cochlear nerve aplasia are less likely to benefit from CI, 
CI prior to ABI is supported as some patients attain closed or open-set levels of speech 
perception after cochlear implantation. 
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Introduction 
Cochlear implantation is a well-established surgical treatment to restore hearing in 
patients with a severe to profound hearing loss. This procedure can result in improved 
auditory skills, especially when performed early in children with congenital deafness. 
However, in some children a cochlear implant (CI) has no or minimal effect on speech and 
language development. One reason for this variation in CI outcomes is cochlear nerve 
deficiency (CND) [1-16]. CND is caused by inadequate development of the cochlear nerve 
and the nerve is partially developed (termed hypoplasia) or is absent (termed aplasia). 
An alternative treatment for patients with CND and no effect of cochlear implantation 
is an auditory brainstem implant (ABI), although the likelihood of ABI success is difficult 
to predict, and generally worse than with CI [17]. 
 During the pre-operative screening stage for a child with CND, it is important to 
consider the likely outcome of cochlear implantation and whether an ABI or a CI will 
provide the child with the best outcome. Various pre-operative diagnostic tools are used 
to diagnose CND. Observing the small diameter of the internal auditory canal (IAC) and/or 
bony cochlear nerve canal (BCNC, synonymous with cochlear aperture) on CT could 
indicate CND [18,19], however, a normal IAC diameter is not a reliable marker for a normally 
developed cochlear nerve [20]. The aspect of the cochleovestibular nerve (CVN) and 
cochlear branch can be assessed on MRI [18,21]. Imaging in combination with auditory 
tests such as (aided) hearing thresholds, (electrically evoked) auditory brainstem responses 
((e)ABRs) and oto-acoustic emissions (OAEs) have a prognostic value [21,22] but the 
presence of the CVN must be considered when there is no CVN visible (MRI) or measurable 
(audiometric tests) on pre-operative evaluations [23].   
 Hearing loss due to CND is frequently seen in patients with CHARGE syndrome [24]. 
The major features of CHARGE syndrome are choanal atresia, and malformations of the 
heart, the inner ear and the eye [25]. Most children with CHARGE syndrome (with or 
without CND) who have undergone cochlear implantation achieve varying but limited 
levels of auditory benefit, after implantation [26,27]. 
 The aim of this study was to answer to the question: When should CI and when 
should ABI be considered the primary treatment option for children with CND? To illustrate 
this dilemma, we present a case study of a child with CHARGE syndrome who had no 
benefit from bilateral cochlear implantation and required an ABI for hearing restoration. 
During case evaluation several steps in the decision process were questioned. This was 
the motivation for a literature review and meta-analysis on this topic to provide an 
evidence-based therapeutic strategy in future cases. 
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Material and Methods 
Case study
After the parents of the child in this case study provided written informed consent, the 
child’s medical, audiological, radiological and surgical data were gathered and reviewed 
by the authors. The child had CHARGE syndrome and one of the characteristics included 
a profound sensorineural hearing loss (see table 2 for full list of characteristics). She had 
undergone sequential bilateral cochlear implantation but both were without benefit. 
After consideration of the treatment options, an ABI was recommended. 
 Postoperative ABI evaluations included pure-tone audiometry, the Dutch version of 
the Speech Intelligibility Rating (SIR-NL)[28], the Categories of Auditory Performance (CAP) 
[29], the Infant-Toddler Meaningful Integration Scale (IT-MAIS) [30] and the Meaningful Use 
of Speech Scale (MUSS) [31].
 Three quality of life (QoL) questionnaires were used to measure the QoL after ABI: 
the Glasgow Children’s Benefit Inventory (GCBI) [32], the Nijmegen Cochlear Implant 
Questionnaire (NCIQ) [33] and the Paediatrics Quality of Life Measurement (PedsQL) [34]. 
The GCBI is designed to measure changes in QoL after an intervention and the PedsQL 
measures general health-related QoL. The NCIQ is a disease-specific health-related QoL 
tool developed for use in CI. Although the NCIQ has not been validated for patients with 
an ABI, the results might give an indication in these patients. 
Literature review
This literature review was performed considering the MOOSE criteria [35]. The criteria were 
adhered to where possible. We searched PubMed database and the Cochrane Database 
of Systematic Reviews for studies published, in the English language, with the following 
search terms: cochlear nerve AND/OR deficiency, CI, ABI, magnetic resonance imaging 
(MRI) and computed tomography (CT). The time period was not specified. This search 
resulted in 618 identified papers. The primary author reviewed all titles and abstracts. 
The full article was reviewed if inclusion or exclusion criteria could not be decided based 
on title and abstract alone. An additional search was performed on the reference lists of 
the included studies. Studies with information in the title and abstract indicating the 
paper focussed on surgery, animals, unilateral hearing loss, general anomalies, vestibular 
anomalies and questionnaire studies were excluded (n=550). All papers with a detailed 
(per patient) description of the results of cochlear implantation in patients with CND on 
MRI were retained (n=15), no assessments of confounding, heterogeneity and study 
quality were performed. The presented case study is not included in meta-analysis. 
Demographics
An overview of the 15 selected studies is listed in Table 1. Walton et al. [4] and Jeong et al. 
[12] described numerous patients with auditory neuropathy. In these two papers, 
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the information included in this literature review was restricted to the subset of patients 
with CND. In the remaining 13 studies, only the cases that identified an aplastic or 
hypoplastic cochlear nerve on MRI were included. 
 Patients underwent MRI with field strength 1.5 Tesla in all studies except Kang et al. [6], 
which used 3 Tesla. All studies included axial T2-weighted images that were reconstructed in 
a coronal oblique plane for assessment of the cochlear nerve (0.7-1mm slice thickness, 
or not reported). In those studies were CT technique was specified, high-resolution CT 
(HRCT) was performed, using a bone algorithm technique. Images were acquired with 
slice thickness of 0.7-1mm with targeted magnified reconstruction. The definitions used 
by the authors to assess the cochlear nerve, CVN, BCNC and IAC are listed in supplement 1. 
 Each included paper reported the outcome of cochlear implantation per individual 
patient. Based on the conducted tests, the patients were categorized in either ‘open-set’, 
‘closed-set’ or ‘sounds’ (see supplement 2). If these test results were not available (34 of the 
108 patients), patients were categorized based on the description of the results. 
 The following pre-operative (diagnostic) data were included in the analysis: age at 
implantation, hearing thresholds, aided hearing thresholds, ABR thresholds, pre-operative 
eABR responses, presence and size of the IAC and BCNC on CT, and presence and size of 
the cochlear nerve and CVN on MRI. 
Statistical analysis
SPSS statistics 22 (IBM Corp, Armonk, NY) was used for statistical analyses. Descriptive 
statistics were used to define baseline characteristics. Continuous data was normally 
distributed and univariate analyses were performed using Fisher exact-tests and independent 
sample t-tests. The ‘relative risk’ (RR) indicates the probability of a patient to have ‘open 
set’ divided by the probability to have ‘closed set’ speech perception after implantation, 
based on the outcomes of the pre-operative diagnostic tools. This relative risk with its 95% 
Confidence Interval (CI) is used to identify indicators of future success.
Results
Case study
Characteristics
Our patient is a 10-month old girl who was diagnosed with (atypical) CHARGE syndrome 
at the age of 10 months. The diagnosis ‘CHARGE syndrome’ was confirmed by the 
mutation (8077-1G>A) in the CHD7 gene. Table 2 lists the characteristics of the patient. 
She was born without complications to Dutch-speaking parents after 41 weeks of 
gestation and had an APGAR score of 10. At age three months, the child was diagnosed 
with congenital severe sensorineural hearing loss and was fitted with hearing aids. Her 
parents reported the child responded to sounds when wearing the hearing aids, however 
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the child demonstrated neither effective hearing nor signs of oral language development. 
Neurodevelopmental assessment at age three years and five months reported below 
average developmental abilities and a non-verbal IQ of 69.
Pre-operative evaluation
Repeated ABR showed no responses to stimuli on the right ear and variable results to 
stimuli on the left ear, namely atypical responses at 75dB HL and 90dB HL at 3kHz. 
 Pre-operative MRI indicated the right cochlear nerve was present but the left cochlear 
nerve could not be identified. The IAC was bilaterally hypoplastic. CT showed bilateral 
hypoplasia type III [36] of the cochlea and dysplasia of the semicircular canals (see Figure 1a). 
The BCNC was not described separately, but the report mentioned a remarkably sclerotic 
boundary of the cochlea on both sides. 
Table 2  Characteristics of a patient with CHARGE syndrome
C Hypermetropia
H Atrial septal defect, ventricle septal defect, small open ductus arteriosus
A No choanal atresia
R Cognitive disability (subnormal), facial nerve palsy
G No genital hypoplasia
E Congenital deafness, severe dysplastic vestibular canals, low ear implant
Figure 1a
Hypoplastic vestibulum and aplastic semicircular canals (black arrow) (CT, slice thickness 
of 0.75mm)
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Cochlear implantation
The patient received a CI (Nucleus Freedom) in the right ear at age one year and two 
months because of lack of effective hearing using hearing aids. The right ear was selected 
as this was the side with a cochlear nerve (confirmed on MRI) but had no measurable 
responses to pre-operative ABR. The procedure was performed via a transmastoidal 
approach with cochleostomy. There were no complications during surgery and post- 
operative CT confirmed full insertion was achieved. During surgery, impedance 
measurements were good, but no neural response telemetry (NRT) responses were 
observed. A year after implantation, the child did not demonstrate reliable responses to 
sounds when using the CI in combination with a contralateral hearing aid. The patient 
communicated with sign language only.
 Subsequently, it was decided to implant the contralateral (left) ear with the same 
device as the first at the age of three years and one month because of the absence of 
auditory benefit of the first CI. There was an assumed presence of the cochlear nerve on 
the left side because of the varying ABR responses measured. There were no complications 
during the second CI surgery and impedance measurements and intra-operative NRT 
responses were obtained over all electrodes.
 At follow-up 13 months after the second implantation, no responses, auditory benefit 
or oral speech and language development were observed. At age four years and three 
months, three years and one month after the first CI and 13 months after the second CI, 
the child was referred to the Leiden University Medical Centre for ABI.
Figure 1b  
Stenotic cochlear aperture/bony cochlear nerve canal left (black arrow) (CT, slice thickness 
of 0.75mm)
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Auditory brainstem implant
Re-evaluation of the pre-operative CT and MRI indicated bilateral stenotic BCNC (see 
Figure 1b) without a visible cochlear nerve in both IACs (see Figure 1c). A thin CVN was 
identified on the right side at the cerebellopontine cistern. 
At age of four years and six months, in a single surgical session the receiver-stimulator of 
the right CI was removed (array was left in the cochlea) and the ABI (MedEl, Synchrony pin) 
was inserted into the right side. The right side was selected as ABI site because the 
presence of the thin CVN in the cerebellopontine cistern indicated potential of a 
well-developed cochlear nucleus. The ABI was implanted via a retrosigmoidal craniotomy 
approach. After opening the dura, the lateral recess of the fourth ventricle was located 
by tracking the vagal and accessory nerves and identifying the facial nerve. The final 
electrode paddle was placed after good bipolar eABR responses with the test electrodes. 
Good responses of all twelve final electrodes were found on monopolar and bipolar 
stimulation. The surgery was without complications.
Performance with ABI
In the first months, five electrodes were switched off because of non-auditory stimulation 
or limited auditory responses. Nine months after surgery, responses were observed with 
seven active electrodes on warble sounds at 45-50dB HL at 500Hz-1-2-4 kHz and 30-40dB HL 
two years after surgery (Figure 2). The child used the ABI almost every day, responded to 
her name and to sounds and was sometimes vocalizing while communicating in sign 
language. Results of the IT-MAIS, the SIR-NL, CAP-NL and MUSS-NL are listed in Table 3. 
Formal testing indicated that language production was barely present and the child’s 
ability to identify words was limited. 
Figure 1c  
Bilateral small internal auditory canal and absent nerve (big white arrowhead; thin white 
arrow is the right facial nerve) (MRI, 1.5 Tesla,  slice thickness of 0.3mm)
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Quality of life
The child’s parents completed QoL-questionnaires 14 months after ABI surgery when the 
child was aged five years and eight months. The results of the GCBI, NCIQ and PedsQL 
questionnaires are displayed in Figure 3. The GCBI results indicated improved QoL post ABI 
and PedsQL results indicated that the patient had a high general QoL.  
Literature review
Figure 4 illustrates widely varying CI outcomes in patients with CND. Of the total number 
of patients (n=108), 27 (25%) attained ‘open-set’ speech perception, 37 (34%) attained 
‘closed-set’ speech perception and 44 (41%) attained sound detection only. The influence 
co-morbidity and cognitive delay on the outcome of CI could not be assessed, because 
the published studies lacked detailed patient information.   
Figure 2  Post ABI audiometry
Table 3  ABI results of the case report
Months after  
ABI implantation
IT-MAIS SIR-NL CAP-NL MUSS-NL
2 2/40 - - -
3 7/40 - - -
9 20/40 1/5 3/7 9/40
24 19/40 2/5 3/7 8/40
ABI: auditory brainstem implant; CAP: Categories of Auditory Performance; MUSS: Meaningful Use of Speech 
Scale; IT-MAIS: Infant-Toddler Meaningful Integration Scale; SIR: Speech Intelligibility Rating.
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Figure 3  Quality of life
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Figure 3  Continued
Figure 4  Literature review results, presented by publication year
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The patients with ‘open-set’ and ‘closed-set’ speech perception were pooled for further 
analysis. The outcomes of 64 patients (59%) of this so-called ‘speech perception group’, 
were compared to the 44 (41%) patients who could detect sounds, called the ‘sound 
perception group’. Table 3a lists the results of the analyses of the different diagnostic tools, 
used in pre-operative screening for CI. The outcomes of the pre-operative diagnostic 
tools were tested whether the scores differed between the two groups, to be able to 
identify indicators of future success. The age at implantation had a wide distribution, and 
is not significantly different between the two groups (independent sample t-test). More 
patients with an aplastic cochlear nerve on MRI fell within the ‘sound perception group’ 
compared to patients with a hypoplastic cochlear nerve on MRI (Fisher exact-test, p<0.05). 
The outcome of the other pre-operative tests were not different between the two groups 
(p>0.05). A normal CVN on MRI could not be proven to be a valid predictor of success 
(speech perception) with cochlear implantation, as the relative risk for success ranged 
between 0.38 and 4.68 (Table 4a).  
 Table 4b lists the relationship between the aspect of the BCNC and the cochlear nerve 
on MRI. More patients with a normal BCNC had a hypoplastic cochlear nerve than patients 
with an absent BCNC (p<0.05). Note that four patients with a normal BCNC had an aplastic 
cochlear nerve and one patient was without BCNC and had a hypoplastic cochlear nerve. 
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Table 4a  Potential predictors of outcome of CI 
Potention 
predictors
Values Sound 
perception
Speech 
perception
RR RR 95%-CI p-value 
RR
Implantation age 
(months) (n = 93)
Mean age 42.9 
(SD 34.5)
44.5 
(SD 32.8)
0.82†
Cochlear nerve
(n: 91)
Aplastic
Hypoplastic
30
7
32
22
1
2 1.00-4.01 0.04*∫
Total 37 54
Cochleovestibular 
nerve (n:40)
Abnormal/absent
Hypoplastic
Normal
3
8
4
6
7
12
1
0.63
1.33
0.22-1.77
0.38-4.68
0.42∫
0.67∫
Total 15 25
Internal auditory 
canal (n: 62)
Small
Normal
18
9
23
12
1
1.02 0.56-1.87 1∫
Total 27 35
Bony cochlear 
nerve canal
(n:51)
Absent 
Small
Normal
8
7
3
11
16
6
1
1.38
1.26
0.61-3.12
0.44-3.66
0.52∫
1∫
Total 18 33
OAE
(n: 45)
Absent 
Present
12
1
31
1
1
0.56 0.13-2.41 0.50∫
Total 13 32
ABR
(n: 59)
No response
Abnormal/absent
Some response
Response
13
0
1
0
36
5
4
0
1
-1
1.36
-1-1
0.22-8.14 1∫
Total 14 45
Hearing thresholds
(N: 17)
No response
Response
1
7
0
9 -
Total 8 9
Aided hearing 
thresholds 
(n: 52)
No response
Vibrotactil
Response 
7
4
13
4
1
23
1
0.80
1.75
0.43-1.49
0.95-3.29
1∫
0.16∫
Total 24 28
eABR
(N: 37)
No response
Abnormal/absent
Some response
Response 
6
10
1
4
2
5
3
6
1
1.13
2.67
1.88
0.66-1.92
0.47-15.11
0.79-4.42
1∫
0.26∫
0.19∫
Total 21 16
* statistically significant result; †: independent sample t-test; ∫: 2-tailed Fisher Exact; ABR: auditory brainstem 
response; CI: confidence interval; eABR: electrical ABR; OAE: oto-acoustic emissions; RR relative risk; 
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Discussion
This study highlights the dilemma of cochlear implantation in patients with CND: Which 
pre-operative variables in patients with CND can indicate successful CI outcome. The case 
study highlighted that neither the presence of the CVN on MRI without pre-operative ABR 
responses on the same side nor lack of indication of the nerve on MRI but with ABR 
responses on the contralateral side lead to a positive hearing outcome post cochlear 
implantation. An ABI was a successful alternative treatment. 
 The review of literature indicated a variety of results of cochlear implantation in 
patients with CND: 25% of the patients attained open-set speech perception, 34% attained 
closed-set speech perception and 41% could detect sounds or less. The appearance of the 
cochlear nerve and presence of CVN on MRI, the diameter of the IAC and BCNC on CT, (e)
ABR, (aided and unaided) pure tone audiometry and OAEs were the variables included in 
our analyses to identify differences between the groups in terms of CI success in patients 
with CND. 
 We found that patients with cochlear nerve aplasia on MRI had a smaller chance of 
attaining a good outcome of cochlear implantation than patients with cochlear nerve 
hypoplasia. This finding corroborates the findings presented in smaller cohorts reported 
in Kutz et al., Wu et al. and Birman et al. [8,14,22]. Note there were exceptions to this finding. 
None of the other investigated variables supported differences between the groups. 
This supports the notion that current imaging and audiometric testing limit the ability to 
identify predictors of CI success. 
 Because our results are not statistically significant, our study can not support the 
hypothesis that a normally developed CVN leads to better CI outcomes than an absent or 
abnormal CVN (one, two or three nerves in IAC) [21]. MRI is indispensible in the pre- 
operative cochlear implantation work-up. Nevertheless, it may be difficult to assess the 
nerves on current MRI, supported by the findings of Song et al. [23]. Song described a high 
correlation between the MRI assessment with the surgical findings regarding presence or 
Table 4b  Presence of bony cochlear nerve and cochlear nerve on MRI
Bony cochlear 
nerve canal
Cochlear nerve on MRI RR 95%- CI p-value RR
Aplastic Hypoplastic 
Absent 17 1 1
Small 13 6 1.38 1.00-1.91 0.09∫
Normal 4 5 2.12 1.01-4.45 0.01∫
Total 34 12
BCNC: bony cochlear nerve canal; CI: confidence interval; ∫: 2-tailed Fisher Exact; RR relative risk
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absence of the CVN, although one very thin CVN identified during ABI surgery was missed 
on MRI. However, the cochlear nerve itself could still be absent. 
 The studies in our literature review used clinical MRI field strengths of 1.5 or 3 Tesla 
and similar sequences and image resolution and there were no major changes in these 
settings over time. Further development of these settings and sequences may be helpful in 
diagnosing CND. Techniques such as high-resolution three-dimensional variable flip-angle 
turbo spin-echo sequence in combination with a surface coil [37], diffusion kurtosis 
imaging [38] or ultra high field imaging [39] could improve sensitivity of MRI to detect 
cochlear nerve fibres. The development of non-invasive diagnostic tools allowing 
investigation of the function of the auditory pathway, such as functional diffusion imaging 
techniques or functional MRI, would improve the identification of optimal therapeutic 
strategies.  
 In agreement with the findings of our literature review, multiple authors [19,20,40] 
reported that a narrow IAC or BCNC suggests a compromised auditory nerve. Nevertheless, 
the diameter of the IAC of BCNC does not always correlate with the presence or absence 
of the cochlear nerve. 
 Given that imaging does not provide answer to the CND dilemma, perhaps audiometric 
results or the combination of imaging with the audiometric results could provide better 
guidance. Of the studies identified in the literature review, ABR was used as a pre-operative 
diagnostic tool in 55% of the patients but none of these patients had normal responses 
and, thus, ABR could not be used as a predictive tool. 
According to Kim et al. and Birman et al. [22,41], pre-operative extra-cochlear ABR could 
be more accurate to diagnose CND than ABR because of effective electric stimulation of 
the auditory pathway. Although pre-operative eABR was used in some of the reviewed studies 
[4,7,10,12,15], our analyses showed it could not predict the outcome of cochlear implantation. 
Yamazaki et al. [21] suggested that  eABR testing during surgery in combination with the 
MRI findings is useful to predict postoperative auditory perception with CI, but precise 
discrimination between patients with poor, moderate or good outcomes might be 
difficult when either eABR or MRI is used alone. The disadvantage of the eABR during 
surgery with stimuli provided by the electrode is that cochlear implantation must be 
performed in order to perform eABR as the predictive (diagnostic) tool. Nevertheless a 
negative eABR could be used as an indicator for ABI after cochlear implantation. 
 Although positive results on implantation would be expected in patients with pre- 
operative responses on pure tone audiometry (aided or unaided), this was not supported 
by our meta-analysis. This might be due to the small numbers of patients. 
 We have considered the MOOSE criteria [35] and have tried to conform the manuscript 
as much as possible. Nevertheless, because of the scarce literature and several case studies 
we could not meet all criteria. In addition to the anatomy and physiology of the ear, factors 
such as co-morbidities, cognitive disability or age at implantation have significant impacts 
on the outcome with CI [22] and with ABI [42,43]. Our review provides little insight into the 
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aetiology of the CND or associated syndromes and cognition.  No more than three studies 
described the presence of cognitive disabilities. We combined various definitions (see SDC 2) to 
categorize the outcomes of the diagnostics tools to allow us to analyse the studies 
together. Using these combinations caused some overlap in definitions, which could have 
biased our results. We (and the reviewed studies) focused on the cochlear (vestibular) 
nerve and disregarded other inner ear anomalies, despite the possibility that CND could 
be associated with other inner ear malformations (e.g. cochlear dysplasia or vestibular 
dysplasia). Inner ear anomalies could negatively influence the outcome of cochlear 
implantation [44]. This possible negative influence is not included in our meta-analysis. 
Despite the relatively large number of patients included in the meta-analysis (n=108), 
it remains a small sample and, as such, lacks statistical power. Multivariate analysis was not 
used because of the small sample size and the various pre-operative diagnostic tools 
across the studies. 
 ABI could be an alternative treatment for cochlear implantation in patients with CND. 
Although outcomes are generally worse for patients with an ABI than patients with a CI 
[17,45,46], with results in terms of vocalisation and alertness to sounds [47] and pattern 
perception [48]. However, open-set speech recognition [43,45] have been reported in 
children with ABI, especially for those without additional disabilities [43]. At this stage 
only short-term results are available for the case study, but the short-term results showed 
increased performance with ABI than with CIs. It is likely the results were negatively 
influenced by the relatively late age of ABI implantation (4;06 years) and the child’s 
cognitive disability. Nevertheless, the child showed positive effect of ABI with positive 
scores on the GCBI. The PedsQL showed a good general quality of life with a total score 
above 65.4 (lower scores have an at-risk status for an impaired HR-QoL status) [34]. 
The NCIQ showed low scores on the physical domains in comparison to the scores on 
these domains in patients with CHARGE syndrome and CI [26]. However, the scores on 
the psychosocial and social domains were quite comparable [26]. The NCIQ results cannot 
be compared to normative data because normative data are not available.
 Based on the results of the meta-analysis and with the knowledge of the poor 
bilateral CI results in this case study, opting to initial treatment using CI on the right side 
would still have been the likely therapeutic decision; the presence of the CVN in cerebello-
pontine angle segment on the right side indicates that a cochlear nerve would be 
present but was too hypoplastic to observe on MRI.  Studies showing good results of CI in 
seemingly cochlear nerve aplasia on MRI, cochlear implantation prior to ABI is advisable 
possibly in conjunction with eABR measurements during surgery. However, when there 
is no response with CI within several months, we believe the preferred course of action 
should be to proceed to ABI surgery on the same side and to avoid cochlear implantation 
on the left side. We base this decision on the limited chances for success of second 
implantation in this case and the desire to limit any further delay in auditory input, which 
negatively influences the potential for speech and language development.
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Conclusion
Based on this case study and literature review meta-analysis, no compelling contraindica-
tions were identified for cochlear implantation in patients with CND. Although children 
with (apparent) cochlear nerve aplasia have decreased chances of successful implantation, 
there are examples of children described with cochlear aplasia on MRI who attain 
closed-set or open-set levels of speech perception months to years after implantation. 
When there is no success with this first CI, we recommend the treating team consider 
proceeding to an ABI rather than attempt a second CI and risk further delay in auditory 
input.  
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Supplement 1
Definitions
Cochlear nerve
at midpoint IAC
Cochleovestibular 
nerve at CPA
Bony cochlear  
nerve canal
Stenotic IAC
Normal - >nVII (4,16)
- Present
- ≥ 2 times nVII (8)
- >nVII (21)
- >1.5mm (16)
- >1.4mm (8,12,20,21)
- >1mm (9)
>3mm (4,16)
Small/deficient - <nVII (4,9,16)
- <1 mm (9)
- <1.5mm (9)
- less than 1.5 times  
nVII (9)
- <1.5mm
- <1.4mm
- <1mm
2-3mm (4,6,9,20)
Absent Not seen on all 
images (4,6,7)
- Not seen on all 
images
- One, two or three 
nerves in IAC (22)
<2mm (4)
CPA: cerebellopontine angle; IAC: internal auditory canal
Supplement 2
Outcome categories
Category Tests scores
MSPS CAP SPC
Open-set 5-7 5-7 6 and 7
Closed-set 3 and 4 3 and 4 3-5
Sounds 1 and 2 1 and 2 0-2
CAP: category auditory perception; MSPS: Melbourne speech perception test; SPC: speech perception category
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Cytomegalovirus DNA detection in  
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Abstract
Objectives 
Congenital cytomegalovirus (CMV) infection is the leading cause of non-genetic 
congenital hearing loss. The contribution of congenital CMV to prelingual deafness and 
the pathophysiology is largely unknown. The aim of this study is 1) to analyse the prevalence 
of congenital CMV among cochlear implant (CI) recipients with prelingual deafness. 2) 
To genotype CMV present in dried blood spots (DBS) and in the inner ear years after birth.
Material and Methods 
Children and adults with prelingual deafness who received a CI in 2010-2011 were included 
prospectively. Perilymphatic fluids were collected during CI surgery and, in the pediatric 
cases, DBS were retrieved for CMV DNA detection. Furthermore, a cohort of children 
with prelingual deafness who received a CI between 2003 and 2008 were included retro-
spectively. CMV detection in DBS and perilymph was followed by gB and gH genotyping. 
Results
Sixtyseven pediatric CI recipients were included. Seventy DBS were tested for CMV DNA, 
resulting in a prevalence of congenital CMV of 14% (10/70). Perilymphatic fluid was 
available from 29 pediatric CI recipients. One perilymph fluid, of a 21-month old girl with 
congenital CMV, asymptomatic at birth, was CMV DNA positive. The CMV strain in the 
perilymph was genotypically identical to the strain present in her DBS (gB1/gH2). Perilymph 
samples from 21 adult CI recipients were CMV DNA negative.  
Conclusions
Our study stresses the important contribution of congenital CMV among pediatric CI 
recipients. Furthermore, our genotyping data support the hypothesis that CMV-related 
hearing loss is associated with ongoing viral replication in the inner ear up to years 
after birth.   
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Background
Congenital cytomegalovirus (cCMV) affects approximately 1 in 200 newborns and is the 
leading cause of non-genetic childhood sensorineural hearing loss [1]. Hearing loss can be 
detected at birth in approximately 10% of children with symptomatic cCMV. Since the 
hearing loss is of late-onset character in approximately half of the cases [2], an additional 
10% of the infected children will develop hearing loss in the years after birth [3]. 
 Bilateral hearing loss has been reported to be attributable to cCMV in 15-40% of cases 
[4-7], depending on the studied population. We previously found 8% cCMV infections 
among children with hearing loss of >40dB at the age of 3-5 years in the Netherlands [8]. 
However, the exact prevalence of cCMV among children with cochlear implant (CI) is 
unknown.
 The pathophysiology of CMV-related hearing loss has been studied in animal models. 
Data from mouse [9] and guinea pig [10] models show the presence of CMV in the inner 
ear predominantly in the coclear perilymphatic epithelial cells of the scala tympani and 
the auditory nerve spiral ganglion cells [11]. Besides a direct viral effect, inflammation may 
play a role in cochlear hair cell death causing hearing loss [9]. Some authors have tried to 
detect CMV in the inner ear during autopsy of congenitally infected fetuses [12] or 
newborns [13, 14]. Data on CMV detection in the inner ear of living children are limited.
Objectives
The aim of this study was to analyse the prevalence of cCMV infections among CI recipients 
with prelingual deafness. Therefore, we retrospectively diagnosed cCMV in a cohort of 
pediatric and adult CI recipients with prelingual deafness using dried blood spots (DBS). 
Furthermore, we analysed perilymphatic fluid, which is routinely exposed during CI 
surgery, for the presence of CMV DNA (including CMV gB/gH genotypes), in an attempt to 
gain insight into the pathophysiology. 
Study design
Study population
Pediatric CI recipients
The pediatric study population consisted of profoundly deaf children who received a 
unilateral CI from October 2010 to December 2011 in the Leiden University Medical Centre 
(LUMC), and from February to December 2011 in the Radboud University Medical Centre 
Nijmegen (UMCN). These children were included prospectively (n=31). Blood and 
perilymphatic fluid were collected during CI surgery and DBSs were retrieved to diagnose 
cCMV infection retrospectively. Because of the limited national storage duration of DBS, 
the inclusion was limited to children up to the age of 6 years. 
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Furthermore, a cohort of profoundly deaf children who received a CI from 2003 to 2008 at 
the age of 0-5 years were included retrospectively (n=45). These children were part of the 
previously published DECIBEL study, which included infants with permanent bilateral 
hearing impairment (≥40 dB in the better ear) at the age of 3 to 5 years [8]. DBS were 
retrieved from these children. Since these children were retrospectively included, no 
blood and perilymphatic fluid samples were available. 
Adult CI recipients
The adult study population consisted of patients with profound prelingual deafness who 
received a unilateral CI from April to December 2011 in the LUMC (n=21).  These adults 
were included prospectively and perilymphatic fluid and blood samples at the time of CI 
surgery were collected. No DBS could be retrieved from these adults because the national 
storage duration of DBS is limited to 6 years.
 Written (parental) informed consent was given. The study was approved by the 
Medical Ethics Committee (CME) of the LUMC, the Netherlands. 
Specimen processing
Blood samples
EDTA-anticoagulated blood samples were drawn during CI surgery from the prospectively 
included pediatric and adult CI recipients. IgG anti-CMV antibodies were measured in 
plasma using an automated chemiluminescent microparticle immunoassay (Architect, 
Abbott Laboratories, Abbott Park, IL). A CMV antibody level ≥6 AU/ml was considered to 
be positive.
Dried blood spots 
In the Netherlands, dried blood spots (DBS) are routinely collected from all newborns 
within a few days of birth for the nationwide metabolic and endocrine screening program. 
These are stored for a maximum of 6 years at the National Institute for Public Health and 
the Environment (RIVM, Bilthoven, the Netherlands). After parental informed consent, DBS 
were retrieved from pediatric CI recipients younger than 6 years of age. 
 DNA was extracted from the DBS using the QIAamp DNA Mini Kit following the 
protocol “Isolation of total DNA from FTA and Guthrie cards”, as described previously[15]. 
 
Perilymphatic fluid
Study participants received standard care cochlear implantation including a mastoi dectomy 
with facial recess approach into the middle ear. During cochleostomy, the scala tympani 
was entered with a 24 gauge needle attached to a 1 ml syringe, and the routinely exposed 
perilymphatic fluid was aspirated. The specimen (10-50 µl) was transferred to the 
laboratory within an hour, where the fluid was supplemented with phosphate buffered 
saline (PBS) to a total of 100 µl.
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DNA was extracted from the perilymphatic fluid using the QIAamp DNA Blood Mini Kit 
following the protocol “Isolation of total DNA from Blood or Body Fluids (spin protocol)”. 
Real-time PCR
CMV DNA amplification
Amplification of a 126-bp fragment from the CMV immediate-early antigen region was 
performed using an internally controlled quantitative real-time PCR as described 
previously [15, 16]. Ten µl of DNA extract was used. Quantification was performed using a 
dilution series of titrated CMV (strain AD169; Advanced Biotechnologies Inc., Columbia, 
MD) as an external standard.
Beta-globin amplification
To control for the presence of human DNA in perilymphatic fluid, a 110-bp fragment of the 
housekeeping gene beta-globin was amplified by means of a monoplex real-time PCR. 
Ten µl of DNA extract of perilymphatic fluid was added to 40 µl PCR pre-mixture obtaining 
final concentrations of 0.5 µM forward beta-globin primer (5’ AAG TGC TCG GTG CCT TTA 
GTG 3’), 0.5 µM reverse beta-globin primer (5’ ACG TGC AGC TTG TCA CAG TG 3’) , 0.2 µM 
beta-globin TaqMan probe (YAK- 5’ TGG CCT GGC TCA CCT GGA CAA CCT 3’ -BHQ-1), 4.5 
mM MgCl2, and 25 µl HotStar Master Mix (QIAGEN, Hilden, Germany). Template denaturation 
and activation of HotStar Taq DNA polymerase for 15 min at 95°C were followed by 50 
cycles of denaturation at 95°C for 5 s, annealing at 55°C for 15 s, and extension at 72°C for 
15 s. Real-time PCR was performed using a CFX96TM Real-Time PCR Detection System 
(Bio-Rad, Veenendaal, The Netherlands). Quantification was performed using a 10-fold 
dilution series of human genomic DNA (Promega Netherlands) (100 ng/µl to 0.1 pg/µl) as 
standard.
Genotyping of CMV
CMV envelope glycoproteins gB (UL55) and gH (UL75) genotypes were determined by 
means of two multiplex real-time PCR assays, as described previously[17]. 
Results
Pediatric CI recipients
Prevalence of cCMV
A total of 76 pediatric CI recipients were included in the study. Thirty-one patients were 
included prospectively and received a CI in the two university medical centres between 
2010 and 2011 (LUMC: n=13, UMCN: n=18). The median age was 1 year (range 8 months - 8 
years). Forty-five patients received a CI from 2003 to 2008 and were included retrospec-
tively (DECIBEL-study [8], age range 3-5 years).  
122
Chapter 3
Blood samples were available from 29 of the 31 prospectively included patients (Table 1), 
of whom 52% (15/29) were CMV IgG seropositive. CMV IgG seronegativity excluded cCMV 
infection.   
DBS of 70 out of 76 patients were available for CMV DNA detection. Thirteen of those were 
from CMV IgG seronegative patients and the other 57 DBS were from seropositive patients 
or from patients with unknown serostatus (no blood sample available from the 45 retro-
spectively included patients). Ten out of 70 tested DBS were CMV DNA positive (14%), 
demonstrating congenital infection.  
CMV in perilymphatic fluid
Intraoperatively collected perilymphatic fluid was available for CMV DNA detection of 29 
of the 31 prospectively included pediatric patients. The beta-globin PCR, which controlled 
the presence of human DNA, was positive in all but one perilymphatic fluids (median 
cycle threshold 31, range 27-37). The single child with the beta-globin negative 
perilymphatic fluid (implicating an insufficient amount of perilymphatic fluid sample for 
DNA detection) was also CMV seronegative, excluding cCMV infection. 
 Two of the perilymphatic fluid samples were from children with CMV positive DBSs, of 
whom one perilymph was CMV DNA positive (50%). The plasma sample (drawn during 
surgery) of the child with CMV positive perilymph was CMV DNA negative, which excluded 
capillary leakage of CMV into the perilymph. 
Table 1   CMV results of pediatric and adult CI recipients with pre- and perilingual 
deafness included in this study. CMV IgG serostatus at the age of CI surgery, 
CMV DNA detection in DBS (drawn at birth) and perilymphatic fluid  
(sampled during CI surgery) are shown. 
CI recipients CMV serostatus CMV DNA positive
DBS Perilymfatic fluid
Children CMV IgG positive (n=15) (15/29=52%) 2/10 1*/14
CMV IgG negative (n=14) 0/13 0/14
CMV IgG NA (n=47) 8/47 0/1
Total (n=76) 10/70 (14%) 1/29
Adults CMV IgG positive (n=11) (11/20=55%) 0/11
CMV IgG negative (n=9) 0/9
CMV IgG NA (n=1) 0/1
Total (n=21) NA 0/21
* Also CMV positive DBS ; NA: not available
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Retrieval of clinical data revealed that the child was asymptomatic at birth and the hearing loss 
was detected in the first few weeks after birth. The MRI cerebrum showed white matter 
lesions. At the age of 2 years, no other neurological sequelae were apparent at physical 
examination.  
 All other perilymphatic fluid samples were CMV DNA negative.
Viral load and genotyping
Viral load and genotype results of the 7 pediatric CI recipients with CMV DNA positive DBS 
and/or perilymphatic fluid samples available (out of 10) for genotyping are shown in table 
2. The median CMV DNA load in DBS was 4.0 (range <2.5 - 5.9) log10 copies/ml. All different 
gB and gH genotypes were detected in the DBSs and no clear association between viral 
load and genotype was seen. 
The CMV strain detected in the perilymph of the congenitally infected girl was genotypically 
identical to the strain present in her DBS (gB1/gH2). 
Adult CI recipients
In total 21 adult CI recipients with profound pre- or perilingual deafness were included 
prospectively (Table 1). They received a CI at the LUMC. The median age was 44 years 
(range 23 to 78 years). 
Table 2   Viral load and genotype results of the pediatric CI recipients (n=7) with  
CMV DNA positive DBS and / or perilymphatic fluid samples available for 
genotyping.
Patient DBS Perilymphatic fluid
CMV DNA load
(copies/ml  
whole blood)
Genotype CMV DNA  
(Cycle  
threshold, Ct)
Genotype
Prospectively included 
1 4.0 log10 gB1 gH1 Negative
2 2.9 log10 gB1 gH1 Positive (Ct 31) gB1 gH2
Retrospectively included 
3 4.9 log10 gB4 gH1 NA 
4 5.9 log10 gB3 gH2 NA
5 5.3 log10 gB2 gH1 NA
6 <2.5 log10 gB2 gH1 NA
7 3.6 log10 ND ND NA
DBS; dried blood spots, gB; glycoprotein B, gH; glycoprotein H, NA; not available, ND; not detected.
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Eleven of 20 the adult recipients were CMV IgG seropositive (55%) at the age of CI surgery, 
demonstrating previous infection with CMV, either congenitally or postnatally acquired. 
Because DBS were not available from adult patients, this distinction could not be made.  
 Six out of 21 adult recipients had possible alternative causes for their deafness 
(meningitis, congenital malformation, and connexin 26 mutation). CMV IgG seroprevalence 
among the adult recipients with deafness of unknown cause was 70% (7/14, median age 
44 years), demonstrating a higher percentage of congenitally or postnatally acquired CMV 
infections.
CMV in perilymphatic fluid
Perilymphatic fluid was available for CMV DNA detection for all 21 adult recipients. The 
beta-globin PCR was positive in all but one perilymphatic fluids (median cycle threshold 
35, range 30-39). The single adult with the beta-globin negative perilymphatic fluid was 
also CMV seronegative, excluding cCMV infection. 
 None of the perilymphatic fluid samples were found to be CMV DNA positive. 
Discussion
We found that one in seven pediatric CI recipients with prelingual deafness was congenitally 
infected with CMV, stressing the role of cCMV in this patient group. Our study is in line with 
smaller studies addressing the cCMV disease burden among deaf children [18] and 
provided valuable information in view of the large number of patients (n=76) analysed.
 Furthermore, we are the first to report detection of a CMV strain in the inner ear of a 
patient at the age of 21 months that was genotypically identical to the strain present in 
this patients DBS drawn shortly after birth. The presence of CMV in the inner ear years after 
Table 3  Literature reports on CMV DNA detection in perilymphatic fluid of CI patients
Reference,  
publication year
Number of 
CI recipients (age)
Population of patients 
(etiology)
Number of patients  
of whom perilymph
Number of  
congenital CMV 
CMV positive  
perilymph/ congenital 
CMV
Clinical symptoms  
at birth of patient with 
CMV-positive perilymph
Age at CMV positive 
perilymph
Present study 76 (0-8 years) Unselected 29 10 1/2 (50%) Asymptomatic 21 months
Di Nardo22;23, 2009, 2011 4 (2-7 years) Unselected 4 1 congenital or postnatal* 1/unknown* Asymptomatic 15-month
Bauer21, 2005 6 (1-4 years) Congenital CMV 6 6 4/6 (67%) Asymptomatic (n=3) and 
symptomatic (n=1)
12, 19, 48, and 54 months
Sugiura24;25, 2003, 2004 15 (1-59 years) Unselected 8 3 2/3 (67%) Symptomatic 2 and 3 years
Literature reports on CMV DNA detection in perilymphatic fluid of CI patients. All reports included pediatric  
patients, none of the reports tested DBS. * CMV IgM seronegative
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birth has already led to the speculation that ongoing viral replication, probably combined 
with inflammation, is responsible for deterioration of hearing after birth. Our finding 
supports this theory, and the magnitude of this deterioration is underscored by the fact 
that this currently profoundly deaf toddler had normal hearing at birth. The hypothesis of 
ongoing viral replication was based on data of prolonged excretion of CMV in the urine of 
congenitally infected newborns (median duration of approximately 4 years [19]), and 
recent data on the efficacy of prolonged treatment (6 months)of cCMV infection [20]. Only 
three authors report having tried to retrieve CMV from the perilymph in a limited number 
of living patients (Table 3) [21-25]. The oldest age at which CMV DNA was reported to be 
detected in the inner ear of a patient was four-and-a-half years [21]. Our data combined 
with these previous reports detecting CMV in perilymph, suggest that a large part of 
congenitally infected children harbor CMV DNA at later ages (50-67%). 
 Our finding that no CMV DNA could be detected in perilymph from adult CI recipients 
could theoretically be explained by an absence of cCMV in this group. However, on the 
basis of available literature, it is likely that a proportion of adult CI recipients with prelingual 
deafness of unknown cause would have cCMV. The CMV seroprevalence in our cohort of 
adult CI recipients was highest (70%) when selecting for patients with deafness of 
unknown cause, demonstrating a larger proportion of congenital and/or postnatally 
acquired infections. Another possibility is that CMV remained present in perilymph for 
only a limited period. Larger series of adult patients with confirmed cCMV infection should 
be studied to test this hypothesis.
 In agreement with earlier studies by our and other groups attempting genotyping 
CMV on DBS, a genotype could be assigned to approximately 75 to 80% of the DBS 
samples [17, 26, 27]. The main limitation for the detection of CMV DNA in DBS is the small 
amount of dried blood (50 µl per spot) available and has been shown to be a challenge 
[15, 26, 28-31]. Genotypes gB1 and gB3 have been reported to be the most prevalent 
Table 3  Literature reports on CMV DNA detection in perilymphatic fluid of CI patients
Reference,  
publication year
Number of 
CI recipients (age)
Population of patients 
(etiology)
Number of patients  
of whom perilymph
Number of  
congenital CMV 
CMV positive  
perilymph/ congenital 
CMV
Clinical symptoms  
at birth of patient with 
CMV-positive perilymph
Age at CMV positive 
perilymph
Present study 76 (0-8 years) Unselected 29 10 1/2 (50%) Asymptomatic 21 months
Di Nardo22;23, 2009, 2011 4 (2-7 years) Unselected 4 1 congenital or postnatal* 1/unknown* Asymptomatic 15-month
Bauer21, 2005 6 (1-4 years) Congenital CMV 6 6 4/6 (67%) Asymptomatic (n=3) and 
symptomatic (n=1)
12, 19, 48, and 54 months
Sugiura24;25, 2003, 2004 15 (1-59 years) Unselected 8 3 2/3 (67%) Symptomatic 2 and 3 years
Literature reports on CMV DNA detection in perilymphatic fluid of CI patients. All reports included pediatric  
patients, none of the reports tested DBS. * CMV IgM seronegative
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genotypes in congenitally infected infants[17, 32-36]. The association of specific genotypes 
with congenital disease has been addressed with controversial results and is limited to the 
association of genotype gN4 with long-term sequelae [37] and genotype gB3 being 
found more often among congenitally CMV-infected than in postnatally infected children 
[38]. In our analysis, no clear association between specific CMV gB and gH genotypes and 
CI recipients and/or viral load was observed. However, the numbers were limited.
 In short, our data stress the role of cCMV among CI recipients with prelingual deafness. 
Evidence accumulates that the congenitally acquired CMV strain is harbored in the inner 
ear for many years, resulting in progressive damage with deterioration of hearing, 
potentially leading to profound deafness. Ongoing viral replication might be influenced 
by antiviral therapy, and future data will reveal the efficacy of prolonged and/or postponed 
antiviral treatment of cCMV infected newborns at risk for profound hearing impairment.  
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Abstract
Objectives 
To investigate health-related quality of life (QoL) in children with a profound hearing loss 
due to congenital cytomegalovirus (cCMV) infection and treated with a cochlear implant 
(CI).  Results of standardized QoL questionnaires are compared with a matched control 
group of children without co-morbidities and with a CI. 
Material and Methods
In this explorative retrospective case-control study, two groups of children with CIs were 
compared: 25 with co-morbidities as a result of cCMV and 37 without co-morbidities. The 
main outcome measures were medical data, non-verbal IQ, age at implantation, months 
of CI use and speech perception results were available for analysis. The Nijmegen Cochlear 
Implant Questionnaire (NCIQ) and the Pediatrics Quality of Life Measurement (PedsQL) 
were administered to measure (health-related) QoL. 
Results
The NCIQ total score and all but one NCIQ sub-domain had more variable score 
distributions compared to the control group. Median NCIQ total scores and sub-domain 
scores indicate lower QoL for the study group compared to the control group. Only half of 
the children in the study group attained a PedsQL total score above 65.4 (“good QoL”). 
Within the study group, IQ, implantation (unilateral or bilateral), hours of daily CI use and 
speech perception were positively associated with QoL outcomes.
Conclusion 
The QoL scores on the disease-specific and general health questionnaires were more 
variable and were generally lower than the control group’s scores. Cognitive impairment, 
co-morbidity and low speech perception could influence QoL after implantation. 
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Introduction
Congenital cytomegalovirus (cCMV) can cause sensorineural hearing loss. cCMV is an 
intrauterine viral infection and has a prevalence of 0.2-2% in western counties. Of the 
children born with cCMV, 90% are asymptomatic. Symptomatic cCMV manifests as severe 
neurologic sequelae, including sensorineural hearing loss in 29% of cases. Before the age 
of five, approximately 15% of initially asymptomatic children develop long-term sequelae, 
including hearing loss and behavioral problems [1, 2].
 Cochlear implantation in children with (symptomatic) cCMV infection and profound 
hearing loss can provide beneficial, but sometimes limited, performance outcomes. 
Speech perception is more severely impaired mainly in cCMV children with cognitive 
disabilities in comparison to children with CI without co-morbidities. The spoken language 
is impaired in the majority of the symptomatic cCMV children (with and without cognitive 
disabilities) and cochlear implant (CI) [3, 4].  Subjective outcome measures, such as (health-
related) quality of life (QoL), are an important adjunct to traditional outcome measures 
especially in children with severe developmental disabilities. Children with CI due to 
cCMV-related deafness have attained improved QoL, based on individual reports from 
parents of the children [5]. 
 The aim of this study is to compare the health-related QoL by means of standardized 
questionnaires in two groups of children who use a CI: those with cCMV infection and 
those without co-morbidities. 
Patients and methods
Ethical considerations
An explorative, retrospective case-control study was performed. After approval of the 
study protocol by the ethic committee, the authors searched the CI databases of several 
academic hospitals in the Netherlands and identified children with cCMV-related deafness 
and were treated with CI.  The control group was selected from records of previous studies 
from the Radboud University Medical Centre in Nijmegen of which the data of QoL 
questionnaires were available [6].
Study group
The parents of 31 children with cCMV infection were invited to participate in this study. 
The parents of 26 children responded to this invitation and provided informed consent 
and 25 children were included in the study group. Note one child was excluded because 
the child’s age at implantation (14 years) was considered an outlier as age at implantation 
for the remainder of the group was below 8 years. The mean age at implantation for the 
25 children in the study group was 2;6 years (SD 18 months). 
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The diagnosis ‘cCMV infection’ was based on PCR (polymerase chain reaction) on Guthrie 
card, or positive urine culture on CMV direct postpartum or increased CMV titre. Children 
were considered ‘symptomatic’ if one or more significant neonatal abnormality was 
identified, including congenital hearing loss, petechien, jaundice, hepatosplenomegaly, 
microcephaly, and/or fundoscopic abnormalities. The remaining children were considered 
‘asymptomatic’ and had progressive hearing loss in the first years of life. 
Control group
The control group consisted of 37 children with congenital severe or profound sensorineural 
hearing loss (hereditary or of unknown origin), had no other reported co-morbidities and 
who were implanted with a CI between 1996 and 2010. None of these children had a 
progressive hearing loss. Mean age at implantation was 3;5 years (SD 24 months). This 
would now be considered a relatively late implantation age for children with congenital 
severe of profound hearing loss and no co-morbidities.  
 Exclusion criteria were prematurity, congenital malformation of the middle or inner 
ear structures, and cognitive disability (IQ<85). Children were then matched with the 
study group for age at implantation and gender. 
Data
Data for the following four variables were obtained from the records of the control and 
study groups: medical information (neonatal investigations) as described above, 
non-verbal IQ, age at time of unilateral or bilateral implantation, months of CI use at time 
of conducting the questionnaires (referred to as ‘follow-up at Q’) and speech perception 
test scores. 
 For both groups, the mean age at implantation was not different (p=0.07, Chi squared 
test)(see Table 1). The distribution of males and females  was not different between the 
study group and the control group (p=0.44, Chi-squared test). The children in the study 
group were older than the children in the control group when the QoL questionnaires 
were completed. We discuss the implications of this later in this paper. 
Cognitive abilities
The Dutch version of the Bayley Scales of Infant Development (BSID-NL-II) [7], the Snijders 
Oomen non-verbal intelligence test (SON-R) [8], or the Kent Infant Development Scale 
(KID-N) [9] was administered to obtain a child’s performance IQ. Children were divided 
into four predetermined categories based on IQ scores: <70, 70-85, 86-115 and >115. There 
were no IQ data for 15 children in the control group because there was no indication of 
developmental delay. 
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Questionnaires
Two standardized parent-proxy questionnaires were used to evaluate QoL: a disease-spe-
cific health-related questionnaire, the Nijmegen Cochlear Implant Questionnaire (NCIQ) 
[10] and a generic health-related questionnaire, the Pediatrics Quality of Life Measurement 
(PedsQL) [11]. Electronic or hardcopies of these questionnaires were sent to parents of 
children, depending on the preference of the parents. 
 Parents of children in the control group had completed the questionnaire as part of 
the clinic’s standard evaluation process. The questionnaires were completed on average 
three years post-implantation [6]. Parents of children in the study group received the 
questionnaires as part of this study on average of six years post-implantation. The results 
of the NCIQ, and PedsQL domains were computed following the guidelines of each 
questionnaire. 
 In addition to the above QoL questionnaires, parents also completed an in-house/
non-validated general questionnaire. This questionnaire asked parents to estimate the 
number of hours per day that his/her child used the CI.  
Speech perception
Speech perception was measured with the NVA test, a Dutch standardized open-set 
monosyllable test. Words were presented at conversational level (65dB SPL). The speech 
perception was conducted no more than one year after ‘follow-up at Q’. Children who 
were too young to complete the NVA speech test, who had limited auditory functions or 
who had poor cognitive abilities completed a closed speech perception test. Speech 
perception tests were conducted with the CI in the optimal fitted condition (i.e. bilateral 
CI, unilateral bimodal or single CI).
Nijmegen Cochlear Implant Questionnaire [10]
The NCIQ contains 60 questions and covers three domains: physical, psychological, and 
social. Each domain can be subdivided. Per domain, scores can range from 0 to 100, where 
0 indicates very low quality of life and 100 indicates very high quality of life. The NCIQ total 
score is the mean score of the six sub-domains [12]. The NCIQ has been used to evaluate 
cochlear implantation in children [13, 14].
Pediatrics Quality of Life Measurement [11]
Different versions of the questionnaire were used depending on the age of the child. The 
questionnaire consists of 23 questions, which are divided into four domains: physical 
functioning, emotional functioning, social functioning and school functioning. The total 
score ranges from 0 to 100 and a higher score indicates a better quality of life. A total score 
of 65.4 is considered a cut-off score and children with scores below this cut-off are 
considered at-risk of an impaired HR-QoL status [11]. The PedsQL has been used in studies 
of children with a CI [14-16].
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Statistical analysis
Statistical analyses were completed using SPSS (statistics 22, IBM Corp, Armonk, NY). 
Descriptive statistics were used to compare baseline characteristics between the groups, 
including child gender, child age at questionnaire administration, child age at implantation, 
years of device use (unilateral or bilateral CI). Nonparametric tests (chi-squared test, 
Mann-Whitney U test) were used to test for differences between the study and control 
groups. Correlations were calculated using Spearman’s rank order correlation coefficient.
Results
Characteristics 
All but one child in the study group had symptomatic cCMV. Co-morbidities included 
cognitive disability, delayed motor development, visual impairment, epilepsy and eating 
disorder. The child with asymptomatic cCMV had a progressive hearing loss and no other 
reported co-morbidities. This child was implanted at 57 months. 
 All children were implanted in the period from 1996 to 2013 and all procedures 
followed standard protocols with complete insertion of the electrodes into the cochlea 
and no major complications.
 Table 1 lists the general characteristics of the study group and control group. Although 
the control group was younger at age of ‘diagnosis of deafness’, mean age at diagnosis 
for both groups was below twelve months. More children with cCMV infection were 
implanted bilaterally compared to the control group (p=0.002; chi-squared test).  ‘Follow-up 
at Q’ for all children in the control group was 8;6 years or less whereas it was below 14;8 years 
for the study group. To account for this difference we performed two analyses: one using 
all participants in the study group and a second analysis, referred to as the  ‘sub analysis’ 
that excluded data  of children in the study group with a follow-up over 8;6 years (in total 
seven children).
 In the study group, for seven children, no open-set speech perception scores were 
available. At the time of data collection, five children had not completed any speech 
perception testing and two children had been tested just with a closed-set speech 
perception test (note that both children attained 100% closed-set scores). In the study 
group, one child  was too young to complete the NVA test, but attained 83% correct score 
on a closed-set speech perception test). The open-set speech perception scores of the 
two groups did not significantly differ (Mann-Whitney-U test p= 0.07).
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Table 1   Patient characteristics
cCMV: 25 Controls:  37
Gender
Female 14 (56%) 20 (54%)
Male 11 (44%) 17 (46%)
Mean age at diagnosis (deafness) 
(months)
8.7 (2-37) 6.3 (0-75)
IQ
<70 4 (20%) 0
70-85 3 (15%) 0
86-115 13 (65%) 16 (73%)
>115 0 6 (27%)
Missing data 5 15
Implantation date (year) 1998-2013 1996-2010
Implantation
Unilateral 15 (60%) 34 (92%)
Bilateral 10 (40%) 3 (8%)
Mean age at implantation 30.2 (11-64) months;  
2;6 years
41.3 (9-87) months;  
3;5 years
Follow-up at Q 81.2 (12-176) months
6;9 years
38.9 (9-102) months;
3;3 years
Mean age at Q 112.7 (30-233) months;  
9;5 years
80.7 (26-162) months;  
6;8 years
Daily CI use (hours)
0-2 2 (9%) 0
2-6 0 0
6-9 1 (5%) 0
9-12 6 (27%) 11 (35%)
12-16 11(50%) 18 (58%)
>16 2 (9%) 2 (7%)
Missing data 3 (-) 6 (-)
Speech perception 65 (0-97) 84 (15-99)
Missing data 7* 1
Between brackets: percentage or range; Q: questionnaires; * two children too young to test, five missing
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NCIQ
Figure 1a displays the results from the NCIQ for the two groups. The NCIQ total score was 
more widespread in the study group compared to the control group (Mann-Whitney-U test). 
This distribution pattern is seen for all sub-domains (p<0.05) except ‘speech production’ 
(p=0.18). The median total NCIQ score and the medians of all but one sub-domain were 
lower in the study group compared to the control group. 
Figure 1a  Total score and domain scores of the total study group and total control group
Figure 1b   Total score and domain scores of the selected study group (follow-up at  
Q< 8;6 years) and total control group
Open boxes: study group; shaded/filled boxes: control group; boxes: 25-75%; horizontal line: median. PSA: Physical 
sound perception advanced; PSB: Physical sound perception basic; PSE: Psychological self-esteem; PSP: Physical 
Speech Production; SAL: Social activity limitations; SAI: Social interactions; SPS Physical speech production; 
* significant difference in distribution between study and control group.
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Figure 1b shows the result after excluding the 5 children with follow-up > 6.8 years. Little 
difference is seen between Figures 1a and 1b. The sub analysis showed that there was no 
statistical difference in outcome between the full group (n=27) and subgroup (n=20) 
(Man-Whitney-U test). The mean speech perception score of this subgroup was 68% and 
did not significantly differ with the mean speech perception score (84%) of the control 
group (Mann-Whitney-U test p=0.12). 
PedsQL
Figure 2a displays the PedsQL results for the two groups. The scores for the study group 
were more widespread than the control group for the PedsQL total score and all 
sub-domains with the exception of emotional (p=0.19). The median total score and 
median sub-domain scores were lower in the study group than in the control group. 
Only half of the children in the study group attained a total PedsQL score above the 65.4 
cut-off (86.5 in control group).
 The sub analysis showed again that there was no statistical difference in distribution 
between the full group (n=27) and subgroup (n=20) (Man-Whitney-U test). However, 
when comparing figures 2a and 2b, differences are obvious with regard to the minimum 
values. Apparently, excluding the seven patients who had completed QoL questionnaires 
more than 8;6 years after CI, resulted in excluding patients with the lowest scores on the 
PedsQL. 
Correlations 
Table 2 lists the results of the correlation analyses. There was a significant positive 
correlation within the study group between performance IQ and both the total score of 
the NCIQ and the PedsQL  (p=0.001 and p=0.016, respectively). Within the study group, 
high daily CI use and bilateral implantation were both significantly associated with higher 
total NCIQ scores (p=0.04 and p=0.01 respectively). Bilateral implantation was significantly 
associated with higher total PedsQL scores (p=0.04). Speech perception scores and the 
NCIQ total score were positively correlated in both the study and the control groups.
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Figure 2a  Total score and domain scores of the total study group and total control group
Figure 2b   Total score and domain scores of the selected study group (follow-up at 
Q< 8;6 years) and total control group
Open boxes: study group; shaded/filled boxes: control group; boxes: 25-75%; horizontal line: median PF: physical 
functioning; PS: psychosocial health summery score (sum score of the items over the numbers of items answered 
in the Emotional, Social and School functioning sub-domains). Dotted line: cut off point 
* significant different in distribution between study and control group.
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Table 2   Correlations
Studygroup Control group
Variables Total  
NCIQ test
Total 
PedsQL
Total NCIQ 
test
Total 
PedsQL
IQ Correlation 
Coefficient
.7** .6* .032 .242
Sig. (2-tailed) 0,001 0,02 ns ns
N 20 17 22 22
Uni/bilateral Correlation 
Coefficient
.5* .2 .102 .334*
Sig. (2-tailed) 0.01 ns ns 0.04
N 25 22 37 37
Implantation age 
(months)
Correlation 
Coefficient
-.3 -.3 -.331* -.004
Sig. (2-tailed) ns ns 0.05 ns
N 25 22 37 37
Follow up at Q Correlation 
Coefficient
-.3 -.4 -.105 -.176
Sig. (2-tailed) ns ns ns ns
N 24 21 37 37
CI use per dag (hours) Correlation 
Coefficient
.5* .3 .234 -.171
Sig. (2-tailed) 0.04 ns ns ns
N 22 19 31 31
Speech perception Correlation 
Coefficient
.6** .2 .378* -.116
Sig. (2-tailed) 0.008 ns 0.02 ns
N 18 16 36 36
* Correlation is significant at the 0.05 level (2-tailed). ** Correlation is significant at the 0.01 level (2-tailed). Shaded 
cells: significant correlations. Spearmans’ rho.
CI: cochlear implant; IQ intelligence quotient; N number; NCIQ Nijmegen Cochlear Implant Questionnaire; ns: not 
significant; PedsQL Paediatrics Quality of Life Measurement; Q questionnaire; Sign: significant
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Discussion
Synopsis of key findings
Children with cCMV-related deafness who use a CI have lower and more wide-spread 
disease-specific QoL scores and generic health-related QoL scores then deaf children 
without co-morbidities who use a CI. Interesting, in 50% of the patients in the study group 
in comparison to 86.5% of the patients in the control group, the total PedsQL showed 
scores above the cut-off value of 65.4 as introduced by Varni et al. [11]. This indicates that 
half the children in the study group had relatively good QoL. For the remaining children, 
scores below cut-off indicate that the parent/caregiver had concerns about the wellbeing 
of his/her child. For the NCIQ results such a cut-off score is not defined. 
Comparison with other studies
The wider spread and lower median scores in almost all sub-domains in the study group 
for both QoL questionnaires might be explained by the co-morbidities and variable 
cognitive abilities of children in the study group. This idea is supported in the work by 
Zaidman et al. [17], who described lower health-related quality of life in people with 
developmental disabilities and our finding of correlation between cognition (IQ) and the 
NICQ total score. The spread in QoL outcomes might correspond to the various presentations 
of cCMV infection, varying from asymptomatic patients to patients with neurologic sequelae 
(intellectual disability and neurologic abnormalities [18, 19]). 
 Several published studies reported that social and emotional well-being is associated 
with speech perception and communication abilities [20, 21]. In agreement with those 
observations, we found a relationship between speech perception scores and total 
PedsQL score. 
Strength and weakness of the study
The retrospective nature of the study is a limitation to the study design and resulted in 
heterogeneous groups that contained missing data. Nevertheless, this aspect played a 
role in either group.  Age at implantation and the duration of CI use differed between the 
groups. As the study group was implanted at a later age and at a later period than the 
control group, this may explain the higher number of children with bilateral CIs in the 
study group. 
 The control group had a shorter duration from implantation to follow-up when QoL 
data was gathered (coded as ‘follow-up at Q’). Excluding children in the study group with 
lengthy follow-up and repeating the analysis did not change any outcomes. We note, 
however, that excluding these subjects also resulted in removal of children with poor 
PedsQL scores. This suggests a (negative) effect of time of follow-up on the quality of life, 
what is not likely. It is speculated that other factor must have played a role like changing 
inclusion criteria over time. 
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For reasons not recorded in the children’s medical records, speech perception results 
were not recorded for five children in the study group. If low auditory functioning was the 
reason speech perception testing was not performed, the average speech perception 
scores we used in our analysis are overestimated. 
 Sophisticated statistical analysis was not possible due to the relatively small sample 
sizes and the heterogeneity within the study group.  Nonetheless these weaknesses, as far 
as we know, the present study comprises the largest group of patients with cCMV with a 
significant follow up, evaluated with one and the same test procedure.
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Abstract
Criteria for cochlear implants are expanding and now include children with disabilities in 
addition to hearing loss, such as children with Kabuki Syndrome. This case report describes 
the language outcomes and changes in quality of life of a female child with KS after 
cochlear implantation. The subject had a profound progressive sensorineural hearing loss, 
cognitive impairments and other disabilities and communicated using vocalised sounds 
and Dutch Sign Language. After cochlear implantation at age 9;03, the patient displayed 
no progress in speech production and minimal progress in receptive language development 
but the subject had increased awareness of the world and an increase in quality of life. 
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Introduction
Hearing impairment is one of the characteristics of Kabuki Syndrome (KS) and is seen in up 
to 50% of cases. Otitis media, malformation of the ossicular chain or various structural 
anomalies of the inner ear [1-3] can cause conductive, sensorineural or mixed hearing loss 
[1, 4]. For patients with KS and a profound sensorineural hearing loss, a cochlear implant 
(CI) can be considered. CI placement, however, can be challenging because of the additional 
handicaps and the anomalies of the petrosal bone. To the best of our knowledge, there 
is no literature describing the application of CI in individuals with KS. The estimated 
prevalence of KS is 1/32,000[5].
 One of the aims of this case study is to provide an overview of the challenges health 
professionals may face when considering CI in children with KS and provide an indication 
of the outcomes so health professionals and families can have realistic expectations of 
what changes to language development and quality of life are possible after implantation. 
The second aim of this report is to investigate whether these challenges are similar to 
those of other patients with a profound hearing loss in addition to another disability. 
We use postoperative speech and language scores and data  as indices of CI outcome. 
Table 1
Clinical characteristics
Peculiar facial expression (“facies myopathica”)
Thin upper lip
High-arched palate
Uvula bifida
Blue sclerae
Left-sided strabismus convergens and a Brown anomaly of the right eye
General muscular hypotonia
Hyper mobile joints in the extremities
Short fifth digit on left hand
Microcephaly (-3 SD)
Left sided congenital hip dysplasia with hip luxation
Cardiovascular anomalies: a slight pulmonary subvalvular stenosis, multiple septal defects and an 
atrial septal defect
Delayed physical growth and neurodevelopmental skills1
1.  Sit up straight without aid at 13 months, walk at two years.
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Case study
The female subject was born via a cesarean section (because of oligohydramnion and 
fetal distress) in the Netherlands in 2001. The child’s mother was Cuban (Spanish speaking) 
and the father was Italian (Italian speaking). The parents communicated in Spanish and 
neither spoke Dutch fluently. At the age of one year, the subject was diagnosed with 
bilateral profound sensorineural hearing loss after brainstem evoked response audiometry 
(BERA) indicated  auditory thresholds of 55 dB for the right ear (AD) and 80 dB for the left 
ear (AS). In the same year, the subject was diagnosed with KS by a pediatric neurologist 
(Table 1, a list of the subject’s clinical features). From the ages of 1;6 to seven years, the 
subject predominately wore bilateral hearing aids only at day care. Audiological 
assessment at eight years of age revealed a progressive hearing loss (Figure 1). At this stage 
no signs of speech perception were observed. 
CT showed bilateral enlarged vestibular aqueducts (EVA) Progressive hearing loss is 
common in people with EVA syndrome. Both left and right ossicular chains had a normal 
aspect, the mastoid appeared normal and no vascular anomalies were observed. The 
right modiolus was incomplete and the cochlea was classified as incomplete partition 
type II [6]. There was also evidence of dysplasia of the vestibulum and semicircular canals 
(Figure 2). On subject’s left side there was evidence of mild dysplasia of the semicirculair 
canals. These abnormalities within the vestibulocochlear system were confirmed using 
MRI (Figure 3). The MRI also showed there were no anomalies of the facial nerves or vestib-
ulocochlear nerves. A velocity step test indicated bilateral areflexia.
Figure 1  Pure tone audiometry before implantation
age: 8 years 7 months
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At the age of six the subject began attending a boarding school for deaf children with 
developmental disabilities and at the school she started learning Dutch Sign Language. At 
the age of 6;4, a Dutch version of the Non Speech Test (NNST; [7]), supported by sign 
language, indicated receptive and expressive language developments levels 
corresponding with a 21 month old hearing child. A cognitive assessment when the 
subject was seven showed an estimated non-verbal IQ of 54 (the Snijders-Oomen 
Nonverbal Intelligence Test; SON-R2,5-7 [8]).  
At the age of 9;6, the subject was implanted with a CI. The right side was selected because 
of its better preoperative hearing abilities and continued use of amplification compared 
to the left ear. The parents received extensive counseling that the outcome of CI may be 
low because of the subject’s relatively high age for CI, her limited preoperative language 
skills and her intellectual disabilities.
Figure 2  Cochlea
CT cochlea right side, incomplete partition type II
Figure 3  
MRI T2; Grey arrows: cochlea; Small white arrow: relatively large vestibulum with dysplasia 
of the semicircular canals; Big white arrow: enlarged vestibular aqueduct
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The surgical procedure was performed via a cortical mastoidectomy and a posterior 
tympanotomy. During the cochleostomy, perilymph was released under slight pressure 
but no real gusher occurred. The cochleostomy was closed effectively with fascia and 
Tissucol. A Nucleus 22-electrode CI (Nucleus ® CI512 with contour advance electrode) was 
completely inserted. Intraoperative testing using stapes reflexes and neural response 
telemetry of all electrodes showed normal device functioning. 
One year after implantation, aided auditory thresholds (using headphones) were 
between 30 and 40 dB (Figure 4). Language comprehension was tested using the Reynell 
Developmental Language Scales (RDLS)[9]. The subject performed at a developmental 
level of an 18 month-old. On the test she could correctly point to some objects on verbal 
request, but she needed additional sign language to understand more than single-word 
tasks. In terms of speech production, at this age she only produced isolated sounds. 
 At two and a half years postoperatively (age of 12 years), the subject’s RDLS level had 
improved to an age equivalent of 23 months. When language was supported with sign 
language, the subject’s language was at a level comparable to a three-year old hearing 
child. Perceptive speech and language skills continued to progress slowly over this time. 
At this stage, the subject was receiving frequent training with a speech therapist. 
Figure 4  Pure tone audiometry after implantation
age: 10 years 9 months. No reaction with the hearing aid on the left side on frequencies of 
>0.5 kHz
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Discussion
The criteria for cochlear implantation continues to expand and children with plural 
disabilities are now eligible for CI. Although there are limited studies evaluating the use of 
CI on communication in children with plural disabilities, the results to date have been 
promising. We present this case study of a child with KS who had a profound hearing loss 
in addition to other impairments. The aim of our study was to contribute to the knowledge 
about the challenges of CI in patients with dual disabilities. 
 The subject was considered a candidate for CI because of her level of aided residual 
hearing in the right ear and her consistent use of a hearing aid throughout childhood. 
The expectations on the success of implantation to develop language skills were low 
given the petrosal bone anomalies, age at implantation, preoperative language abilities, 
intellectual disability and the use of more than one language in the home situation. 
 No intra-operative or postoperative complications occurred during implantation. 
Postoperatively, hearing and speech perception performance skills improved, but receptive 
and expressive language skills remained below average for the subject’s chronological age. 
The subject required lip-reading and sign-language to supplement receptive language. 
In addition to improved language, the subject had improved recognition of environmental 
sounds, displayed stronger communicative skills.
 The surgical procedure is challenging when the inner ear is malformed, however, the 
malformation observed in this subject was not regarded as a contraindication for cochlear 
implantation. No real gusher occurred during surgery, meanwhile research has shown that 
gusher does not influence postoperative speech perception performance [10]. Despite 
the incomplete partition of the cochlea, as seen on CT and MRI, there was sufficient 
cochlear lumen for an insertion of all electrodes. 
 The subject’s intellectual disability and additional handicaps made it difficult to develop 
receptive and expressive language skills after implantation. Children with additional 
disabilities, including intellectual disabilities, generally have slower progress in language 
development compared to age-matched peers [11, 12]. The majority of children with KS 
have impairments across the areas of language, speech and oro-motor functions [13, 14]. 
Regardless of whether a child has a hearing loss only or has a disability in addition to the 
hearing loss, there is a relationship between increased age at implantation and poor 
performance [15]. In this case study, this means that despite the subject’s residual hearing 
during her first years of life, her age at implantation meant she had experienced 9.5years 
with limited aural input. 
 KS and CHARGE syndrome have similar clinical features [16]. The challenges with CI 
described in this case study for a subject with KS are applicable to individuals with CHARGE 
syndrome who are eligible for CI. That is, both groups have handicaps in addition to the 
hearing loss and both groups have intellectual disabilities and anomalies of the petrosal 
bone [17]. Given the similarity between the groups and the lack of research on CI in KS, 
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studies investigating CI in individuals with CHARGE syndrome could aid clinical decision 
making when it comes to implantation in subjects with KS.
 The heterogeneity of KS characteristics ensures it is difficult to generalize the results 
of individual cases. Whether a child with KS and a hearing impairment will benefit from 
cochlear implantation depends on each individual’s profile. Although CI surgery and 
rehabilitation is challenging, our experience with the subject discussed in this case study 
indicates that CI in individuals with KS may assist language development.  
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General Discussion 
Cochlear implantation is a well-established method that enables children with profound 
to severe hearing loss to develop spoken language. The success of cochlear implantation 
in children with pre-lingual deafness without other co-morbidities has resulted in an 
expansion of the criteria for cochlear implantation. Amongst others, this expansion means 
that cochlear implantation is available for children who in addition to a hearing loss have 
another impairment, such as cognitive delay. It is, therefore, of utmost importance to identify 
the challenges and benefits of cochlear implantation in children with complex needs. 
Surgery
This thesis focuses on the challenges of cochlear implantation in children with profound 
to severe hearing loss in addition to other co-morbidities. In children with CHARGE syndrome, 
cochlear implant surgery is challenging because of the presence of congenital anomalies 
in the temporal bone at the level of the middle ear, and inner ear. Most anomalies can be 
assessed on a CT, however in some cases anomalies can only be determined on MRI. The 
anomalies vary within the population (see Sections 2.1 and 2.3 for detailed information). 
 Reduced development of the mastoid, especially in young children, may impede the 
creation of a mastoidectomy and a sufficient exposure of the area where the posterior 
tympanotomy should be performed for a clear access to the round window niche. This 
situation may be further complicated if the facial nerve has an aberrant route, which is 
frequently found in these children. In cases with an aberrant facial route and reduced 
development of the mastoid, an endaural approach instead of mastoidectomy [1], or a 
temporary intra-operative removal or anterior displacement of the posterior wall of the 
outer ear canal should be considered. Mastoidectomy can also be hindered by vascular 
anomalies such as a large emissary vein or petrosquamos sinus. The petrosquamosal sinus 
is seen more often in CHARGE syndrome than in the general population [2]. Anomalies of 
the semicircular canals, a hallmark of CHARGE syndrome, can challenge surgery because it 
is an important landmark during mastoidectomy. Probably because of the partly or total 
absence of the semicircular canals, the route of the mastoid portion of the facial nerve is 
more medial compared to the general population, which provides a wider entrance to the 
middle ear. On the other hand, the aberrant route of the tympanic portion of the facial 
nerve may result in a position over the oval window, and a more anterior route of the 
vertical portion of the nerve over the round window, which complicates the cochleostomy. 
Identifying the round window is difficult on CT and during surgery. Removal of the incus 
may render more space and a better view. The surgeon may use a combined surgical 
approach using the abovementioned endaural route with the transmastoidal route. The 
posterior tympanotomy or the endaural route, after creating a tympanomeatal flap may 
be used to perform the cochleostomy to the scala tympani. In some cases, the 
cochleostomy may have to be performed anterior to the facial nerve, and the insertion of 
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the cochlear implant’s electrode maybe executed working endaurally after passing the 
electrode array through the posterior tympanotomy. A recently published study described 
an osteoplastic approach via the posterior wall and an endaural approach in these cases 
with an aberrant route of the facial nerve [3]. Because of the difficulties localizing the 
round window and positioning and orientating the cochleostomy [4, 5], the use of a 
navigation system could be of value [5]. 
 Anomalies of the cochlea vary from a fused second and apical turn to a cochlea with 
1.5 turns. In Section 2.1, some of the children with CHARGE syndrome reported in our 
study, presented with an abnormal cochlea, shortened despite the presence of a basal, 
second and apical turn, which has not been described before in CHARGE syndrome. This 
cochlear type appears to be consistent with cochlear hypoplasia type IV as recently 
described by Sennaroglu [6]. The size and shape of the cochlea influences the choice of 
type of cochlear implant (CI) suitable for implantation. Despite the presence of cochlear 
anomalies in the children described in our studies, a standard electrode was implanted in 
all participants.  All other anomalies observed in our children were in accordance with the 
anomalies described in the literature. 
 Cochlear nerve deficiency in the form of hypoplasticity or aplasticity is frequently 
observed in individuals with CHARGE syndrome [7] (see Sections 2.3 and 2.4 for details). 
This nerve deficiency is diagnosed on MRI. Because of the positive results of cochlear 
implantation reported in children with cochlear nerve deficiency, there is indirect evidence 
of the presence of functional nerve fibres. Measuring the diameter of the internal auditory 
canal and bony cochlear nerve could help to be more aware on cochlear nerve deficiency. 
However, these measurements cannot exclude the presence or absence of cochlear nerve 
fibres. Although there are exceptions, children with cochlear nerve aplasia as observed on 
MRI have a lower chance of successful cochlear implantation compared to children with 
cochlear nerve hypoplasia [8-12]. Other than visualization of the cochlear nerve on MRI, 
there is no pre-operative diagnostic alternative to indicate the presence of the cochlear 
nerve. This makes the pre-operative assessment phase very difficult. Despite this pre- 
operative difficulty, our results indicate that every patient with (apparent) cochlear nerve 
deficiency should be considered for cochlear implantation before an alternative treatment 
using an auditory brainstem implant is considered. 
Complications 
No major complications related to temporal bone anatomy were observed in our studies 
despite the aberrant facial nerve course often associated with CHARGE syndrome.  An 
aberrant nerve course puts the facial nerve at risk of damage during cochlear implant 
surgery. The surgical techniques described above should be considered in the event the 
facial nerve deviates from its typical path. In all cases, it is advisable to use facial monitoring 
and to use the stimulus probe to diminish the risk of damaging the nerve. 
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In four of our children excessive bleeding occurred during surgery due to significant 
emissary veins. Adequate pre-operative assessment of the presence and position of aberrant 
vascular structures using CT may reduce the occurrence of preoperative haemorrhage, 
which in small children may lead to serious loss of blood volume. One may even consider 
implantation in the contra-lateral ear if emissary veins are identified. 
 In the general cochlear implant population, post-implantation infection is the most 
frequently reported complication in cochlear implantation [13]. Local infections a few 
years after surgery are described in this thesis and have been reported in CHARGE 
syndrome [4]. The incidence of post-operative infections in CHARGE syndrome is difficult 
to estimate, but may be higher than in the general population. Children with CHARGE 
syndrome may have a higher risk of persistent middle ear disease because of eustachian tube 
dysfunction due to choanal atresia [14]. Pre-existing middle ear disease may predispose 
children for post-implantation infections [15, 16]. In children with recurrent or chronic otitis 
media pre-implantation, staged surgery should be advised involving a masto idectomy 
and tympanoplasty or a subtotal petrosectomy followed by cochlear implantation several 
months later to decrease the risk of post-implantation infections [17-20]. 
 Although not described in the literature, the complications occurring during cochlear 
implantation in children with CHARGE syndrome can also occur in people with Kabuki 
syndrome. This is because of the overlap in anatomical anomalies associated with both 
syndromes. Although not studied in this thesis, cochlear implantation in children with 
congenital cytomegalovirus (cCMV) infection are likely to have similar risks for 
complications as in the general CI population as there are no cCMV-related anatomical 
anomalies of the petrosal bone [13]. 
 In addition to post-surgical complications related to anatomy, anaesthesia-related 
complications have been observed in children with Kabuki syndrome and with CHARGE 
syndrome [21, 22].  Paediatric anaesthesiologists should be aware of the possibility of 
difficulties associated with tracheal intubation, cardiac lesions and respiratory problems. 
Prolonged post-anaesthetic observation is recommended after cochlear implant surgery.
Outcomes of cochlear implantation
Cochlear implantation in children with CHARGE syndrome is beneficial; our study has 
reported open speech perception scores up to 78%. The children with the best results 
were relatively young at age of implantation and had a relatively high IQ. In addition to 
speech recognition, speech and language development might be considered one of the 
primary outcomes of cochlear implantation in children. Owing to the variability in 
co-morbidities and its severity, such as in CHARGE syndrome, the speech and language 
development will be variable as well. As an example, Section 2.2 discusses the diversity of 
cognitive abilities, hearing loss and speech and language development in children with 
CHARGE syndrome with variable degrees of hearing loss (excluding the CI users). These 
data were used as a referential dataset. 
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As demonstrated in Section 2.3, the language development in deaf children with CHARGE 
syndrome using a CI is comparable to that of CHARGE children with hearing impairment, 
fitted with hearing aids. However, as illustrated in Section 2.4, cochlear implantation is not 
always successful. In Section 2.3 we suggested that cochlear implantation is contraindicat-
ed in deaf children when aplasia of the cochlear nerve is observed on MRI, no response on 
ABR is observed and the child does not respond to sounds while using well-fitted hearing 
aids. In this case, the CI team might consider an auditory brainstem implant (ABI). Owing 
to positive results of cochlear implantation in children with cochlear nerve deficiency and 
the reported relatively modest outcomes with ABI, a possible treatment modality might 
still be to implant such children with a CI before considering an ABI. This apparent 
contradiction shows the difficulty in the decisionmaking process in children with cochlear 
nerve deficiency. The suggestion to try CI before ABI, is based on a comprehensive 
literature search and statistical analyses of pre-operative assessment imaging, audiology 
measures and performance outcomes. 
 Similar to the other groups of children, hearing and speech perception improved 
after implantation in the patient with Kabuki syndrome. This progress was, however, slow 
and limited. The child’s relatively high age at implantation, cognitive impairment and 
multilingual education likely impeded progress. 
 Cochlear implantation in children with cCMV is, overall, beneficial. Although significant 
improvements are reported [23-25] at group level, children with cCMV might not achieve 
the same levels of improvement as children without cCMV. In the literature, results have 
been reported varying from no benefit to accurate discrimination of speech sounds and 
common phrases without lip reading. Co-morbidities such as cognitive impairment, 
cerebral anomalies and psycho-neurological disorders affected the outcomes [23-25]. 
In addition to outcomes related to speech and language development, outcomes related 
to quality of life are an important marker of benefit, especially in children with multiple 
impairments and compromised development. In our studies, we compared the post-im-
plantation quality of life of children with CHARGE syndrome and of children with cCMV 
infection with a control group. The control subjects concerned cochlear implant recipients 
without co-morbidities. In both the CHARGE and cCMV study groups lower scores on the 
disease-specific quality of life questionnaire (NCIQ) were observed in comparison with the 
control groups. However, the positive scores in the CHARGE group of the GCBI that 
assesses benefit of the treatment, indicated an increase in quality of life. 
 In 50% of the children with cCMV infection, the generic health-related quality of life 
score (PedsQL) was “acceptable” [26]; the lower score for the remainder of the group 
indicated the caregivers had concerns regarding their child’s wellbeing. Both study groups 
scored significantly lower on the psychosocial domains of the generic quality of life 
questionnaire than the control group. Psychosocial wellbeing might be influenced by 
communicative abilities, and thus, by speech perception abilities [27, 28]. In general, the 
children with CHARGE syndrome and the children with symptomatic cCMV had lower 
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speech perception scores than the implanted children without co-morbidities. As discussed 
in Section 3.2, lower quality of life scores on the psychosocial domains may also have been 
linked to overall developmental delay. This is in accordance with Zaidman et al. [29] who 
reported lower health-related quality of life in children with developmental disabilities. 
 Limited improvement in generic quality of life for children with CHARGE syndrome or 
cCMV infection compared to control groups is not a contra-indication for cochlear 
implantation. This likely outcome should be discussed with caregivers during pre-implan-
tation counselling. Continued monitoring of the speech abilities and quality of life is an 
important part of post-implantation rehabilitation and should play a role in the guidance 
of these children. 
Factors influencing cochlear implantation outcomes
As described in Sections 2.3, 3.2 and 4.1, period of follow-up, cognitive abilities and other 
co-morbidities were associated with the outcomes. These conclusions are in line with 
published data  [30-33]. In our studies age at implantation was relatively high compared to 
most CI studies in children without co-morbidities, published during the last decade. One 
explanation might be that in our study group, treatment for hearing loss occurred after 
medical treatment of potentially life-threatening co-morbidities. A second explanation 
could be that implantation can only occur after time consuming, careful assessment of 
the child’s capacities and communicative needs. Coupled with this delayed development, 
caregivers may have a conservative attitude towards this group and may be reluctant to 
decide upon implantation before the developmental capacity of the child has been 
evaluated extensively. 
 Within the general CHARGE population, 78% of children present with IQ scores below 
normal levels (defined as IQ<85). Cognitive impairment is also observed in children with 
cCMV infection [34, 35] and Kabuki syndrome [36]. A relationship between cognitive 
development and communicative abilities has been reported [37] which is supported by 
the correlation between cognitive abilities and receptive language quotient, see Section 
2.2. Determining individually the influence of cognitive development on the outcome of 
cochlear implantation is not simple owing to possible confounding variables related to 
co-morbidities as found in CHARGE syndrome, cCMV infection and Kabuki syndrome. 
Two children in our group with CHARGE syndrome stopped using their CI due to serious 
general health problems. In addition to general health problems, co-morbidities such as 
visual defects, cranial nerve dysfunction and motor developmental delays might influence 
the outcome of cochlear implantation [38-40]. 
Study limitations
This thesis focuses on three specific patient groups. As CHARGE syndrome and Kabuki 
syndrome have a low incidence, the groups of children were rather limited in size. 
Although the incidence of cCMV is higher, the variability in comorbidities implies that it is 
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difficult to obtain a study group of sufficient size and homogeneity. The result of limited 
group sizes is poor statistical power. Despite the lack of statistical power, descriptive 
research remains valuable as it improves our knowledge, which is helpful when counselling 
parents and caregivers of the children. 
 The use of questionnaires to assess the benefit of cochlear implantation might also 
be viewed as a limitation. We used disease-specific and generic health-related quality of 
life questionnaires. The majority of the children in our studies were unable to complete 
questionnaires due to age or cognitive impairment and, therefore, questionnaires to be 
filled in by parents or caregivers were used. Published results concluded that parental 
proxy provides reliable information in studies comprising children with CI [41, 42] and that 
high levels of agreement were present between children who use a CI and their parents. 
In contrast, when responses of children with normal hearing are compared to his/her 
proxy completed quality of life questionnaires, the agreement is lower; an explanation for 
this discordance might be that children with a CI require more parental guidance than 
children with normal hearing [41]. This might lead to an increase in a parent’s awareness of 
the child’s wellbeing.
Future developments
Imaging is a vital component in the cochlear implantation assessment phase and the 
pre-operative implantation work-up. CT provides sufficient pre-operative information on 
a person’s temporal bone anatomy. If the surgical team uses a per-operative navigation 
system, specialized sequences are required for the CT imaging. Many clinics use ‘cone 
beam CT’ for the pre-implantation work-up. The main benefit of cone beam CT is the 
lower radiation dosage. However, high-resolution CT of the temporal bone may also be 
achieved at low dose while achieving results of comparable image quality with cone-beam 
CT [43]. Future development of other MRI sequences could improve the detection of 
cochlear nerve fibres and could make the diagnosis of cochlear nerve deficiency more 
reliable. MRI techniques such as high-resolution three-dimensional variable flip-angle 
turbo spin-echo sequencing in combination with a surface coil and diffusion kurtosis 
imaging or ultra high field imaging could improve sensitivity of MRI to allow the user to 
detect cochlear nerve fibres. 
 In addition to image improvement, diagnostic tools require improvement to assist in 
determining the functionality of any nerve fibres. To date, audiometric tools (pure tone 
audiometry, ABR, and ABR with electric stimulation via a temporarily placed electrode in 
the round window niche) lack sensitivity to predict the functionality of the nerve fibres. 
Development of other non-invasive diagnostic tools, such as diffusion weight techniques 
or functional MRI, would allow us to investigate the activity within the auditory pathway.  
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Research on the pathophysiology and treatment of cCMV is an ongoing process. No 
standardized diagnostic and therapeutic strategies are used yet [44]. Further research is 
necessary to understand the pathophysiology and to be able to treat the disease. Until the 
detrimental result of a cCMV infection on hearing may become preventable or treatable, 
it is important to be able to predict the outcomes of cochlear implantation in these 
children. 
 To perform more powerful research in these specific groups of cochlear implant 
recipients, a possibility would be to combine outcomes of evaluation studies across 
implant centres. Especially if studies used similar outcome measures and used similar 
measurement protocols, study results could be pooled. Different speech and language 
tests can be compared across studies as long as the raw data can be compared to norms 
and expressed accordingly (e.g. quotient scores). By 2018 there will be a compulsory 
national registry of people with cochlear implants in the Netherlands. A national implant 
complication registry will be linked to the system. In the future, outcome data and user 
characteristics might be linked to this system and could be used for further research (as 
long as patient data remain protected). 
 Nowadays, cochlear implantation of children with special needs occur in all cochlear 
implant centres. This thesis describes the complex diagnostic work-up, surgery and 
aftercare in these children. Because of the variety of presentations of the diseases, it is 
important that expert teams assess and are involved in providing personalized health care 
for these children. Centralization would improve care, because of the expertise present 
and the presence of multidisciplinary professionals needed. The cochlear implant team 
should cooperate with recently recognized centres of expertise (CHARGE outpatient clinic 
University Medical Centre Groningen). This recommendation applies not only to the 
patient groups described in this thesis, but could apply to all children with a hearing loss 
as a result of a rare syndrome.
General conclusion
Children with CHARGE syndrome, cCMV infection and Kabuki syndrome present with 
anatomical anomalies, cognitive disabilities and other co-morbidities that pose a challenge 
for the team considering cochlear implantation. Despite these challenges, in general 
cochlear implantation in these children is beneficial. Nevertheless, the outcomes of 
cochlear implantation in terms of speech and language development and quality of life 
are lower than that of peers without co-morbidities who use a CI. The studies described in 
this thesis suggest that aside from medical/surgical issues, cognitive abilities rather than 
the disease itself is a significant factor in the outcome of cochlear implantation. Our results 
indicated no strict contra-indications for cochlear implantation and highlighted the 
importance of the multi-disciplinary team discussing all potential candidates on a 
case-by-case basis. This thesis might contribute to the knowledge on these syndromes 
and diseases and optimization of the care of children with complex diseases. 
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Introduction
Chapter 1 is a general introduction to cochlear implantation in deaf children and to the 
three syndromes studied in this thesis. 
 A cochlear implant (CI) is an electronic device that can restore hearing in deaf people. 
It consists of an electronic array implanted in the cochlea that directly stimulates the 
cochlear nerve fibres. Cochlear implantation has become a regular treatment option for 
children and adults with severe or profound sensorineural hearing loss who cannot be 
treated with conventional hearing aids. Based on positive results with CI in children with 
isolated deafness, the criteria for implantation have gradually become more flexible, for 
example now allowing children with cognitive delay to undergo implantation. CHARGE 
syndrome, congenital cytomegalovirus (cCMV) infection and Kabuki syndrome are all 
complex in nature, and children with these syndromes can have (severe to profound) 
hearing loss and cognitive delay in addition to other co-morbidities. These children could 
benefit from CI.
 The criteria for the clinical diagnosis of CHARGE syndrome (MIM, Mendelian Inheritance 
in Man, 214800) have been defined by Blake et al. (1998) and Verloes (2005). CHARGE 
syndrome is an acronym of Coloboma, Heart disease, choanal Atresia, Retardation, Genital 
hypoplasia and Ear anomalies. In 2004, the causative gene was identified as CHD7 on 
chromosome 8q12. Hearing loss, which is present in 80–100% of the children, is one of the 
most common characteristics and can be due to anatomical anomalies of the middle or 
inner ear, to aplasia or hypoplasia of the cochlear nerve, or to middle ear disease. As a 
consequence, hearing in children with CHARGE syndrome can range from normal to 
profound hearing loss. 
 Congenital CMV affects approximately 1 in 200 newborns and is the leading cause of 
non-genetic childhood sensorineural hearing loss. Hearing loss can be detected at birth 
in approximately 10% of children with symptomatic cCMV. Since the hearing loss has a late 
onset in approximately half of the individuals, an additional 10% of the infected children 
will develop hearing loss in the first years after birth.
 Kabuki syndrome has characteristics such as distinctive facial features, cognitive 
disabilities, postnatal growth deficiency, dermatoglyphic abnormalities and skeletal 
anomalies. Hearing loss is one of the associated anomalies in Kabuki syndrome and is 
observed in 65% of cases. 
CHARGE syndrome
Chapter 2 focuses on several factors in CHARGE syndrome that can be challenging in 
cochlear implantation. Temporal bone anatomy in patients with CHARGE syndrome varies 
widely as described in section 2.1. Analyses of CTs of the temporal bone have found 
vascular structures like petrosquamosal sinus and large emissary veins, an underdeveloped 
mastoid and an aberrant facial nerve crossing the round window and/or the promontory. 
These structures can make it challenging to perform the mastoidectomy and posteri-
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or-tympanotomy. The cochleostomy can be difficult in patients with a stenotic round 
window (which is often seen in these patients). The appearance of the inner ear varies 
widely from partial to total absence of the semicircular canals and from normal to severely 
hypoplastic cochlea. More anomalies were observed in patients with truncating mutations 
than in those with non-truncating mutations in the CHD7 gene.
 The hearing loss, cognitive development and speech and language development of 
patients with CHARGE syndrome (without CI) is studied in section 2.2. Here we established 
an indicative dataset for a group of patients with multiple needs by analysing the 
relationship of hearing loss and cognitive abilities with language development. Data was 
analysed from 50 patients (age 5 months-48 years) known by ‘the Dutch CHARGE centre 
of expertise’ (University Medical Center Groningen, the Netherlands). The auditory abilities, 
cognitive abilities and language development in CHARGE syndrome vary widely, but they 
are mainly below average. The majority (83%) of the patients suffered from hearing loss 
and were almost equally divided among the various categories of hearing loss (mild, 
moderate, severe, deaf). Of the 41 patients for whom there was available cognitive data, 
the majority had an IQ below 70. The mean receptive language quotient (22 patients) was 
close to two standard deviations below the norm. The mean expressive language quotient 
(14 patients) was more than one standard deviation below the norm. Positive correlations 
were found between receptive language quotient and degree of functional hearing loss, 
between receptive language quotient and cognitive abilities, and between expressive 
language quotient and degree of functional hearing loss. Language and cognitive data 
were not available for all patients. It is possible that the group for whom data was available 
represent a pre-selection of patients with a developmental delay through exclusion of 
patients too well-performing to have tests done and of patients too poor-performing to 
participate in language tests. To avoid this pre-selection and improve the quality of care 
for CHARGE patients, hearing and developmental tests should be performed regularly to 
differentiate the contributions of hearing loss versus cognitive delay to delayed language 
development and to provide adequate hearing amplification in the case of hearing loss.
 In section 2.3 we evaluate data from ten children who received a CI between 2002 and 
2012 to provide an overview of the challenges and benefits encountered in cochlear 
implant surgery in CHARGE syndrome. Imaging and surgical findings were analysed. 
Language development and Quality-of-life (QoL) in our group were compared to those of 
two control groups: (1) 34 non-syndromic CI-users and (2) 13 children with CHARGE 
syndrome but without CI because of sufficient hearing. Based on this section, we have 
developed a suggested guideline for cochlear implantation in CHARGE syndrome. 
 All children with CHARGE syndrome studied in this section were congenitally deaf 
and had cognitive abilities below average as well as other co-morbidities. In three children, 
pre-operative subjective and objective audiometry and MRI were necessary to confirm 
the presence of the cochlear nerve. In all children, surgery was challenging due to enlarged 
emissary veins, semi-circular canal aplasia, an aberrant facial nerve and dysplastic cochlear 
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windows, which made CT indispensable during the surgical preparations. No major in-
tra-operative complications occurred. Despite additional handicaps, all patients showed 
auditory benefit and improvement in disease-specific QoL. The children with relatively 
long follow up who underwent implantation at a young age developed spoken language 
at a basic level comparable to that of the control group. Four children had speech 
perception scores between 60-90% after 60 to 120 months. In the other six children, 
speech perception could not be measured with standard tests, but with the CI these 
children could detect sounds adequately. General health status influenced CI-use, and 
possibly language development, in two patients including one non-user. Although the 
absolute scores on the QoL-test were lower in the children with CHARGE syndrome than 
in the control group, an improvement of disease-specific QoL after implantation was 
measured. Based on this evaluation, we conclude that a CI should be considered for all 
children with CHARGE syndrome and severe sensorineural hearing loss. A careful work-up 
is required —comprising CT, MRI, and objective and subjective audiometry— as is assessment 
by a specialized multidisciplinary team. Cochlear implantation in CHARGE syndrome 
might be complicated due to syndrome-related temporal-bone anatomy. The outcome 
of the CI is more individually determined. Early implantation should be aimed for.
 As we discuss in section 2.3, the CI-team must be aware of cochlear nerve deficiency 
(CND) in patients with CHARGE syndrome. When CND is suggested, an auditory brainstem 
implant (ABI) could be an alternative treatment of CI. Section 2.4 illustrates the dilemma 
faced when deciding between CI and ABI using a case report and literature review. We 
present a case study of a child with CHARGE syndrome who had no benefit from bilateral 
cochlear implantation and required an ABI for hearing rehabilitation. During the evaluation 
of this particular case, several steps in the decision process were questioned. The 
motivation for the literature review and meta-analysis on this topic was thus to provide an 
evidence-based therapeutic strategy for future cases. 
 In the case study, the MRI showed the presence of the cochleovestibular nerve in one 
ear, but there were no preoperative auditory brainstem responses. In the contralateral ear, 
the nerve could not be identified on MRI despite present auditory brainstem responses. 
Nevertheless, there was no positive outcome with bilateral CI. Therefore the decision was 
made to implant an ABI. With the ABI, the patient displayed benefit in terms of speech, 
language and QoL. 
 In the literature review, 108 cases of patients with CND and CI were identified. Of 
these patients, 25% attained open-set speech perception, 34% attained closed-set speech 
perception and 41% detected sounds or less. We studied which of the following variables 
could predict the effect of CI in patients with CND: the appearance of the cochlear nerve 
and presence of cochleovestibular nerve on MRI, the diameter of the internal auditory 
canal and bony cochlear nerve canal on CT, (electrically evoked) auditory brainstem 
response, (aided and unaided) pure tone audiometry and oto-acoustic-emissions. We 
found that patients with cochlear nerve aplasia on MRI had a smaller chance of attaining 
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a good outcome from cochlear implantation than patients with cochlear nerve hypoplasia, 
but there were exceptions to this finding. None of the other variables investigated could 
predict the outcome of cochlear implantation. This supports the idea that current imaging 
and audiometric testing limit our ability to identify predictors of CI success. ABI could be 
an alternative treatment for cochlear implantation in patients with CND, but outcomes are 
generally worse for patients with an ABI than patients with a CI. Based on these results, we 
concluded that the initial treatment in patients with (apparent) cochlear nerve aplasia is CI. 
When there is no success with a CI, we recommend considering proceeding to an ABI 
rather than attempting a second CI and risking further delay in auditory input. 
Cochlear implantation in patients deafened by congenital 
cytomegalovirus infection
Chapter 3 focuses on cochlear implantation in patients with severe to profound hearing 
loss as a result of cCMV infection. cCMV is the leading cause of non-genetic congenital 
hearing loss. Section 3.1 focuses on the prevalence of cCMV infections among CI recipients 
with prelingual deafness and the pathophysiology of cCMV and severe to profound 
hearing loss. For that purpose, cCMV was diagnosed retrospectively in a cohort of pediatric 
and adult CI recipients with prelingual deafness using dried blood spots (DBS). Furthermore, 
perilymphatic fluid, which is routinely exposed during CI surgery, was analysed for the 
presence of CMV DNA (including CMV gB/gH genotypes). A total of 76 pediatric recipients 
were included. Blood samples were available for 29 of the included patients, of whom 
52% (15/29) were CMV IgG seropositive. CMV IgG seronegativity excluded cCMV infection. 
Seventy DBS were tested for CMV DNA, resulting in a prevalence of cCMV of 14% (10/70). 
Perilymphatic fluid was available from 29 pediatric CI recipients. One perilymphatic fluid, 
from a 21-month old girl with cCMV, was CMV DNA positive. The child was asymptomatic 
at birth and hearing loss was detected in the first few weeks after birth. The CMV strain in 
the perilymph was genotypically identical to the strain present in her DBS. Perilymph 
samples from 21 adult CI recipients were CMV DNA negative. These data stress the role of 
cCMV among CI recipients with prelingual deafness. Furthermore, the genotyping data 
support the hypothesis that CMV-related hearing loss is associated with on-going viral 
replication in the inner ear up to years after birth. On-going viral replication might be 
influenced by antiviral therapy, and future data should reveal the efficacy of prolonged 
and/or postponed antiviral treatment of cCMV-infected newborns at risk for profound 
hearing impairment.  
 In patients with CI, benefit is not necessarily optimally expressed in improvement of 
speech and language abilities, particularly in patients with cognitive disabilities. In these 
patients, benefit may better be expressed in terms of changes to QoL. Section 3.2 
investigates health-related QoL in children with a profound hearing loss due to cCMV 
infection and treated with a CI (25 children). Results of standardized QoL questionnaires 
were compared with a matched control group of children without co-morbidities and 
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with a CI (37 children). Medical data, non-verbal IQ, age at implantation, months of CI use 
and speech perception results were available for analysis. The Nijmegen Cochlear Implant 
Questionnaire (NCIQ) and the Pediatrics Quality of Life Measurement (PedsQL) were 
administered to measure (health-related) QoL. The NCIQ total score and all but one NCIQ 
sub-domain had more variable score distributions compared to the control group. Median 
NCIQ total scores and sub-domain scores indicate a lower QoL for the study group 
compared to the control group. Only half of the children in the study group attained a 
PedsQL total score above 65.4 (“good QoL”), as compared to 86.5% of the children in the 
control group. Within the study group, IQ, implantation (unilateral or bilateral), hours of 
daily CI use and speech perception were positively associated with QoL outcomes. In 
conclusion, the QoL scores on the disease-specific and general health questionnaires 
were more variable and generally lower than the control group’s scores. Cognitive 
impairment, co-morbidity and low speech perception may have a negative influence on 
the improvement in QoL outcome after implantation.
Cochlear implantation in Kabuki syndrome
Chapter 4 describes the results of cochlear implantation in a child with hearing loss due to 
Kabuki syndrome. In addition to hearing loss, the child had cognitive impairment and 
other disabilities and communicated using vocalised sounds and Dutch Sign Language. 
Between the ages of one and a half years and seven years, the patient predominately wore 
bilateral hearing aids only at day-care. At eight years of age, progressive hearing loss was 
measured. After cochlear implantation at nine years of age, the patient displayed no 
progress in speech production and minimal progress in receptive language development, 
but she had increased awareness of the world and an increase in the outcome on the QoL 
assessment.
Discussion
In Chapter 5 the previous chapters are discussed, and the challenges and benefits of 
cochlear implantation in children with complex needs are summarized. We conclude that 
children deafened by CHARGE syndrome, cCMV infection or Kabuki syndrome present 
challenging cases for the CI-team because of anatomical abnormalities, cognitive 
disabilities and other co-morbidities. However, even in the face of these challenges, 
cochlear implantation in these children is beneficial and no strict contra-indications are 
indicated. Nevertheless, the outcomes of cochlear implantation in terms of speech and 
language development and quality of life are lower than that of peers without 
co-morbidities who use a CI. The outcome of cochlear implantation is more determined 
by medical/surgical issues and cognitive abilities of the child than by the disease itself. It is 
therefore important that a multi-disciplinary team discusses all potential CI candidates on 
a case-by-case basis. 
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Introductie
Hoofdstuk 1 is een algemene introductie over cochleaire implantatie bij dove kinderen en 
over de drie syndromen welke worden beschreven in deze thesis. 
 Een cochleair implantaat (CI) is een elektronisch apparaat dat dove mensen weer kan 
laten horen. Het bestaat uit een in de cochlea geïmplanteerde elektrode die direct de 
cochleaire zenuwvezels stimuleert. Cochleaire implantatie is een standaard behandeloptie 
geworden voor kinderen en volwassenen met ernstig tot zeer ernstig sensorineuraal 
gehoorverlies, die onvoldoende horen met een conventioneel hoortoestel. Op basis van 
de positieve resultaten van CI bij kinderen met geïsoleerde doofheid zijn de implantatie-
criteria geleidelijk uitgebreid. Inmiddels wordt de CI ook bij kinderen met cognitieve 
achterstand geïmplanteerd. Het CHARGE syndroom, congenitale cytomegalovirus (cCMV) 
infectie en Kabuki syndroom zijn complex. Kinderen met deze syndromen kunnen (ernstig 
tot zeer ernstig) gehoorverlies en een cognitieve achterstand hebben naast andere 
co-morbiditeiten. Ook deze kinderen zouden baat kunnen hebben bij een CI. 
 De criteria voor de klinische diagnose van het CHARGE syndroom (MIM, Mendelian 
Inheritance in Man, 214800) zijn gedefinieerd door Blake (1998) en Verloes (2005).  Het 
CHARGE syndroom is een acroniem van Colobomen, Hartafwijkingen, choanaal Atresie, 
Retardatie, Genitale hypoplasie en Oor (ear) anomalieën. In 2004 werd het verantwoorde-
lijke gen geïdentificeerd als CHD7 op chromostoom 8q12. Gehoorverlies is een van de 
meest voorkomende karakteristieken, en komt voor bij 80-100% van de kinderen. Het 
gehoorverlies kan worden veroorzaakt door anatomische afwijkingen van zowel het 
binnenoor als middenoor, door aplasie of hypoplasie van de nervus cochlearis, of door 
middenoorpathologie zoals chronische otitis media met effusie. Dit leidt bij kinderen met 
het CHARGE syndroom tot gehoorverlies van verschillende aard en variërend van normaal 
tot zeer ernstig.  
 Congenitale CMV infectie komt voor bij 1 op de 200 geborenen en is de voornaamste 
oorzaak van niet-genetische pediatrisch sensorineuraal gehoorverlies. In ongeveer 10% 
van de kinderen met symptomatische cCMV infectie kan gehoorverlies reeds bij de 
neonatale screening worden vastgesteld. In de helft van de kinderen met gehoorverlies 
ontstaat het in de eerste jaren na de geboorte, wat leidt tot 10% extra kinderen met 
gehoorverlies.
 Kabuki syndroom heeft karakteristieken zoals typische gezichtskenmerken, cognitieve 
achterstand, postnatale groei deficiëntie, afwijkingen aan de handen en skelet afwijkingen. 
Gehoorverlies is een van de geassocieerde anomalieën in Kabuki syndroom en geobserveerd 
in 65% van de kinderen. 
CHARGE syndroom
Hoofdstuk 2 richt zich op verschillende factoren van het CHARGE syndroom die cochleaire 
implantatie kunnen bemoeilijken. Dat de anatomie van het os temporale sterk varieert in 
patiënten met CHARGE syndroom wordt beschreven in sectie 2.1. Analyse van CTs van het 
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os temporale toonde vasculaire structuren aan zoals een petrosquameuse sinus en grote 
vena emissaria, een onderontwikkeld mastoid en een afwijkend beloop van de nervus 
facialis over het ronde venster en/of promotorium.  Deze structuren kunnen het maken 
van een mastoidectomie en posterieure-tympanotomie bemoeilijken. Het maken van de 
cochleostomie kan lastig zijn bij patiënten met een stenotisch ronde venster (wat vaak 
gezien wordt bij deze patiënten). Het aspect van het binnenoor varieert sterk van partiële 
tot totale afwezigheid van de semicirculaire kanalen en van een normale tot ernstig hypo- 
plastische cochlea. Patiënten met truncerende mutaties vertoonden meer anomalieën 
dan de patiënt met niet-truncerende mutaties in het CHD7 gen. 
 In sectie 2.2 wordt het gehoorverlies, cognitieve ontwikkeling en spraak en taal-
ontwikkeling van patiënten met CHARGE syndroom (zonder CI) bestudeerd. Door het 
analyseren van de relatie tussen gehoorverlies en cognitieve ontwikkeling met taalont-
wikkeling, hebben we een indicatieve dataset vastgesteld voor een groep patiënten met 
complexe problematiek. Van 50 patiënten (5 maanden-48 jaar oud) van ‘het Nederlandse 
CHARGE expertise centrum’ (Universitair Medisch Centrum Groningen, Nederland) is de 
data geanalyseerd. De auditieve mogelijkheden, cognitieve mogelijkheden en taal-
ontwikkeling bij patiënten met het CHARGE syndroom variëren sterk, maar zijn over het 
algemeen onder gemiddeld. De meerderheid (83%) van de patiënten had gehoorverlies, 
nagenoeg verdeeld over de verschillende categorieën van gehoorverlies (mild, matig, 
ernstig, doof).  Van de 41 patiënten waarvan de cognitieve data beschikbaar was, had de 
meerderheid een IQ lager dan 70. Het gemiddelde receptieve taalquotiënt (22 patiënten) 
was bijna twee standaard deviaties onder de norm. Het gemiddeld expressieve taal - 
quotiënt (14 patiënten) was meer dan een standaard deviatie onder de norm. Zowel 
receptieve taalquotiënt en mate van het functioneel gehoorverlies als receptieve 
taalquotiënt en cognitieve mogelijkheden, als expressieve taalquotiënt en mate van 
functioneel gehoorverlies waren positief met elkaar gecorreleerd. Taal en cognitieve data 
waren niet van alle patiënten beschikbaar. Het is mogelijk dat de groep van wie de data 
beschikbaar was, een preselectie van patiënten was met een ontwikkelingsachterstand 
doordat er een exclusie is opgetreden van patiënten die zo goed presteerden dat er geen 
testen werden gedaan, of patiënten te slecht presteerden om mee te doen aan taaltesten. 
Om deze preselectie tegen te gaan en de kwaliteit van zorg rondom patiënten met het 
CHARGE syndroom te verbeteren, zouden hoor- en ontwikkelingstesten standaard 
moeten worden afgenomen om te kunnen differentiëren tussen de rol van het gehoor- 
verlies versus cognitieve achterstand in de achterstand in taalontwikkeling. Hierdoor zal 
ook adequate hoortoestelaanpassing kunnen plaatsvinden bij patiënten met gehoorverlies. 
 In sectie 2.3 wordt de data geëvalueerd van tien kinderen die een CI kregen tussen 
2002 en 2012 om een overzicht te verkrijgen van de uitdagingen en voordelen van CI 
chirurgie bij CHARGE syndroom. Beeldvorming en chirurgische bevindingen werden 
geanalyseerd. Taalontwikkeling en kwaliteit van leven in onze groep werd vergeleken met 
twee controlegroepen: (1) 34 niet-syndromale CI-gebruikers en (2) 13 kinderen met 
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CHARGE syndroom, maar zonder CI vanwege voldoende gehoor. Op basis van deze 
studie hebben we een voorstel gedaan voor een richtlijn voor cochleaire implantatie bij 
het CHARGE syndroom. 
 Alle kinderen met CHARGE syndroom die in deze sectie werden beschreven waren 
congenitaal doof en hadden een beneden gemiddeld cognitieve ontwikkeling naast 
andere comorbiditeiten. In drie kinderen was zowel pre-operatief subjectieve audiometrie, 
objectieve audiometrie en MRI noodzakelijk om de aanwezigheid van de nervus cochlearis 
te bevestigen. In alle kinderen was de chirurgie uitdagend door vergrote vena emissaria, 
semi-circulaire kanaal aplasie, een aberrant verlopende nervus facialis en dysplastische 
cochleaire vensters, wat het gebruik van de CT bij de pre-operatieve voorbereidingen 
onmisbaar maakte. Er hebben zich geen grote intra-operatieve complicaties voorgedaan. 
Ondanks de bijkomende handicaps lieten alle patiënten auditief voordeel zien en 
verbetering van de ziekte specifieke kwaliteit van leven. De kinderen met relatief lange 
follow-up die op jonge leeftijd een CI kregen ontwikkelden gesproken taal op basisniveau 
in vergelijking met dat van de controlegroep. Vier kinderen hadden spraakverstaanscores 
tussen de 60-90% na 60 tot 120 maanden. In de andere zes kinderen, kon het spraakverstaan 
niet worden gemeten met standaard testen, maar de kinderen konden geluiden adequaat 
detecteren. Het CI-gebruik en mogelijk ook de taalontwikkeling werd beïnvloed door de 
algemene gezondheidstatus, inclusief een niet-gebruiker als gevolg. Ondanks dat de 
absolute scores op de kwaliteit van leven-test van de kinderen met CHARGE syndroom 
lager waren dan van de controlegroep, werd een toename van kwaliteit van leven na 
implantatie gemeten. Op basis van deze evaluatie kunnen we concluderen dat CI 
overwogen moet worden in alle kinderen met CHARGE syndroom en ernstig sensorineuraal 
gehoorverlies. Een zorgvuldige work-up is vereist – met CT, MRI en objectieve en 
subjectieve audiometrie -  beoordeeld door een gespecialiseerd multidisciplinair team. 
Cochleaire implantatie bij CHARGE syndroom is mogelijk gecompliceerd door syndroom- 
gerelateerde anatomie van het os temporale. Maar de uitkomst van CI wordt meer door 
het individu bepaald. Implantatie op jonge leeftijd moet worden nagestreefd. 
 Zoals we in sectie 2.3 beschrijven, moet het CI-team bewust zijn van een eventuele 
deficiëntie van de nervus cochlearis (CND) bij patiënten met het CHARGE syndroom. Als er 
sprake lijkt te zijn van CND is een auditory brainstem implant (ABI) een alternatieve 
behandeling voor een CI. Sectie 2.4 illustreert aan de hand van een casusbespreking en li-
teratuuroverzicht, het dilemma wat zich voordoet wanneer de keuze tussen een CI of ABI 
gemaakt moet worden. We presenteren een casus van een kind met het CHARGE 
syndroom dat geen baat had van bilaterale cochleaire implantatie en een ABI nodig had 
voor gehoorverbetering. 
 In deze casus was op MRI de nervus cochleovestibularis aanwezig in het ene oor, 
maar er waren geen pre-operatieve auditieve hersenstamresponsies. In het contralaterale 
oor kon de zenuw niet worden geïdentificeerd op de MRI, ook al waren hiervan wel 
auditieve hersenstamresponsies gemeten. Niettemin, was er geen reactie op geluid met 
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bilaterale CI. Daarom werd besloten over te gaan tot het implanteren van een ABI. Patiënt 
had baat van de ABI op het gebied van spraak, taal en kwaliteit van leven.  
 Tijdens de evaluatie van deze casus werden verschillende stappen in de besluit-
vorming voor cochleaire implantatie kritisch bezien. Een literatuuroverzicht en meta- 
analyse over dit onderwerp leidde tot een evidence-based behandelstrategie. In het 
 literatuuroverzicht werden 108 patiënten met CND en CI geïdentificeerd. Van deze patiënten 
bereikte 25% open-set spraakverstaan, 35% bereikte gesloten-set spraakverstaan en 41% 
kon geluiden detecteren of minder. We bestudeerden welke van de volgende variabelen 
het effect van CI bij patiënten met CND kon voorspellen: het aspect van de nervus 
cochlearis en de waarneming van de nervus cochleovestibularis op MRI, de diameter van 
de inwendige gehoorgang en benige nervus cochlearis kanaal op CT, (electrische) 
auditieve hersenstamrepons, (geholpen en ongeholpen) toonaudiometrie en oto-acous-
tische emissies. We vonden dat patiënten waarbij de nervus cochlearis op MRI niet kon 
worden waargenomen, een kleinere kans hadden op goede uitkomst van cochleaire 
implantatie dan patiënten met hypoplasie van de cochleaire zenuw, maar er waren 
uitzonderingen op deze bevinding. Geen van de andere variabele die onderzocht zijn, 
konden de uitkomst van cochleaire implantatie voorspellen. Dit ondersteunt het idee dat 
de huidige beeldvorming en audiometrische testen ons vermogen om voorspellers van 
CI-succes te identificeren, beperken. ABI kan een alternatieve behandeling zijn van 
cochleaire implantie bij patiënten met CND, maar de uitkomsten zijn over het algemeen 
slechter dan van patiënten met CI. Gebaseerd op deze resultaten concluderen we dat de 
initiële behandeling van patiënten met (ogenschijnlijke) aplasie van de nervus cochlearis 
een CI is. Als er geen succes met CI wordt bereikt, adviseren we te overwegen door te 
gaan met een ABI, eerder dan een tweede CI en het risico op verder vertraging van 
auditieve input te voorkomen. 
Cochleaire implantatie bij patiënten doof door congenitale 
cytomegalovirus infectie
Hoofdstuk 3 focust op cochleaire implantatie bij patiënten met ernstig tot zeer ernstig 
gehoorverlies door een cCMV infectie. cCMV is de meest voorkomende oorzaak van 
niet-genetisch congenitaal gehoorverlies. Sectie 3.1 focust op de prevalentie van cCMV 
infecties bij CI ontvangers met prelinguale doofheid en de pathofysiologie van cCMV en 
ernstig tot zeer ernstig gehoorverlies. 
 Voor dat doel werd cCMV retrospectief gediagnosticeerd met behulp van de hiel- 
prikkaart in een cohort van kinderen en volwassenen met CI met prelinguale doofheid. 
Daarnaast werd perilymfatische vloeistof die standaard vrijkomt tijdens CI-chirurgie 
geanalyseerd op de aanwezigheid van CMV DNA (inclusief CMV gB/gH genotypes). In 
totaal werden 76 kinderen geincludeerd. Bloedmonsters waren beschikbaar van 29 van 
de geincludeerde patiënten waarvan 52% (15/29) CMV IgG seropositief waren. Indien CMV 
IgG seronegatief was, werd cCMV infectie als oorzaak van de doofheid verworpen. 
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Zeventig hielprikkaarten werden getest op CMV DNA, met als resultaat een prevalentie 
van cCMV van 14% (10/70). Perilymfe vloeistof was beschikbaar van 29 kinderen die een CI 
kregen. Van één patiënt, een 21 maanden oud meisje met cCMV, had CMV DNA positief 
perilymfe vloeistof. Het kind was asymptomatisch bij geboorte en het gehoorverlies werd 
gediagnosticeerd in de eerste weken na de geboorte. De CMV-stam in de perilymfe was 
genotypisch identiek aan de stam die aanwezig was in haar hielprikkaart. Perilymfe monsters 
van 21 volwassen CI ontvangers waren CMV DNA negatief. Deze data benadrukken de 
rol van cCMV bij CI ontvangers met pre-linguale doofheid. Daarnaast wordt door de 
genotypering de hypothese ondersteund dat CMV gerelateerde doofheid is geassocieerd 
met voortdurende virale replicatie in het binnenoor tot jaren na de geboorte. De 
voortdurende virale replicatie zou kunnen worden beïnvloed door antivirale therapie en 
uit toekomstige data zou de werkzaamheid moeten blijken van langdurige of uitgestelde 
antivirale behandeling van met cCMV geïnfecteerde pasgeborenen met een hoog risico 
op ernstig gehoorverlies.  
 Het voordeel van CI is niet altijd het best uitgedrukt in verbetering van spraaktaal-
ontwikkeling, met name niet bij patiënten met cognitieve beperkingen. In deze patiënten 
is het voordeel soms beter uit te drukken in verandering van kwaliteit van leven. Sectie 3.2 
onderzoekt de gezondheidgerelateerde kwaliteit van leven in kinderen met zeer ernstig 
gehoorverlies door een cCMV infectie en behandeld met een CI (25 kinderen). Resultaten 
van de gestandaardiseerde kwaliteit van leven vragenlijsten werden vergelen met een 
controlegroep van kinderen zonder comorbiditeiten en een CI (37 kinderen). Medische 
data, niet-verbale IQ, leeftijd bij implantatie, aantal maanden CI gebruik en spraakverstaan 
resultaten werden gebruikt voor de analyses. De Nijmegen Cochlear Implant Questionnaire 
(NCIQ) en de Pediatrics Quality of Life Measurement (PedsQL) werden ingevuld om de 
(gezondheidsgerelateerde) kwaliteit van leven te meten. In de studiegroep werd voor 
de NCIQ totaalscore en voor alle subdomeinen van de NCIQ, op een subdomein na, 
een meer variabele score verdeling waargenomen in vergelijking met de controlegroep. 
De mediaan van de NCIQ totaalscore en subdomeinen duiden op een lagere kwaliteit 
van leven van de studiegroep in vergelijking met de controlegroep. Slechts de helft van 
de kinderen in de studiegroep behaalde een totaalscore op de PedsQL boven de 65,4 
(‘goede kwaliteit van leven’), in vergelijking met 86,5% van de kinderen in de controlegroep. 
Binnen de studiegroep waren IQ, implantatie (unilateraal of bilateraal), aantal uren van 
dagelijks CI gebruik en spraakverstaan positief geassocieerd met de kwaliteit van leven 
uitkomsten. Hieruit kunnen we concluderen dat uitkomsten van de ziektespecifieke en 
algemene gezondheid vragenlijsten meer gevarieerd en over het algemeen lager waren 
dan de uitkomsten van de controlegroep. Cognitieve beperkingen, comorbiditeit en laag 
niveau spraakverstaan, hebben mogelijke een negatieve invloed op de verbetering in 
kwaliteit van leven na implantatie. 
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Cochleaire implantatie bij Kabuki syndroom
Hoofdstuk 4 beschrijft de resultaten van cochleaire implantatie bij een kind met gehoor- 
verlies door het Kabuki syndroom. Naast het gehoorverlies had patiënt cognitieve en 
andere beperkingen en communiceerde door middel van geluid en Nederlands gebaren- 
taal. Tussen de leeftijd van anderhalf en zeven jaar droeg ze haar bilaterale hoortoestellen 
alleen op de dagopvang. Op acht jarige leeftijd werd een toename van gehoorverlies 
gemeten. Na cochleaire implantatie op negenjarige leeftijd vertoonde patiënt geen 
toename in spraakproductie en minimale verbetering in receptieve taalontwikkeling, 
maar er was een toename van bewustzijn van de wereld om haar heen en een verbetering 
in kwaliteit van leven. 
Discussie
In hoofdstuk 5 worden de voorgaande hoofdstukken bediscussieerd en zijn de uitdagingen 
en voordelen van cochleaire implantatie bij kinderen met complexe problematiek samen- 
gevat. We concluderen dat kinderen met doofheid door het CHARGE syndroom, cCMV 
infectie of Kabuki syndroom een uitdaging bieden voor het CI-team vanwege anatomische 
afwijkingen, cognitieve achterstand en andere comorbiditeiten. Maar zelfs in het licht van 
deze uitdagingen is cochleaire implantatie bij deze kinderen gunstig en zijn er geen strikte 
contra-indicaties indicaties aan te wijzen. 
 Desondanks zijn de uitkomsten van cochleaire implantatie in termen van spraak- 
en taalontwikkeling en kwaliteit van leven lager dan die van leeftijdsgenoten zonder 
 comorbiditeiten die een CI gebruiken. Het resultaat van cochleaire implantatie wordt 
meer bepaald door medisch-chirurgische problemen en cognitieve vermogens van het 
kind dan door de ziekte zelf. Het is daarom belangrijk dat voor deze groep kinderen een 
gespecialiseerd multidisciplinair team alle potentiële CI-kandidaten van geval tot geval 
bespreekt, behandeld en een toegespitst zorgpad creëert.
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5.4.1  List of abbreviations
ABR: auditory brainstem response
AP: anterior-posterior
BCNC: bony cochlear nerve canal
BER(A): brainstem evoked response (audiometry)
cCMV: congenital cytomegalovirus
CHARGE: Coloboma, Heart disease, Atresia of the choanae, Retarded growth  
and development and/or CNS anomalies, Genital hypoplasia,  
and Ear anomalies
CI: cochlear implant
CND: cochlear nerve deficiency
CVN: cochleovestibular nerve
CT: computed tomography
dB: decibel
DBS: dried blood spots
IAC: internal auditory canal
IP: incomplete partition
IQ: intelligence quotient
LM: lateral-medial
LQ: language quotient
MRI: magnetic resonance imaging
OW: oval window
PCR: polymerase chain reaction
PPS: persistent petrosquamosal sinus
PTA: pure tone average
QoL: quality of life
RW: round window
SCC: semicircular canal
SD: standard deviation
UTI: unable to identify
UV: unknown-variant
VA: vestibular aqueduct
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5.4.2  Dankwoord
Het maken van een proefschrift doe je gelukkig niet alleen. Zonder de hulp van vele mensen 
was dit boekje niet tot stand gekomen. Een aantal van hen zou ik in het bijzonder willen 
bedanken.
Professor E.A.M. Mylanus, beste Emmanuel, er zijn maar weinig mensen met zo’n drukke 
agenda als jij. Ondanks deze drukte wist jij altijd een mogelijkheid te vinden voor overleg. 
Het is bewonderenswaardig hoeveel ballen jij in de lucht weet te houden en daarnaast 
een promotietraject weet te begeleiden. Fijn dat er naast de inhoudelijke zaken ook altijd 
aandacht was voor activiteiten buiten het ziekenhuis zoals hockey, fietsen en skiën. Dank 
voor je begeleiding!
Professor A. F.M. Snik, beste Ad, pas laat in het traject ben je bij mijn onderzoek betrokken 
geraakt, maar het was een groot voorrecht om met jou te mogen samenwerken. Jouw 
wetenschappelijke kennis, goede ideeën en (en soms vaderlijke) adviezen waren voor mij 
erg waardevol en heb ik erg gewaardeerd. 
Professor C.M.A. van Ravenswaaij, beste Conny, jouw jarenlange ervaring in de wetenschap 
met name op het gebied van het CHARGE syndroom is van grote waarde geweest voor 
dit manuscript. Via jou heb ik veel data kunnen verkrijgen, maar ook jouw kritische blik 
heeft mij erg geholpen. Het was erg fijn met je samen te werken. Dank voor je goede 
adviezen en je begeleiding. 
Dr. B. Verbist, beste Berit, met veel plezier kijk ik terug naar de uren die we in de ‘badkamer’ 
van de radiologie hebben doorgebracht. Ik heb veel van je geleerd en je bent onmisbaar 
geweest in de totstandkoming van enkele hoofdstukken. Dank voor je inzet en bijdrage 
aan mijn onderzoek en dank voor de gezelligheid tijdens het beoordelen van het de grote 
hoeveelheid scans. 
Dr  R.H. Free, beste Rolien, het was erg fijn om met jou samen te werken. Jouw inspanning 
bij het beoordelen van de scans, je ideeën en je motiverende mailtjes waren onmisbaar, 
heel veel dank voor het meedenken en je inzet. 
Dr. M.C.  Langereis, beste Margreet, ik kijk met plezier terug op onze samenwerking. Dank 
voor je eindeloos geduld om met mij door alle taaldata heen te werken, dank dat je 
ondanks je drukke agenda altijd tijd wist te maken voor overleg. 
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Leden van de manuscriptcommissie, professor. dr. I. Dhooge , professor dr. M.A.A.P. Willemsen, 
professor dr. H.E.T. Knoors hartelijk dank dat u het manuscript heeft willen lezen en 
beoordelen.
Drs. Snels, beste Chantal dank voor je hulp bij twee artikelen. Het was heel gezellig om samen 
te werken en het was fijn dat ik gebruik kon maken van jouw statistische vaardigheden. 
Staf van de KNO Radboud. Dank voor de fijne en zeer goed opleiding. Bewonderenswaardig 
hoe jullie een veilige en motiverende leeromgeving weten te creëren, waarbij de gezelligheid 
niet vergeten wordt! 
(oud-)AIOS van de KNO, dank voor alle gezelligheid in de afgelopen jaren. Fijn hoe je wordt 
opgenomen binnen de KNO-wereld en lief en leed met elkaar kan delen. En bijzonder dat 
je naast collega’s ook goede vrienden kan zijn! De IMMG in het bijzonder!
Lieve oud-teamgenoten van dames 2/3 NMHC, dank voor de gezelligheid tijdens mijn 
Nijmeegse jaren. Zo fijn om naast het werken jullie als gezellige en sportieve uitlaatklep te 
hebben gehad!
Lieve paranimfen Eline en Nicole, dank dat jullie mij willen bijstaan! Eline, de jaren die wij 
samen op de researchgang hebben doorgebracht zal ik nooit vergeten, de kinderen- 
voor-kinderenliedjes, de grappen en het eindeloze kletsen waren een zeer aangename 
afleiding van het harde werken. Lieve Nicole, dank dat je altijd voor me klaar staat en dat 
ik alles met je kan bespreken. Ik bewonder je positieve instelling en gebruik vaak jou 
uitspraak: alles komt goed, uiteindelijk, altijd. 
Lieve meisjes van JC Stout, bijzonder hoeveel we samen al meegemaakt hebben en 
hoeveel fantastische jaren we tot nu toe hebben beleefd! Door mijn verhuizing naar de 
andere kant van het land zagen we elkaar veel minder, maar de vriendschap is zeker niet 
minder geworden. Jullie hebben het af en toe zwaar met mij gehad, dank voor jullie 
luisterende oren en de afleiding in de afgelopen jaren.  
Lieve pappa en mamma, Ernst Jan en Noor, dank voor jullie onvoorwaardelijke steun 
tijdens mijn promotietraject, maar ook in de rest van mijn leven. Dank dat jullie mij altijd 
hebben gestimuleerd om op ontdekking te gaan, door te zetten en dat jullie mij hebben 
geleerd door hard te werken ergens te komen. En Noor, heel veel dank dat ik gebruik heb 
kunnen maken van jouw vormgevende kwaliteiten, de kaft is prachtig! 
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Allerliefste Jasper, wat ben ik blij dat ik jou ben tegen gekomen, tegen al mijn verwachtingen in, 
een Brabander uit Nijmegen. De steun die jouw begrip, vertrouwen, liefde en gezelligheid 
mij hebben gegeven zijn niet in woorden uit te drukken, maar hebben een zeer grote rol 
gespeeld bij de totstandkoming van dit boekje, heel veel dank daarvoor! Daarnaast heb je 
gezorgd dat we heel veel leuke dingen samen deden als ik (wij) niet aan mijn promotie 
werkte. Die leuke dingen gaan we alleen nog maar meer doen…We gaan, samen met 
Thomas, nog een geweldig leven tegemoet! Ik hou van je!
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5.4.3  Curriculum Vitae
Annemarie Vesseur, geboren op 2 april 1984, groeide op in Rotterdam. Vanaf haar tiende 
woonde ze in Zwolle, waar ze in 2002 haar diploma haalde aan het Gymnasium Celeanum. 
Ze studeerde geneeskunde aan de Universiteit Leiden. Tijdens haar studie was ze actief bij 
de Leidse studentenvereniging Minerva. Na haar studie startte ze in 2010 als arts-onder-
zoeker aan de afdeling KNO-heelkunde van het Radboud UMC, waar ze in 2011 begon aan 
de opleiding tot KNO-arts. Na haar opleiding in 2016 was ze werkzaam als KNO-arts in het 
Diakonessenhuis in Utrecht. Sinds april 2018 werkt ze in het Rijnstate in Arnhem. 
Ze woont sinds 2015 samen met Jasper en zij hebben samen een zoon, Thomas. 
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